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Abstract 
There is currently no effective treatment for spinal cord injury (SCI). Long chain omega-3 
polyunsaturated fatty acids (PUFA) such as docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA) have beneficial effects in various neurological disorders. 
DHA and EPA have neuroprotective effects when given intravenously (i.v.) after SCI, but 
dietary enrichment with these fatty acids is less well-characterized.  It is important to 
characterize the effect of these compounds after parenteral and oral administration, as both 
regimes could be used clinically. The aims of this thesis were to: i) characterize the 
inflammatory response in the rat after T12 compression SCI, ii) characterize the effects of 
acute i.v. injection of DHA or EPA on inflammation after SCI, iii) explore the effects of i.v. 
DHA in a rat contusion model of SCI, iv) assess the effects of dietary enrichment with 
DHA or EPA before and/or after SCI.  
Compression SCI led to acute infiltration of neutrophils and delayed accumulation of 
macrophages/microglia in the spinal cord, and a systemic inflammatory response in plasma 
and liver. DHA i.v. injection reduced neutrophil infiltration to the epicentre and C-reactive 
protein in the plasma, whereas EPA had no significant effect. There was no effect of i.v. 
EPA or DHA on the increase in cytokines/chemokines following injury. Acute DHA 
restored stepping ability after contusion SCI, but there was no effect on histological 
markers. Dietary enrichment with EPA after compression SCI had a detrimental effect on 
recovery, but this was not correlated with changes in neurones, oligodendrocytes or 
macrophages/microglia. Dietary pre-treatment with DHA had no effect on locomotor 
outcome after compression SCI. 
Therefore, the inflammatory response after SCI is not changed significantly by acute 
administration of EPA and DHA. The study did not reveal a beneficial prophylactic effect 
of dietary DHA, but highlighted a possible risk associated with dietary EPA after SCI.  
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Chapter 1: General Introduction 
 
It is estimated that the worldwide annual incidence of spinal cord injury (SCI) is 22 per 
million of population, nearly 1000 new cases occurring in the UK each year (Grundy and 
Swain, 2002; Rossignol et al., 2007). There is currently no effective treatment. Although 
these numbers are not large compared to illnesses such as cancer or heart disease, people 
living with SCI are left with debilitating consequences, depending on the level and severity 
of the lesion. Paralysis, sensory loss, intractable pain, pressure sores, and urinary and other 
infections seriously diminish their quality of life. The cost of living with SCI can be 
immense. The average cost varies depending on the amount of care needed and the 
unemployment rate for people with SCI is high. Therefore, it is essential to pursue research 
into basic mechanisms involved in SCI in the hope of developing efficacious therapeutic 
strategies (Rossignol et al., 2007). 
 
Recently, our laboratory has shown that omega-3 polyunsaturated fatty acids (PUFAs) have 
the potential to act as neuroprotective agents in SCI (King et al., 2006; Huang et al., 2007a; 
Lim et al., in press). The purpose of this doctoral research project is to further investigate 
the effects of treatment with omega-3 polyunsaturated fatty acids (PUFAs) in models of 
SCI, and in particular to explore whether they alter the inflammatory response following 
SCI. This work will be introduced with a review of SCI pathology and the inflammatory 
response following injury, followed by an overview of existing neuroprotective strategies 
and the field of PUFAs, finishing with an introduction to the methodology that has been 
used. 
 
1.1 Gross anatomy of the spinal cord 
 
The spinal cord is contained in the vertebral column and extends from the brainstem to the 
cauda equina (Fig. 1.1A). In the human, it can be divided into segmental levels by the pairs 
of nerves that arise from it, into cervical (C1-C8), thoracic (T1-T12), lumbar (L1-L5), 
sacral (S1-S5) and coccygeal (1 pair) regions. This makes up 31 spinal cord segments in the 
human, whereas in the rat there are 34: 8 cervical, 13 thoracic, 6 lumbar, 4 sacral and 3 
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coccygeal segments (Paxinos, 2004). The nerves have both dorsal and ventral roots and 
leave the vertebral column through the intervertebral foramina that lie adjacent to each 
vertebral body. The dorsal roots convey sensory information from the afferent axons of the 
spinal nerves and motor commands are sent via the ventral roots (Purves et al., 2001). 
 
 
Figure 1.1 Anatomy of the spinal cord. (A) Transverse sections of the spinal cord, which 
can be divided into cervical, thoracic, lumbar and sacral regions and is made up of both 
gray and white matter. (B) Transverse section of the spinal cord showing the major 
ascending and descending tracts, which project to both the brain and the periphery (image 
reproduced from Purves, et al., 2001). 
 
The regions of the spinal cord which innervate the limbs are enlarged to accommodate the 
greater number of nerve cells and connections. Thus, the cervical enlargement spans C5-T1 
and corresponds to the arms; the lumbar enlargement spans L2-S3 and corresponds to the 
legs. The cauda equina is a collection of lumbar and sacral nerve roots that run for some 
distance in the vertebral canal before emerging (Purves et al., 2001). 
 
Sensory dorsal root ganglia (DRG) lie adjacent and connect to the spinal cord. They send 
axons that constitute the sensory component of the peripheral nervous system (PNS). These 
axons end in specialized receptors that process information about a wide range of stimuli 
such as pain, temperature and pressure. The PNS is also divided into the somatic motor 
component, where peripheral motor axons innervate muscle to control skeletal movement 
17 
 
and most voluntary behaviour and the autonomic portion, which contains preganglionic 
visceral motor neurones in the spinal cord and brainstem that form synapses with post 
ganglionic motor neurones that lie in the autonomic ganglia. These ganglia innervate 
smooth muscle, glands and cardiac muscle, controlling most involuntary behaviour. There 
is a sympathetic division of the autonomic nervous system, where the ganglia are located 
along or in front of the vertebral column and send their axons to peripheral targets. In the 
parasympathetic division, the ganglia are located within the organs they innervate. The 
gut contains small ganglia scattered throughout its wall, making up the enteric nervous 
system (Purves et al., 2001).  
 
Internal anatomy of the spinal cord 
 
The spinal cord is a component of the central nervous system (CNS) and is made up of gray 
matter containing cell bodies, surrounded by white matter which consists of axonal tracts. 
In transverse sections, the gray matter is divided into dorsal, lateral and ventral „horns‟ 
(Fig. 1.1B). The dorsal horns receive sensory information that enters the spinal cord via 
the dorsal roots. The lateral horns are largely found in the thoracic region and contain the 
preganglionic visceral motor neurones that project to the sympathetic ganglia. The ventral 
horns contain the cell bodies of motor neurones that send axons through the ventral roots to 
terminate in muscle tissue. The white matter is divided into dorsal, lateral and ventral 
columns. The axons of the dorsal columns carry ascending sensory information from 
somatic mechanoreceptors. The lateral columns carry information from the cerebral cortex 
in the brain to contact spinal motor neurones, also known as the corticospinal tracts, 
located in rodents beneath the dorsal columns as well as a minor ventral component. The 
ventral (and ventrolateral) columns carry ascending information such as pain and 
temperature, as well as descending motor information (Purves et al., 2001). 
 
Blood supply of the spinal cord 
 
Since this thesis will be dealing with the inflammatory response to SCI, it is pertinent that a 
brief overview of the bloody supply to the nervous system is given, as blood provides the 
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vehicle for systemic cells involved in the inflammatory reaction which are recruited to the 
injury site. 
  
The entire blood supply of the brain and spinal cord originates from two sets of branches 
from the dorsal aorta (Fig. 1.2). The vertebral arteries arise from the subclavian arteries, 
and together with the medullary arteries that arise from segmental branches of the aorta, 
provide the primary vascularisation of the spinal cord (Purves et al., 2001). The medullary 
arteries join to form the anterior and posterior spinal arteries. If any of the medullary 
arteries are obstructed or damaged, for example during a surgical procedure, the blood 
supply to specific parts of the spinal cord may be compromised and result in neurological 
damage. A loss of posterior supply generally leads to loss of sensory functions, whereas 
loss of the anterior supply more likely causes motor deficits (Purves et al., 2001).  
 
 
Figure 1.2 Blood supply to the spinal cord. (A) Ventral and (B) dorsal aspects of the 
spinal cord surface, displaying the major arteries that supply blood to the spinal cord. (C) 
Transverse section of the spinal cord showing the vascularisation of the grey and white 
matter (image reproduced from Purves, et al., 2001). 
 
The main outcome following SCI that will be measured in the experiments that follow is 
the recovery of locomotor function. In some cases, measures of autonomic function of the 
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bladder and somatosensory tests, such as the development of allodynia/hyperalgesia will be 
carried out. Therefore, a brief description of the physiological control of these functions 
will follow. 
 
The locomotor system  
 
After SCI, one of the most dramatic impairments is the loss of locomotor function. In 
humans, the American Spinal Injury Association (ASIA) Impairment Scale is widely used 
to determine the level of SCI and assess motor function and pin-prick and light-touch 
sensory function. In clinical trials, an improvement in the ASIA scale is the main outcome 
measure for the efficacy of treatments and ranges from A-E, where A is a complete SCI (no 
motor or sensory function) and E is normal motor and sensory function. In rodent models 
of SCI, there are several tests that can be used to assess the recovery of sensory and motor 
function. These will be discussed in chapter 6. The main functional measurement that will 
be taken in this thesis is an assessment of locomotor recovery. Therefore, a brief overview 
of motor function and the systems involved in locomotion will be given here. 
 
All movements produced by the skeletal musculature, whether reflexive or voluntary, are 
ultimately dependent on lower motor neurones in the ventral horn spinal cord gray matter 
that directly innervate skeletal muscle. Activation of lower motor neurones is determined 
by local circuits within the brain and spinal cord. Descending pathways comprised of 
upper motor neurones modulate the lower motor neurone circuitry. The cell bodies of 
upper motor neurones are located either in the cortex or in the brainstem, i.e. the vestibular 
nucleus, the red nucleus, or the reticular formation. The motor and „premotor‟ areas of the 
frontal lobe are responsible for the planning and precise control of voluntary movements. 
The cerebellum controls movement by regulating the activity of the upper motor neurons. 
Finally the basal ganglia, a group of structures in the forebrain, suppress unwanted 
movements and prime upper motor neurone circuits for the initiation of movements. 
Disorders of the basal ganglia such as Parkinson‟s disease and Huntington‟s disease 
highlight the importance of such a process. The local circuit neurones also receive direct 
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input from sensory neurones. All of these inputs together provide coordination between the 
different muscle groups essential for organised movement (Purves et al., 2001).  
 
The lower motor neurones form a pool that innervates a single muscle and their axons 
extend up and down one or more spinal cord segments. Two types of lower motor neurone 
are found in these neuronal pools: γ motor neurones and α motor neurones. The most 
medial part of the ventral horn contains lower motor neurone pools that innervate axial or 
proximal muscles of the limbs, whereas the lateral parts contain lower motor neurones that 
innervate the distal muscles of the limbs (Purves et al., 2001). When there is damage to 
lower motor neurones of the spinal cord, this is referred to as the „lower motor neurone 
syndrome‟. This results in paralysis of the affected muscles, including a loss of reflexes, 
muscle tone and wasting of the affected muscles due to denervation and disuse. Damage to 
any of the descending motor pathways gives rise to the „upper motor neurone syndrome‟, 
characterised by spasticity of muscles, which is most severe in the arms and legs. This is 
preceded by an initial period referred to as spinal shock, which reflects the decreased 
activity of spinal circuits suddenly deprived of input from the motor cortex and brainstem 
(Purves et al., 2001).   
 
The movement of a single limb during locomotion is a cycle consisting of a stance phase, 
during which the limb is extended and placed in contact with the ground to propel the body 
forward and a swing phase, during which the limb is flexed to leave the ground and then 
brought forward to begin the next stance phase. In quadrupeds, changes in locomotor speed 
are also accompanied by changes in the sequences of limb movements. At low speeds, there 
is back-to-front progression of leg movements, first on one side and then on the other. As 
the speed increases, the movements of the right forelimb and left hindlimb are synchronised 
with the left forelimb and right hindlimb. Incredibly, despite the precise coordination and 
timing of the movement of individual limbs required for locomotion, following transection 
of the thoracic spinal cord, a cat or rat‟s hindlimbs will still make coordinated locomotor 
movements if the animal is supported and placed on a moving treadmill (Pearson, 1976; 
Edgerton and Roy, 2002; Rossignol et al., 2002). The speed of locomotion is determined by 
the speed of the treadmill, suggesting that the movement may be merely a reflex response 
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to stretching the muscles. However, this was ruled out because when the dorsal roots were 
also sectioned there were still locomotor movements, although they were slower and less 
coordinated (Pearson, 1976). These experiments led to the discovery that the basic rhythmic 
patterns of each limb involved in locomotion are dependent on central pattern generators 
– a local circuit in the spinal cord responsible for the alternating flexion and extension of 
the limb. In the human, this ability to mediate rhythmic stepping is reduced and likely 
reflects the dependence for bipedal locomotion on an increased requirement of upper motor 
neurone pathways, such as those involved in postural control (Purves et al., 2001). 
 
After SCI, considerable recovery of motor/locomotor function is generally achieved when 
the ventral and lateral white matter is preserved (Basso et al., 2002). Injuries to either the 
dorsal corticospinal tract (CST) or rubrospinal tract do not produce persistent and severe 
locomotion deficits, except deficits of fine paw and digit movements (Whishaw and Gorny, 
1998; Muir and Whishaw, 1999, 2000; Metz and Whishaw, 2000; Loy et al., 2002). In 
contrast, the reticulospinal tract plays a crucial role in the initiation of locomotor function 
(Jordan, 1998). In the acute decerebrate cat, the pontomedullary medial reticular formation 
is the origin of long fast-conducting descending projections that travel in the ventrolateral 
funiculus, and this pathway must remain intact to elicit hindlimb locomotor activity in 
response to brainstem electrical stimulation (Steeves and Jordan, 1980; Noga et al., 1991; 
Whelan, 1996). The loss of propriospinal tracts in the white matter may also contribute to 
the loss of locomotor function after SCI. Propriospinal cells are involved in the 
coordination of locomotor information between cervical and lumbar enlargements and may 
not be essential for locomotor function under normal conditions (McClellan, 1994). 
However, in the injured spinal cord, propriospinal projections may play a part in 
compensating functions of damaged supraspinal projections (McClellan, 1994; Rouse and 
McClellan, 1997). In mice, propriospinal relay connections that bypass one or more injury 
sites are able to mediate spontaneous functional recovery and supraspinal control of 
stepping, even when there has been essentially total and irreversible interruption of long 
descending supraspinal pathways (Courtine et al., 2008). Since regeneration of short 
propriospinal tracts may be a more achievable goal compared to long-distance axonal 
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regeneration (Guest et al., 1997), their axonal regrowth across a SCI site may be very 
important for restoration of locomotor function. 
 
Locomotion on a grid requires sensorimotor coordination that allows proper placement of 
the foot on the grid bar. Descending pathways modulate locomotor function mediated by 
the lumbosacral circuitry, such as the rubrospinal tract in the dorsolateral funiculus and the 
reticulospinal tract that is more diffusely distributed in the ventral and lateral white matter 
(Zemlan et al., 1984; Jones and Yang, 1985; Brosamle and Schwab, 1997). The grid test 
shows long-term disruption, with increased footfaults, after a dorsal hemisection lesion or 
contusion that includes the dorsal columns and the CST (Grill et al., 1997). Changes in 
descending serotonergic and noradrenergic pathways and in primary afferent pathways 
could also be expected to modify locomotor function, e.g. through projections to the 
interneuronal pools comprising the central pattern generator (Mitsui et al., 2005).  
 
The somatic sensory system 
 
After SCI, there is considerable loss of sensation and there are tests in models of SCI that 
can measure recovery of sensation. The somatic sensory system can be divided into two 
major components: the mechanosensory system, for the detection of mechanical stimuli 
such as light touch and pressure, and the pain and temperature sensory system for the 
detection of painful stimuli and temperature.  
 
A diverse set of cutaneous and subcutaneous sensory receptors at the body‟s surface relay 
information to the CNS for interpretation and action. There are additional 
mechanoreceptors located in joints, muscle and other deep structures called proprioceptors, 
which relay information generated by the musculoskeletal system. Mechanosensory 
information is carried to the brain by several ascending pathways that run in parallel 
through the spinal cord, brainstem and thalamus, to reach the primary somatic sensory 
cortex in the brain. The primary ascending sensory pathways in the human are the dorsal 
column-medial lemniscus, carrying the majority of mechano and proprioceptor information, 
and the spinothalamic pathways, mediating pain and temperature sensation. In the rat brain, 
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a substantial amount of the somatic sensory cortex represents the large facial whiskers that 
provide a large part of the sensory input for rats and mice. In humans, a larger amount of 
somatic sensory cortex is devoted to the hands and face. Thus, the sensory input that is 
particularly significant to a species gets relatively more cortical representation (Purves et 
al., 2001).  
 
The cutaneous and subcutaneous sensory receptors can be subdivided based on function 
into at least three groups: mechanoreceptors, nociceptors, and thermoceptors. The 
perception of innocuous mechanical stimuli is associated primarily with myelinated Aα and 
Aβ axons that have relatively rapid conduction velocities: 70-120 m/s and 30-70m/s 
respectively (Loeser and Bonica, 2001; Djourhi and Lawson, 2004). In contrast, the axons 
associated with nociceptors conduct relatively slowly, but there are fast (about 20 m/s) and 
slow (about 2 m/s) pathways, which are commonly made up of finely myelinated Aδ axons, 
and unmyelinated C fibres (Purves et al., 2001). 
 
Upon entering the spinal cord, afferents from peripheral mechanoreceptors branch into 
ascending and descending branches, which then send collateral branches to several spinal 
segments. The majority of the incoming axons ascend ipsilaterally through the dorsal 
columns to the lower medulla, where they terminate in the gracile and cuneate nuclei 
(together called the dorsal column nuclei). Axons in the dorsal columns that convey 
information from lower limbs are in the medial subdivision of the dorsal columns, called 
the gracile tract, and information from the upper limbs, trunk and neck are in the lateral 
subdivision, called the cuneate tract. At the upper thoracic levels, the dorsal columns 
account for more than a third of the cross-sectional areas of the human spinal cord. Despite 
this, lesions to the dorsal columns of the spinal cord have only a modest effect on simple 
tactile tasks. The ability to initiate movements related to tactile exploration may be 
impaired. This relatively mild deficit is possibly due to the fact that some axons involved in 
mechanosensation also run in the spinothalamic tract (Purves et al., 2001).  
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Pain 
 
The sensation of pain is initiated by nociceptors, which are mainly „free nerve cell endings‟. 
Like somatic sensory receptors, nociceptors arise from cell bodies in dorsal root ganglia, 
sending one axonal process to the periphery and the other into the spinal cord. A variety of 
stimuli trigger afferent signals via these nerve cells. Painful stimuli are usually associated 
with tissue damage, such as from cuts or bruises. These may be caused by the release of 
pro-inflammatory substances such a prostaglandins and histamine, which enhance or 
sensitise the responsiveness of nociceptor endings. This has led to analgesic treatments 
such as aspirin, which acts by inhibiting the synthesis of pro-inflammatory prostaglandins. 
However, in some cases of nerve injury, painful sensation can last far beyond the period of 
initial damage. Chronic or neuropathic pain is experienced by a significant number of 
people living with SCI and is rather vaguely defined as “pain initiated or caused by a 
primary lesion or dysfunction in the nervous system” (Merskey and Bogduk, 1994). 
Neuropathic pain can arise from inflammation (e.g. neuritis), injury to nerve endings (e.g. 
from amputation) or nerve invasion by tumours.   
 
The main pathways that carry information about noxious stimuli to the brain are the 
spinothalamic and spinoreticular tracts and they ascend anterolaterally in the spinal cord 
white matter. Like the sensory neurones in DRGs, the centrally projecting axons of 
nociceptive neurones enter the spinal cord via the dorsal roots and branch into ascending 
and descending collaterals, called the dorsolateral tract of Lissauer. Axons in Lissauer‟s 
tract run up and down for one or two spinal cord segments and then penetrate the gray 
matter of the dorsal horn.  Once within the dorsal horn, the axons branch and contact 
neurones in several laminae. Axons from neurones in these laminae cross the midline and 
project to the brainstem and thalamus in the ventrolateral quadrant of the contralateral half 
of the spinal cord, forming the spinothalamic tract.  
 
Since the mechanosensory pathway ascends ipsilaterally in the cord, a unilateral spinal 
lesion will produce loss of touch, pressure and proprioception below the lesion on the same 
side. However, diminished sensation of pain below the lesion will be observed on the side 
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opposite to the mechanosensory loss. This helps define the level of the SCI. The 
complexity of the pathways and mechanisms involved in the perception of pain makes 
chronic or neuropathic pain difficult to treat, such that the currently prescribed analgesics 
are largely ineffective. Therefore, research focused on the reduction of chronic pain is 
essential, since this pain greatly affects the quality of life, and frequently leads to 
depression and suicide (Segatore, 1994; Cairns et al., 1996).   
The autonomic nervous system 
Individuals with SCI have identified the recovery of autonomic functions as a high priority 
for improving their quality of life (Anderson, 2004). Recovery of bladder function will be 
explored in this thesis and is discussed in more detail in chapter 6. Briefly, normal lower 
urinary tract function requires the coordinated activity of the sympathetic, parasympathetic 
and somatic nervous systems. SCI induces profound changes in bladder innervation, 
particularly afferent circuitry, morphology and structure (Beattie et al., 1993). If the SCI is 
below the thoracic level (a lower motor neurone injury) areflexia persists (Blaivas et al., 
1981; Kaplan et al., 1991). If the lesion is to the thoracolumbar region, and involves 
sympathetic preganglionic neurons, the bladder neck may also become hypoactive. 
Suprasacral (supraconal) SCI (an upper motor neuron injury) typically produces 
hyperreflexia of the smooth (detrusor) muscle of the bladder and tonic activation of the 
striated urethral sphincter. Detrusor hyperreflexia and detrusor–sphincter dyssynergia result 
from both a loss of tonic supraspinal inhibition and the emergence of aberrant spinal 
reflexes (Inskip et al., 2009). 
1.2 Pathology of SCI 
 
Traumatic SCI leads to several pathological changes, extending from minutes to years after 
the injury. The response to SCI can be divided into three phases: the acute phase, a phase of 
secondary tissue loss and a chronic phase (Bareyre and Schwab, 2003). In the acute phase, 
directly following impact, there is immediate mechanical damage to neuronal tracts from 
shearing of neuronal and endothelial cell membranes, leading to a haemorrhagic zone of 
necrosis predominantly in the grey matter due to the abundant vascularisation of this region 
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(Tator, 1995; Profyris et al., 2004). Blood flow is reduced, creating necrotic ischaemic 
conditions. Oedema of the cord develops and there is accumulation of intra-neuronal Ca
2+
 
and extracellular K
+
. These processes result in failure of normal neural function, vasospasm 
and spinal shock (Schwab and Bartholdi, 1996; Bareyre and Schwab, 2003). 
 
In the secondary phase of pathological changes, minutes to weeks after injury, there is 
expansion of the haemorrhagic front rostral and caudal to the primary injury site, 
continuing up to 3 days. This is accompanied by increased release of lipids and eicosanoid 
production, increased production of free radicals, inflammatory reactions and excessive 
release of excitatory neurotransmitters such as glutamate, thus overstimulating glutamate 
N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors and producing excitotoxic conditions. There is both necrotic and 
apoptotic cell death of neurons, oligodendrocytes and microglia. Chronic depolarization 
leads to massive influx of intracellular calcium, together with mobilization from 
intracellular stores, and activation of calcium-dependent enzymes, leading to cell death 
(Anderson and Hall, 1993; Bareyre and Schwab, 2003; Profyris et al., 2004).   
Traumatic SCI provokes a significant inflammatory response, with the recruitment of 
peripherally derived immune cells 6 h to several weeks after the injury. Continual 
activation of the immune system drives persistent inflammation, which extends in the 
chronic phase from days to years after the trauma. Apoptotic cell death continues, channel 
and receptor functions are impaired, and scarring and demyelination accompany Wallerian 
degeneration and conduction deficits (Lawrence et al., 2002).  This secondary period of 
pathology may be amenable to treatment.  
1.2.1 The cellular inflammatory response after SCI 
 
One the first aims of this thesis is to characterize the inflammatory response after SCI. An 
overview of what has been described in various SCI models is given below.  
 
The CNS has historically been considered to be an „immune privileged‟ environment due to 
its inability to mount an immune response and to process antigens. This view was 
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consistent with our understanding of the blood-brain barrier, a specialised endothelium with 
tight junctions, separating the brain parenchyma from the blood. This was initially 
considered a barrier to protect the CNS. Tissue grafts, bacteria and viruses were all 
observed to evade immune recognition when delivered to the brain parenchyma, but in the 
1920‟s it was reported that rejection of a foreign tumour did occur in the brain if it 
approached the ventricles (Galea et al., 2007). Since then, the definition of „immune 
privilege‟ of the CNS has become too ambiguous to hold up to the discoveries made in 
recent decades. We now know that the CNS has the ability to mount a well-organised 
immune response, specific to different regions of the brain and spinal cord (Trivedi et al., 
2006; Galea et al., 2007).  
 
The innate immune response 
 
The inflammatory response to trauma in the CNS involves the innate immune response, 
which is non-specific and acts as the immediate, first line of defence (Lawrence et al., 
2002; Trivedi et al., 2006). The cells responsible for the innate immune response are 
principally the white blood cells (leukocytes) and microglia, the resident macrophages of 
the CNS (Trivedi et al., 2006). All of these cells originate in the bone marrow from a 
common progenitor called the hematopoietic stem cell (Fig. 1.3). 
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Figure 1.3 Origin of inflammatory cells of the immune system. Pluripotent 
hematopoietic stem cells divide and differentiate into progenitor cells that give rise to the 
lymphoid lineage, the myeloid lineage, and the erythrocyte lineage. 
 
Blood granulocytes are the first cells to infiltrate into the injured parenchyma (Fig. 1.4), 
typically polymorphonuclear neutrophils. Approximately 100 billion neutrophils enter and 
leave the circulation daily in normal adults, outweighing production of erythrocytes by at 
least 2:1, and they usually live for only 1 or 2 days (Gallin and Snyderman, 1999).  They 
are principally phagocytic and microbicidal cells, engulfing and killing microorganisms 
(Parham, 2000).  They accumulate within hours in tissues and release their contents  
including myeloperoxidase (MPO), metalloproteases (MMPs), cytokines and chemokines, 
such as tumour necrosis factor-α (TNF-α), interleukins-1 and 8 (IL-1, IL-8) and 
transforming growth factor-β (TGF-β), which aid in loosening the extracellular matrix and 
activating resident macrophages (Profyris et al., 2004). They also generate reactive oxygen 
species that eliminate and digest invading organisms (Lawrence et al., 2002).  Not long 
after releasing their contents, neutrophils enter the process of programmed cell death and 
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following apoptosis, their debris is phagocytosed by macrophages. Neutrophils are crucial 
for the first line of response and for summoning macrophages, as well as for the re-
establishment of homeostasis. However, in the context of brain injury and SCI they are 
considered to play a significant role in lesion exacerbation, illustrated in studies showing 
that either depletion of circulating neutrophils, inhibition of neutrophil-related proteolytic 
enzyme activities, or inhibition of neutrophil adhesion, result in neuroprotection (Clark et 
al., 1996; Trivedi et al., 2006).   
 
 
Figure 1.4 Time course of acute inflammation after spinal cord injury. This schematic 
illustrates the timing after SCI, of distinct cellular events as observed from animal studies 
to date (adapted from Trivedi et al, 2006) 
 
By 48 h after injury, the recruitment of neutrophils declines (Profyris et al., 2004) and is 
followed by the entry of monocytes to the injured parenchyma, where they differentiate into 
macrophages (Popovich et al., 1997; Trivedi et al., 2006). The recruitment of monocytes 
after SCI is delayed, their numbers peaking between 7 and 14 days (Fig. 1.4). Macrophages 
are larger than neutrophils and are characterized by an extensive cytoplasm with numerous 
vacuoles (Gallin and Snyderman, 1999; Parham, 2000). Inflammatory macrophages 
proliferate and phagocytose debris. This further activates microglia, the resident 
macrophages in the nervous system (Gallin and Snyderman, 1999; Serhan and Savill, 
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2005). Activation of macrophages leads to secretion of inflammatory and potentially 
damaging mediators such as free radicals, eicosanoids, glutamate, cytokines and NOS, 
which drive leukocyte recruitment and activation. Macrophages are diverse in their 
response to injury and these same cells in non-neuronal tissues are usually self-limiting and 
considered to play a beneficial role by triggering the initiation of the resolution of 
inflammation by suppressing pro-inflammatory signalling. They can promote wound 
healing through the secretion of matrix metalloproteases (MMPs) that break down exudate, 
and of mediators that stimulate angiogenesis and even regeneration (Popovich et al., 1997; 
Lawrence et al., 2002; Serhan and Savill, 2005). In the injured spinal cord, macrophages 
accumulate chronically without any obvious benefit to recovery. Gensel et al. (2009) 
demonstrated that a single mode of activation (injection of zymosan), relevant to SCI, 
endows macrophages with the ability to simultaneously promote axon regeneration and kill 
cells. Acute non-specific depletion or inhibition of CNS macrophages is neuroprotective 
after SCI (Giulian and Robertson 1990; Blight 1994; Popovich et al. 1999; Mabon et al. 
2000), but delayed implantation of macrophages stimulated by regenerating peripheral 
nerve segments is beneficial (Ralapino et al., 1998). Given the functional heterogeneity 
exhibited by CNS macrophages, selective therapies targeting these cells may only be 
feasible and safe clinically once we fully understand the mechanisms controlling CNS 
macrophage activation after SCI (Kigerl et al., 2007). 
 
Glial cells, i.e. the microglia, astrocytes and oligodendrocytes, make up more than 70% of 
the total cell population in the CNS. Once thought of as merely a supportive system for 
neurons, glial cells are now regarded as key modulatory, trophic, and immune elements in 
the brain tissue. The main mediators of neuroinflammation are microglial cells and they 
migrate rapidly to the injury site (Banati et al., 1993; Kettenmann, 2007). Microglia express 
multiple phenotypes, with corresponding functions in tissue repair and/or damage 
(Schwartz and Yoles, 2006). In the adult CNS, they show three main phenotypes: 1) 
“resting”, with ramified processes extending in all directions from the soma; 2) activated, 
slightly larger, with retracted processes; and 3) reactive, or phagocytic, with swollen cell 
bodies and short cytoplasmic extensions (Flaris et al., 1993; Popovich et al., 1997). In the 
latter phenotype, microglia become difficult to distinguish from infiltrating macrophages 
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(Popovich et al., 1997; Schnell et al., 1999), which can make it difficult to interpret their 
potentially different roles in tissue. 
 
After SCI, microglia are activated by various ligands released at the injury site and by 
antigen-presenting cells such as macrophages, via Toll-like receptors (TLRs), a family of 
receptors first discovered in Drosophila (Anderson et al. 1985) and located on the cell 
surface. Subsequently they produce growth factors, cytokines and chemokines, start to 
phagocytose debris and express major histocompatibility complex II (MHC II) molecules. 
They may present degraded peptides on their cell surface to helper T-lymphocytes as part 
of the adaptive immune response (discussed below). Activated microglia have been 
observed, using immunohistochemistry, by the first day after SCI, to increase in number by 
7 days, then reach a plateau between 2 and 4 weeks (Fig. 1.4) (Popovich et al., 1997; 
Trivedi et al., 2006). Microglia have been implicated in necrotic and apoptotic neuronal cell 
death, through production of TNF-α, IL-1, reactive free radicals, and nitric oxide, each of 
which can be damaging to the spinal cord (Banati et al., 1993; Popovich, 2000; Profyris et 
al., 2004; Trivedi et al., 2006). 
 
Glial-fibrillary-acidic protein (GFAP) content is increased in astrocytes after SCI, in a 
process termed reactive gliosis (Schnell et al., 1999). Astrocytes form a glial scar at the 
interface with the macrophage-infiltrated destruction zone (Klusman and Schwab, 1997) 
and upregulate chondroitin sulphate proteoglycans (CSPGs), extracellular matrix molecules 
which are inhibitory to neuronal growth, although the exact mechanisms remain to be 
clarified. Astrocytes release the proinflammatory cytokine IL-1, as well as mediators that 
promote CNS repair such as brain derived neurotrophic factor (BDNF), nerve growth factor 
(NGF), ciliary neurotrophic factor (CNTF), in response to stimulation of macrophages and 
microglia, by IL-1 and TNFα (Profyris et al., 2004). Although scar formation provides a 
barrier for axonal regeneration, several recent studies have found that reduced astrocyte 
activity and astrogliosis after SCI worsened functional outcome (Faulkner et al., 2004; 
Herrmann et al., 2008; Renault-Mihara et al., 2008). Reactive astrocytes help seal off and 
isolate the necrotic core of the lesion site, re-establish the integrity of the blood-brain 
barrier, and detoxify molecules such as free radicals and glutamate (Sofroniew, 2005). 
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There are clear differences in the magnitude and timing of the innate inflammatory 
response, mainly involving monocytes, in peripheral tissues and the PNS compared to the 
CNS parenchyma, in response to the same stimulus. There are further differences between 
the brain and spinal cord, possibly due to differences in the amount of vascularisation 
(Andersson, 1992; Schnell et al., 1999). Leukocytes are noted to be preferentially recruited 
via the venous blood system and only occasionally from the arterial side. In the rat spinal 
cord, veins entering from the anterior median sulcus are almost twice as numerous as 
arteries, whereas in the rat brain there is a roughly equal proportion of veins and arteries 
(Schnell et al., 1999). The numbers of monocytes infiltrating the injury site after SCI is 
thought to be delayed and inadequate, and thus might mean there is inadequate removal of 
debris, leading to  can persistence of macrophages in the injury site after SCI without any 
improvement in recovery. 
 
In summary, after SCI, prolonged presence of macrophages and activated microglia 
indicate a state of chronic neuroinflammation. The usual outcome of inflammation is 
successful resolution and repair of tissue damage, rather than the persistence of the 
inflammatory response, when there is scarring, loss of organ function and chronic disease, 
such as in the case of atherosclerosis and rheumatoid arthritis. Understanding why there is 
persistence of inflammation might help to explain the reasons why SCI leads to many 
irreversible destructive processes. It remains unclear to what extent the relative 
contributions of the opposing functions of macrophages affect progression of secondary 
damage. The beneficial events may be overshadowed by an excessive accumulation of 
toxic molecules produced by inflammatory cells that damage otherwise intact tissue 
(Trivedi et al., 2006; Farooqui et al., 1997b). Consequently, there has been a development 
of therapeutic strategies to modulate wound repair using macrophage secretory products.  If 
after SCI, manipulation of the immune response can aid in recovery, it is a worthwhile goal 
to optimise the potential anti-inflammatory properties of compounds such as omega-3 
PUFAs (discussed later). 
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The adaptive immune response 
 
There has been evidence of the involvement of the adaptive immune response after SCI 
from observations of lymphocyte infiltration to the injury site (Popovich et al., 1997; 
Schnell et al., 1999; Sroga et al., 2003). Compared to the innate immune response, the 
adaptive immune response is delayed but more specific, due to the processes of activation 
involved. It is not clear exactly how the adaptive immune system is activated after SCI, and 
there are differences between species in the amount and time course of lymphocyte 
infiltration. This will be discussed only briefly below, since the adaptive immune system 
will not form a major part of the work covered in this thesis.   
 
Lymphocytes are smaller than leukocytes and have a life span of 1-2 months. They 
circulate in the blood and congregate in lymphoid tissues or organs such as the thymus, 
spleen, lymph nodes and adenoids. B lymphocytes (B cells) and T lymphocytes (T cells) 
are the two most important types. In mouse models, B cells have been found scattered 
throughout the site of SCI 1 – 7 days after injury (Schnell et al., 1999; Ankeny et al., 2006). 
In the area quantified, their numbers increased to several hundred by 42 days and B cells 
were found in large clusters resembling lymphoid follicles found in spleen/lymph nodes 
(Ankeny et al., 2006). There is very little known about the involvement of B cells in the 
injured cord. In a model of chronic neuroinflammation, i.e. experimental allergic 
encephalomyelitis, they are known to promote demyelination (Trivedi et al., 2006). B cells 
secrete antibodies – soluble forms of immunoglobulins that are released into the blood and 
extracellular fluid, and in particular autoantibodies which can bind CNS antigens and cause 
neuropathology in multiple sclerosis (Ankeny et al., 2006). All individuals have low 
numbers of autoantibodies present, but progression to autoimmune disease is rare 
(Popovich et al., 1996a). In contrast, in SCI, data from other laboratories has shown that B 
cells may help promote remyelination and axonal growth (Rodriguez and Lennon, 1990; 
Huang et al., 1999). These data have not been confirmed in human tissue. 
 
Activated T cells are classified according to their function. Cytotoxic T cells typically 
express the molecule CD8 on their cell surface and kill tumour cells and infected cells. T 
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cells expressing the cell surface molecule CD4
 
activate the cells they recognise, such as 
macrophages and B cells, by secreting cytokines, in the lymph node or at the site of 
infection (Janeway et al., 2005; Trivedi et al., 2006). Using immunohistochemistry, 
Popovich et al. (1997), Sroga et al. (2003) and Schnell et al., (1999) have observed T 
lymphocytes in low numbers in the uninjured spinal cord. Recruitment to the injured 
parenchyma in rat tissue after SCI occurs within the first week, in parallel with microglial 
activation and infiltration of circulating macrophages.  Since they are able to recognize 
specific antigens, such as myelin basic protein, and proliferate in response to those 
antigens, T cells have the potential for promoting more selective tissue damage than 
macrophages and neutrophils (Popovich et al., 1996a; Trivedi et al., 2006). In terminal 
human cases after SCI, very low numbers of CD8 T cells and even lower numbers of CD4 
T cells have been found in the first 10 days and up to one year after SCI, but not B cells 
(Fleming et al., 2006). Some studies have demonstrated a neuroprotective role of 
autoimmune T cells (Hauben et al., 2000a; Schwartz and Hauben, 2002). Hauben (2000a) 
demonstrated the beneficial secretion of neuroprotective factors, remyelination, repair and 
recovery after SCI following immunization with T cells in rats. However, the timing, 
number and site of implantation of T cells is crucial (Schwartz and Yoles, 2006).  
 
Individuals with SCI are highly susceptible to infection (Cruse et al., 1993) and this 
immune suppression is level-dependent, since lymphoid organs are innervated by 
sympathetic preganglionic neurones distributed throughout the thoracolumbar spinal cord. 
Therefore, a T3 SCI has been shown to impair antibody synthesis when compared to T9 
SCI, which did not (Lucin et al., 2009). Clearly, there is dysregulation of the adaptive 
immune system after SCI, but this is only recently being understood. 
 
1.2.2 The inflammatory cytokine response after SCI 
 
Cytokines are small cell-signalling proteins and can be divided into interleukins, 
interferons, the TNF family and chemokines (Janeway et al., 2005). Apart from exploring 
the cellular inflammatory response after SCI, it will be important to consider the cytokine 
response after SCI, which precedes and regulates inflammatory cell infiltration and which 
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may be amenable to treatment with omega-3 PUFAs.  Some of the more well-studied 
cytokines that are upregulated after SCI are summarized in Table 1.1.  
 
  
Cytokine DNA/mRNA/protein  Timepoint              Up/down (+/-)  
          regulated 
                                         
TNF-α    mRNA2, 7, 9   2, 3 h                    +, normal by 6 h 
   protein
5   
1, 6 h   + 
                                                                          
TGF-β           mRNA1, 3, 5, 7  24 h – 7 d, 35 d  + 
   protein
5   
24 h, 168 h  + 
 
MCP-1            mRNA
8 1
  acute - hours  +    
 
MIP-1α            mRNA2, 3  3, 24 h – 4 d, 7d  +  
   
   
 
MIP-1β            mRNA2, 3  acute - hours  +   
 
IL-6            mRNA
1, 2, 3,7, 9
   2, 3, 6 h   +, - by 24 h 
                    
CINC  mRNA
6, 8
  6h   + 
   protein
6
   4, 8, 12 h  + 
 
IL-1β            mRNA1, 2, 3, 7, 9  2 h   +, - by 24 h 
                              Protein
4
 
 
Table 1.1 Changes in cytokine mRNA and protein expression in the spinal cord 
following SCI. 
1 
= Bareyre & Schwab (2003); 
2 
= Bartholdi and Schwab (1997), 
3
 = 
Aimone et al. (2004),
 4
 = Nesic et al.,(2001), 
5
 = Tyor et al., (2002),
 6 
= Tonai et al., (2001), 
7
 = Streit et al., 1998, 
8 
= McTigue et al., 1998. 
9
=Pan et al., 2002. 
 
The release of cytokines after SCI is triggered by the binding of various injury-induced 
ligands such as heat shock proteins (HSPs), proteolytic cleavage products and extracellular 
matrix, binding to cell surface Toll-like receptors (TLR), such as TLR 2 and TLR 4 (Ohashi 
et al. 2000; Asea et al. 2002; Termeer et al. 2002). Under pathological conditions in the 
CNS, TLRs are found predominantly on microglia and macrophages (Laflamme and Rivest 
2001; Zekki et al. 2002). Following SCI, the mRNA for TLR1, 2, 4, 5, and 7 are increased 
(Kigerl, et al., 2007). Zymosan (a TLR2 agonist) or lipopolysaccharide (a TLR4 ligand)-
mediated activation of CNS macrophages causes focal axon pathology and demyelination, 
with transient loss of motor function (Popovich et al. 2002; Felts et al. 2005). However, 
TLR4 mutant and TLR2 knockout mice have impaired locomotor recovery relative to SCI 
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wild-type controls, which demonstrates that TLR2 and TLR4 are important in events which 
lead to post- SCI recovery (Kigerl et al., 2007). 
 
Cells migrate towards the site of injury along gradients of chemoattractants such as 
macrophage inflammatory proteins (MIP) α and β, and the CXC chemokine cytokine-
induced neutrophil chemoattractant-1 (CINC-1) (Bartholdi and Schwab, 1997; Parham, 
2000; Profyris et al., 2004). Blocking the interaction between specific molecules expressed 
on leukocytes which bind to the surface of endothelial cells, attenuates the inflammatory 
response in the injured spinal cord, resulting in decreased oxidative damage and lipid 
peroxidation, and leads to improved neurological function (Mabon et al,. 2000). 
 
Using in situ hybridization Bartholdi and Schwab (1997) showed that after spinal cord 
trauma IL-1β, TNFα and IL-6 were found in most cell types at the injury site 3 and 6 h after 
injury. IL-1β and TNFα have been shown to stimulate the production of each other (Pan et 
al., 2002), reaching a peak several hours after injury, but becoming negligible by 24 h. 
Binding of IL-1β and TNFα to their receptors induces the nuclear factor κ B (NFκB) 
pathway in neurones, microglia and endothelial cells, within 30 min after SCI. Active 
NFκB stimulates the production of inflammatory mediators such as reactive oxygen species 
(ROS), cytokines such as TNF-α, IL-1β and IL-6, the respiratory burst enzyme inducible 
nitric oxide synthase (iNOS), prostaglandins, arachidonic acid, proteases and endothelial 
cell adhesion molecules (CAMs) (Allan and Rothwell, 2001; Profyris et al., 2004). SCI also 
induces expression of TGF-β, although its expression is delayed compared to the pro-
inflammatory cytokines, becoming measurable from 24 h and reaching a peak at 7 days. 
The protein levels of TGF-β continue to increase during the first week following SCI, and 
this is attributed to leukocyte infiltration and secretion of cytokines at the site of injury 
(Tyor et al., 2002). TGF-β counteracts the effects of proinflammatory cytokines by down-
regulating iNOS and decreasing endothelial CAMs (Profyris et al., 2004). Monocyte 
chemotactic protein-1 (MCP-1) is a chemokine that acts on monocytes and T cells and 
expression levels for this cytokine were found to be upregulated 3 and 24 h after SCI (Allan 
et al., 2001; Aimone et al., 2004). It has been found in astrocytes, endothelial cells, and 
macrophages of rodents subjected to brain trauma, together with MIP α and β, and CINC-1 
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(Glabinski et al., 1996).  Close correlation has been found between macrophage infiltration 
and elevated levels of these chemokines (Bartholdi and Schwab, 1997; Campbell 1997, 
2003; Parham, 2000; Profyris et al., 2004). 
 
Cytokines induce vasodilation and increase the permeability of blood vessels. This slows 
the blood flow and aids the migration of leukocytes through the epithelium of blood vessels 
into the tissues (Fig. 1.5). Crossing the specialised endothelium that constitutes the blood 
brain barrier is kept to a low level under normal physiological conditions (Engelhardt et al., 
2006). On exposure to inflammatory mediators such as TNF-α, selectins and intercellular 
adhesion molecule (e.g. ICAM-1) are mobilized and delivered to the endothelial cell 
surface and bind to selectin ligands expressed on leukocytes. These interactions facilitate 
reversible cell-cell interactions such as rolling and „intravascular crawling‟ along the 
vascular endothelium (Woodfin, et al., 2010). Integrins mediate firm arrest of leukocytes 
(Parham, 2000; Trivedi et al., 1996). Diapedesis of leukocytes of the endothelium can occur 
intercellularly, through the endothelium cell-cell junctions. Real-time imaging of activated 
lymphocytes (Engelhardt et al., 2006) has allowed us to see that crossing the compromised 
blood brain barrier, for example in the experimental autoimmune encephalomyelitis (EAE) 
model of multiple sclerosis, occurs intracellularly (Fig. 1.5) and is dependent on integrins 
such as alpha4-integrins. Cells then cross the extracellular matrix, a movement facilitated 
by proteases that break down the membrane, followed by migration towards the site of 
injury (Fig 1.5; Parham, 2000).  
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selectin ligand
ICAM-1
selectin
integrin
CD31
(i) (ii)
 
Figure 1.5 Diapedesis of inflammatory cells. Upon activation by inflammatory mediators, 
endothelial cells and leukocytes express receptors on their cell surface such as CD31 and 
selectins that bind to integrins and cell adhesion molecules (e.g. ICAM-1). The 
inflammatory cells in the blood are forced to slow and roll along the endothelial surface and 
then squeeze either i) intercellularly, or ii) intracellularly, through into the infected tissue.  
 
The complement system will not be explored in this thesis, but it is also involved in the 
response to SCI. The complement system has been implicated in numerous CNS 
conditions, including traumatic brain injury (Kossmann et al., 1997; Stahel et al., 1998; 
Hicks et al., 2002; Rancan et al., 2003) and has recently been shown to be activated and 
play a role for at least 6 weeks after SCI (Anderson et al., 2004, Galvan et al., 2008; Beck 
et al., 2010). The three pathways of activation: classical, mannose-lectin binding and 
alternative, involve a series of plasma proteins which activate complement and the terminal 
pathway, i.e. the assembly of a lytic membrane complex, which can be bound to by 
phagocytic receptors on macrophages (Janeway et al., 2005). The three pathways can be 
activated by myelin (Morgan et al., 1995; Eggleton et al., 1998) and the therapeutic efficacy 
of complement inhibition has been demonstrated in stroke and brain ischemia models 
(Makrides, 1998; Barnum, 1999; Huang et al., 1999).  
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In summary, the cellular and molecular components of the inflammatory response after SCI 
are complex and remain to be fully understood. The findings described above offer some 
insight into how immunomodulation with anti-inflammatory treatments may be used to 
restore function after injury.  
 
1.2.3 Systemic response to SCI 
 
Cellular injury can release endogenous„damage‟-associated molecular patterns (DAMPs; 
Matzinger, 1994). Zhang et al. (2010) have shown that injury releases mitochondrial 
DAMPs into the circulation. Thus, apart from the inflammatory response at the site of SCI, 
there is also a significant systemic influence, where acute-phase proteins (APPs) such as 
IL-1, IL-6 and TNF-α are secreted by hepatocytes in the liver and released into the 
circulation. The processes that are influenced by these APPs, such as leukocyte 
mobilization, fever, and changes in serum levels of glucocorticoids and cytokines, are part 
of the acute-phase response (APR) (Parham, 2000; Campbell et al., 2003). The systemic 
APR promotes a return to homeostasis in most cases. However, post-trauma recovery may 
be impeded by the development of multi-organ dysfunction syndrome and chronic disease 
(Campbell et al., 2003).   
 
After SCI in the rat, the production of APPs is found to enhance the response to injury, 
increasing leukocyte recruitment, amplifying the inflammatory response in the damaged 
spinal cord and causing damage to the lungs and kidneys (Gris et al., 2008). Blocking this 
response using chemokine antagonists has been shown to lead to a corresponding decrease 
in the numbers of leukocytes recruited to the injured spinal cord and a reduction of damage 
to the blood brain barrier (Campbell et al., 2003, 2005; Davis et al., 2005). Although the 
hepatic chemokine response may not be specific to CNS injury, it opens the possibility for 
a new target for therapeutic intervention (Campbell et al., 2003). It will be interesting 
therefore, to also explore the systemic response in our model of SCI and changes after 
treatment with PUFAs. 
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1.3 Neuroprotective strategies following SCI 
 
In the last decade there have not been any major developments in the treatment of SCI. 
However, there have been several promising advances in preclinical studies, some of which 
are in the process of being translated to the clinic and will be discussed below. Surgical 
intervention is usually the first approach made after SCI, in order to stabilise and 
decompress the spinal cord, followed by rehabilitative management, but these interventions 
will not be reviewed here. It has been shown that significant functional outcome after SCI 
could depend on the protection of a small number of axons. In rodents, the sparing of just 
10–15% white matter can lead to recovery of stepping (Basso et al., 1996). Thus, 
neuroprotective strategies aim to attenuate the pathophysiological processes triggered after 
acute injury, thereby minimizing secondary damage and spread of damage. Studies which 
aim to enhance injury-induced adaptive changes (plasticity) rather than regeneration are 
also proving promising (Fouad et al., 2010). In addition, there are several novel methods of 
therapeutic delivery to the spinal cord that are being tested, such as viral vectors, 
nanoparticles and biomaterials. The following section will briefly highlight some of the 
most promising neuroprotective approaches that are being pursued. 
 
Very recently, a selection of systematic reviews was published in the Journal of 
Neurotrauma (2010). The reviews were divided into three subjects and covered non-
invasive pharmacologic treatments (Kwon 2010), cellular transplantation therapies 
(Tetzlaff 2010) and directly applied biologic therapies (Kwon BK, 2010). The review 
criteria were to select those with the most promising translational potential. A brief review 
of some of the most promising treatments will be given here. 
 
Methylprednisolone (MP), a glucocorticoid, is the only approved drug therapy for SCI and 
has been shown to inhibit reactive oxygen-induced lipid peroxidation (Hall and Braughler, 
1981), and decrease the number of neutrophils and macrophages in the injured spinal cord 
via the NFκB pathway (Bartholdi and Schwab, 1995; Klusman and Schwab, 1997; Profyris 
et al., 2004). Initial clinical results were promising, demonstrating a “modestly effective 
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therapy” when given within 8 h after SCI (Bracken et al., 1990). However, there remain 
serious concerns that the modest neurological improvements are not worth the associated 
side effects such as gastrointestinal bleeding and suppression of the immune system (Hall  
and Springer, 2004; Trivedi et al., 2006).  
 
The main pharmacological interventions for SCI which are already in a form that can be 
used in the clinic include: erythropoietin, non-steroidal anti-inflammatory drugs (NSAIDs), 
anti-CD11d antibodies, minocycline, progesterone, estrogen, magnesium, riluzole, 
polyethylene glycol, atorvastatin, inosine, and pioglitazone. Some of these will be 
discussed below. A further treatment that has potential is systemic hypothermia (Jou et al., 
2000; Yu et al., 2000; Morino et al., 2008; Lo et al., 2009).  
 
Erythropoietin (EPO), a cytokine/hormone that regulates red blood cell production, has 
been shown to be neuroprotective in a variety of models of CNS and PNS injury such as 
stroke, peripheral nerve injury and contusion or compression SCI (Gorio et al., 2002; 
Grasso et al., 2006; King et al., 2007). Evidence in our laboratory has shown that 
derivatives of EPO such as carbamylated EPO (CEPO), that lack its erythropoietic effects, 
also show neuroprotective effects comparable to that of EPO, following a unilateral 
hemisection (King et al., 2007) and elsewhere following compression SCI (Leist et al., 
2004).  
 
Ibuprofen, a NSAID which reduces RhoA activation, has recently been found to promote 
both histological and behavioural improvements in thoracic contusion SCI models when 
administered 3 days post injury (Wang et al., 2009) or 7 days post injury (Fu et al., 2007).  
 
The anti-CD11d antibody approach has been studied primarily by Dr. Lynne Weaver and 
colleagues (Gris et al., 2004; Saville, et al., 2004; Weaver, et al., 2005). The CD11d 
antibody is directed against a subunit of the CD11d/CD18 integrin that is expressed only by 
certain leukocytes such as neutrophils and monocytes. It reduces neutrophil and 
macrophage invasion, decreasing inflammation and lipid peroxidation, and improving 
tissue sparing. Behavioural outcomes revealed improved locomotion, decreased autonomic 
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dysreflexia, and reduced mechanical allodynia. Other CD11 integrins containing the 
subunits a–c have more widespread cellular distributions and antibodies directed against 
them have not been as effective as neuroprotective treatments. A 6-12 h post injury time 
window of intervention has been established, which is important with respect to clinical 
applicability.  
 
The pathogenic influx of sodium into cells after CNS injury has led to research into the use 
of sodium channel blockers such as riluzole (Ates et al., 2007). Schwartz and Fehlings 
(2001) found that rats given riluzole after compression SCI had sparing of grey and white 
matter and recovery of behavioural function. Therapeutic neuroprotective efficacy has been 
reported with a delay in intervention of 15 min (Springer et al.,1997) and 30 min 
(Stutzmann et al., 1996). Mu and colleagues (2000b) reported that with a delay of 2 h after 
thoracic contusion SCI, riluzole alone did not have a beneficial effect either histologically 
or behaviorally, but it did when given in combination with methylprednisolone. 
 
Minocycline, a second generation tetracycline and anti-inflammatory agent has been shown 
to provide significant neuroprotection and recovery of hindlimb function after contusion 
injury in rats. The drug inhibits mitochondrial cytochrome c release and reactive 
microgliosis (Teng et al., 2004). A recent study in a balloon-compression model of SCI in 
rats, showed that treatment with MC led to sparing of axons, but there was no locomotor 
recovery (Saganova et al., 2008). Other studies reported neuroprotective effects of 
minocycline (Wu et al., 2002; Wells et al., 2003). A recent study by Marchand and 
colleagues (2008) reported an attenuation of neuropathic pain after intraperitoneally 
administered minocycline. Presently, intravenously administered minocycline is under 
evaluation for the management of SCI in a phase I-II pilot study in Calgary, Alberta. 
 
Labombarda and colleagues (2002) demonstrated that the hormone progesterone is 
neuroprotective. Progesterone is produced by neurones and glia in the central and 
peripheral nervous system of both male and female individuals. It has been tested 
worldwide in models of CNS trauma. However, of the two studies that utilized contusion 
SCI injuries, the results are contradictory. One reported no histological or behavioural 
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improvement in progesterone-treated animals (Fee et al., 2007), while the other reported 
more white matter sparing and significant behavioural improvement (Thomas et al., 1999). 
 
Although pro-regenerative rather than neuroprotective strategies, the degradation of 
inhibitory chondroitin sulfate proteoglycans with chondroitinase ABC (Bradbury et al., 
2002), the neutralization of myelin-mediated inhibition of neurite outgrowth with anti-
Nogo (IN-1) antibodies (Schnell and Schwab 1990)  and the inhibition of Rho activation 
with, for example,  the Rho antagonist Cethrin® (Dergham, et al., 2002), have all been 
successfully attempted in pre-clinical studies, and some of them are at present in clinical 
studies. The positive effects of these treatments are thought to be due to regeneration of 
damaged axons but it is difficult to tell and equally possible that the behavioural 
improvements from these studies are due to compensatory sprouting of axons above the 
injury site. The main target of these agents is promotion of axonal 
growth/sprouting/plasticity by altering the inhibitory SCI environment or the response of 
axons to this environment. Yet most of the agents are tested in an acute injury paradigm, 
with immediate application at the time of injury. Separating the behavioral responses 
attributable to axonal growth versus those attributable to neuroprotection is difficult (Kwon 
et al., 2010). These studies need to be repeated with a clinically relevant therapeutic 
paradigm, along with the establishment of a clear and realistic time window of intervention 
before successful translation will be achieved. 
 
Cellular transplantation therapies used in SCI research are promising and those studied 
have included Schwann cells (Lu et al., 2007; Zhang et al., 2007), olfactory ensheathing 
glial cells (Li et al., 1997), embryonic and adult neural stem/progenitor cells (Iwanami et 
al., 2005; Alexanian et al., 2006), fate-restricted neural/glial precursor cells (Han et al., 
2004; Cao et al., 2005), and bone-marrow stromal cells (Ankeny et al., 2004). Many of 
these cell types when transplanted secrete trophic factors, which may have neuroprotective 
effects and/or promote plasticity in the spared spinal cord. Hence, it is difficult to attribute 
to one single mechanism the beneficial effects of these therapies. Nearly all cellular 
transplantation studies have been conducted in rodents, with the transplantations occurring 
1-2 weeks after SCI, since transplantations performed immediately after injury generally 
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yielded poor results. This was mostly attributed to the initial phase of the inflammatory 
response. Treatments delivered in the chronic have been rare and have often failed to yield 
functional benefits (Tetzlaff et al., 2010).  
 
There is an active search to provide better treatments for SCI patients, and although several 
novel and effective advances have been made in preclinical work, we have only just begun 
to see some of these treatments translated successfully into clinical trials in the human. One 
of the reasons for this is the complexity of the secondary degenerative response. Many 
treatments affect only one aspect of this response, and a successful treatment will probably 
have to target several of these mechanisms, i.e. possibly use a combination of the 
treatments described above. Combinatorial attempts have already been made in 
experimental models of SCI, such as the combination of cell transplants with neurotrophins 
(For review, Bunge and Pearse, 2003) or chondroitinase (Fouad et al., 2005). The main 
lesson that has been learned is that two or more treatments that are successful alone, when 
combined have complex interactions and may not act synergistically as expected.   
 
1.4 Polyunsaturated Fatty Acids (PUFAs)  
 
Fatty acids (FAs) consist of a carboxylic acid head and a long unbranched, carbon-
hydrogen tail of varying lengths, which is either saturated or unsaturated. FAs required by 
mammals can be divided into three categories: i) saturated FAs, which do not have any 
double bonds, ii) monounsaturated FAs with a single double bond, and iii) polyunsaturated 
fatty acids (PUFAs) which contain multiple double bonds. The nomenclature for FAs is 
based on the number of carbon atoms and their saturation state. Thus, docosahexaenoic acid 
(DHA) contains 22 carbons and 6 double bonds and is therefore denoted 22:6; 
eicosapentaenoic acid (EPA) has 20 carbons and 5 double bonds and is therefore, 20:5. 
PUFAs can be further categorised according to the position of the first double bond from 
the methyl end of the acyl chain. Omega-3 fatty acids such as alpha-linolenic acid (ALA, 
18:3), EPA, and DHA contain the double bond at the third carbon position from the methyl 
group and omega-6 fatty acids such as linoleic acid (LA, 18:2) and arachidonic acid (AA, 
20:4) contain the double bond at position 6 from the methyl group (Fig. 1.6).  
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Omega-6 PUFA
Omega-3 PUFA
 
Fig. 1.6 Structural formulae of common omega-3 and omega-6 PUFA  
 
Mammals are unable to synthesize PUFAs de novo, since they lack the necessary 
desaturase enzymes to introduce double bonds between carbon 1 and 9 (Salem Jr., 1989). 
Hence, they are primarily obtained directly from the diet or synthesized from the dietary 
precursors LA and ALA by a series of elongation and desaturation steps in the liver, and 
delivered by specific transporters to the brain. PUFAs such as DHA (to a lesser extent 
EPA) are located primarily in cell membranes as a structural component of phospholipids 
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and are released upon enzymatic action of phospholipases (Sprecher et al., 1995; Youdim et 
al., 2000; Igarashi et al., 2007a, b; for review, see Schwenk et al., 2010). 
 
The CNS has the second highest concentration of lipids after adipose tissue, with a large 
proportion of brain lipids being comprised of PUFAs, particularly AA and DHA (Crawford 
et al., 1981; Salem Jr, 1989; Horrocks and Farooqui, 2004). Lipids constitute 70 – 75 % of 
the dry weight of myelin (Sastry, 1985).  Normal brain function and structure has been 
proposed to depend on an optimal balance between omega-3 and omega-6 PUFAs and if 
this balance is disturbed, neurological deficits (Noaghiul, et al., 2003) and cognitive 
changes (Conquer, et al., 2000) may result, such as impaired learning in rodents (Enslen et 
al., 1991) and visual abnormalities in humans (Birch et al., 1992). Not surprisingly, 
therefore, the brain is highly resistant to dietary deficiency of PUFAs and of DHA in 
particular (Bourre et al., 1992; Rapoport et al., 2007). 
 
Replacement of omega-6 with omega-3 fatty acids, such as EPA and DHA from enrichment 
in the diet, into structural phospholipids of neural membranes influences membrane 
fluidity, membrane vesicle formation and function, membrane permeability and gene 
expression, and decreases the transcriptional activation of many genes, including adhesion 
molecules, chemoattractants, and inflammatory cytokines (Stubbs and Smith, 1984; 
Stillwell and Wassall, 2003; De Caterina and Massaro, 2005).  Lipid rafts have been 
proposed to float within the plasma membrane and influence signal transduction, trafficking 
and dynamics of receptors, enzymes and ion channels in the lipid bilayer (Tsutsumi et al., 
1995; Yehuda et al., 2002; Isbilen et al., 2006; Farooqui et al., 2007a). Lipid rafts 
incorporate and are potentially modifiable by dietary fatty acids which can increase the 
clustering of lipid raft proteins (for review, see Yaqoob and Shaikh, 2010). By a direct 
interaction with the membrane and membrane-bound proteins, phospholipid-bound DHA 
can alter the speed of signal transduction and the formation of lipid rafts.  PUFAs and DHA 
in particular, enhance neurite outgrowth, modulate neuronal signalling and 
neurotransmission and regulate gene expression (For review, see Farooqui et al., 2007a-c). 
Omega-3 PUFAs reduce neuronal excitability via background K
+
 channels (Lauritzen et al., 
2002, Chemin et al., 2005). PUFAs are agonists of transcription factors, including those of 
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the steroid/thyroid/retinoid superfamily, which includes the peroxisome 
proliferator-activated receptors (PPARs) and the retinoid-X-receptors (RXRs; for review, 
see Neerven and Mey, 2007).  In the normal and contused spinal cord, RXR and PPARs 
have been shown using immunohistochemistry, to appear in the nuclei of reactive microglia 
and macrophages but the interpretation of changes in RXR and PPARs signalling after SCI 
remains to be clarified (Genovese et al., 2005; Schrage et al., 2006; Mucida et al., 2007).  
 
1.4.1 PUFAs and Inflammation 
 
Work in several laboratories has shown that DHA and EPA have potent anti-inflammatory 
properties on a wide range of immune functions, such as lymphocyte adhesion to 
endothelial cells (Khalfoun et al., 1996), antigen presentation (Hughes et al., 1997) and 
adhesion molecule expression (Harbige, 2003), and production of proinflammatory 
cytokines such as IL-1, IL-6 and TNF-α (Caughey et al., 1996; Wu and Meydani, 1998).  
DHA and EPA can inhibit the NFκB system, thus preventing the expression of pro-
inflammatory cytokines including TNF-α and IL-1α and β, and can modulate leukocyte 
trafficking (De Caterina and Massaro, 2005; De Smedt-Peyrusse et al., 2008).   
 
Human immune and inflammatory cells are typically rich in omega-6, with LA and AA 
comprising about 30% of fatty acids present (Gibney and Hunter, 1993; Yaqoob et al., 
2000). This can affect pro-inflammatory signalling, since AA is oxidized into pro-
inflammatory  eicosanoids through three major metabolic routes: (i) the cyclooxygenase 
(COX) pathway to produce 2-series prostaglandins and thromboxanes, (ii) the lipoxygenase 
(LOX) pathway producing 4-series leukotrienes, hydroxyeicosatetraeneoic acids (HETEs) 
and lipoxins, and (iii) the cytochrome P450 (CYP) pathway to produce epoxyeicosatrienoic 
fatty acids (EETs) and hydroxylated HETEs, which are respectively primarily vasodilators 
or vasoconstrictors (Capdevila, et al., 2002a, b; Spector and Norris 2007). CYPs play a 
central role in the metabolism of endogenous eicosanoids (Capdevila et al., 1992; Oliw et 
al., 1982).  
 
48 
 
The intake of DHA and EPA, when provided in sufficient amounts, enriches the omega-3 
content of leukocytes and can modify the functional responses of immune cells and 
modulate the expression of pro-inflammatory genes and the availability of lipid mediators 
(De Caterina and Massaro, 2005). EPA (VanRollins et al., 1988) and DHA (VanRollins et 
al, 1984) are metabolised into epoxidised and hydroxylated derivatives by CYPs from rat 
liver microsomes. EPA acts as a competitive substrate to AA for COX and generates the 
less inflammatory products, 3-series prostaglandins and thromboxanes, and 5-series 
leukotrienes. DHA metabolism by LOX produces docosatrienes, protectins, maresins and 
neuroprotectins (Hong et al., 2003; Marcheselli et al., 2003; Serhan et al., 2004, 2009; 
Serhan and Savill, 2005). At the same time, the metabolism of EPA and DHA by COX and 
LOX enzymes can generate anti-inflammatory and pro-resolving metabolites such as the 
resolvins of the E and D series, respectively, which antagonise the action of pro-
inflammatory eicosanoids and are actively involved in the resolution of inflammation (Fig. 
1.7) (for review, see Serhan et al. 2005, 2008; Farooqui et al., 2007b; Calder 2010). Thus, 
evidence suggests that the generation of omega-3 fatty acid metabolites from EPA and 
DHA may provide potent anti-inflammatory protective mechanisms for preventing 
neuronal damage after trauma.  
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Figure 1.7 Anti-inflammatory effects of DHA, EPA and their metabolites after injury. 
Arachidonic acid (AA), via cyclooxygenase (COX) produces prostaglandins (PG), 
leukotrienes (LT), and thromboxanes (TB). DHA and EPA are metabolised into resolvins, 
docosatrienes and neuroprotectins. Together with DHA and EPA, these lipid mediators 
antagonise the effects of AA-derived PG and TB. Plasma membrane (PM); calcium-
dependent cytosolic phospholipase A2 (cPLA2); calcium-independent (iPLA2); secretory 
phospholipase A2 (sPLA2). Adapted from Seki et al. (2009).  
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 1.4.2 PUFAs, CNS injury and SCI  
 
After SCI, there is fast release of free fatty acids (FFA), due to the activation of membrane 
phospholipases and lipases (Anderson and Hall, 1993). After impact injury to the spinal 
cord, significant elevation of total FFAs in grey matter can occur as early as 1 min. The 
increase in total FFAs in white matter occurs later and is less marked compared with that in 
grey matter. This correlates with the progression of spinal cord trauma, which after 
contusion or compression SCI extends from gray matter to white matter. Because of the 
specific phospholipid composition of neurones, AA is the primary fatty acid released. 
Levels of free AA in the injured spinal cord can exceed 20 times the control values, 6 h 
after the initial injury (Demediuk et al., 1985a, b, 1989; Murphy et al., 1994).  Demediuk 
and colleagues (1989) demonstrated that a severe impact SCI resulted in decreased total 
phospholipid content for up to 3 days. However, there was no major class of phospholipids 
selectively hydrolyzed (Demediuk et al., 1985a; Demediuk et al., 1989; Yoshihara and 
Watanabe, 1990).  Murphy et al. (1994) reported no detectable changes in phospholipid 
levels after a severe SCI to rat thoracic spinal cord. It was suggested that the release of 
FFAs and, in particular of AA, may not always involve general membrane degradation but 
rather an up-regulation and/or overstimulation of phospholipases (Murphy et al., 1994). 
Cytosolic phospholipase A2 (cPLA2) and secretory PLA2 (sPLA2; Fig. 1.7) may be the 
primary enzymes responsible for phospholipid hydrolysis and the AA release associated 
with SCI (Keyser and Alger, 1990). As discussed earlier, AA is the major source of 
eicosanoid synthesis and therefore the high levels released after SCI are likely play a 
significant influence in the subsequent inflammatory response. 
 
In a model of transient spinal cord ischaemia in rats, the administration of an omega-3 fatty 
acid, α-linolenic acid (ALA) after injury, decreased neuronal loss and improved functional 
outcome (Lang-Lazdunski et al., 2003). In addition, DHA can counteract glutamate-
induced excitotoxicity (Wang, et al., 2003). As excitotoxicity, inflammation and oxidative 
stress are part of the pathogenetic mechanisms involved in the secondary injury associated 
with SCI, this led King, Huang and colleagues (2006, 2007a) in our laboratory to explore 
the potential of using omega-3 fatty acids as neuroprotective agents after SCI. They found 
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that a single bolus intravenous injection of ALA, or DHA ( 250 nmol/kg), within 1 hour of 
hemisection SCI, or of DHA within 30 min of compression SCI, induced significant 
neuroprotection, by reducing neuronal and oligodendrocyte cell loss at 1 and 6 weeks and 
protection of myelin in the injury epicentre.  Furthermore, locomotor function was 
improved, lipid peroxidation, protein oxidation and cyclooxygenase-2 levels were 
decreased at 24 h, and there was decreased macrophage recruitment to the spinal cord at 1 
and 6 weeks (Huang et al., 2007a). In contrast, the omega-6 fatty acid AA administered 
after injury exacerbated injury, increased the size of the spinal cord lesion, decreased 
neuronal and glial cell survival and worsened the functional outcome. We have yet to 
explore whether the neuroprotection of neuronal and non-neuronal cells extends above and 
below the injury site and whether the effect is dose related.  
 
Huang et al. (2007a) demonstrated that by adding DHA to the diet of the animals after 
injury for 6 weeks (400 mg/kg/day) led to additional improvements of the above outcome 
measures and amplified the effects of the DHA injection (Huang et al., 2007a). To explore 
the effects of increasing endogenous levels of omega-3 PUFAs, the fat-1 transgenic mouse 
has been manipulated by researchers to express the Caenorhabditis elegans fat-1 gene 
encoding an omega-3 fatty acid desaturase that does not exist in mammalian cells. This 
enzyme enables the generation of endogenous omega-3 PUFA by introducing a double 
bond, thus converting dietary omega-6 to omega-3 PUFA and leads to an abundance of 
omega-3 fatty acids in organs and tissues. Preliminary data from our laboratory suggests 
that the endogenously raised levels of omega-3 fatty acid confer resistance to injury in a 
mouse model of compression SCI. Recently, we have shown that intravenous EPA 
injection at 30 min after compression SCI in the rat is also neuroprotective, inducing tissue 
protection and better functional outcome (Lim et al., in press), although the effects appear 
to be weaker than those of DHA.  We have not yet considered the effects of enrichment of 
EPA in the diet and it is important that we explore the effects of both EPA and DHA in 
other models of SCI, apart from compression and hemisection SCI. 
 
In summary, omega-3 PUFAs are pleiotropic compounds and have been shown to regulate 
neuronal function by various mechanisms. The mechanisms are far from being fully 
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elucidated but it is evident that both structural and biochemical mechanisms play central 
roles in their actions.  Alongside these studies, a considerable amount of research has 
revealed anti-inflammatory properties of PUFA and since there is a significant 
inflammatory component to SCI pathology, the potential interaction of this response with 
PUFA needs to be explored in more detail in SCI. Our laboratory previously found that 
DHA injection led to a reduction in the amount of macrophages in the epicentre after SCI, 
but we have not yet looked at neutrophils, activation of microglia and the additional cellular 
and molecular markers of inflammation. 
 
 1.5 Models of SCI 
 
Before transfer into clinical trials, the efficacy and safety of new treatments for SCI must be 
investigated in animal models. Historically, the first experimental model of SCI, a weight-
drop procedure in dogs, was introduced by Allen nearly a century ago (1911).  Nowadays, 
rats and mice are most frequently used in SCI studies, as well as invertebrates, for 
developmental and regeneration studies. There are also various in vitro models of neuronal 
injury and SCI but these will not be reviewed here.  
 
There are various in vivo models of SCI that can be used in preclinical research, and the 
choice of these depends mainly on the questions being addressed. For example, to explore 
the regeneration/sprouting of axons or a particular mechanism of neurone-glia interaction, a 
smaller, more reproducible, „clean‟ lesion is preferred, such as a partial or full transection 
injury such as a dorsal column lesion, or a dorsal/lateral hemisection. On the other hand, in 
order to assess the efficacy of treatment for use in clinical trials, a more clinically relevant 
model of SCI should be used, such as the contusion (impact) or compression models of 
SCI. These models mimic many of the pathophysiological and morphological alterations 
observed in human SCI. 
 
The modern contusion model induces instant mechanical deformation of the spinal cord by 
dropping a controlled weight onto it (discussed in chapter 5). Compression models of SCI 
involve a static injury to the spinal cord in which either a weight is placed on the spinal 
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cord (Nystrom et al., 1988; Holtz et al., 1989, 1990a), or the tissue is compressed using a 
modified aneurysm clip (Rivlin and Tator, 1978; Fehlings and Tator, 1995). Contusion and 
compression injuries are usually severe and this means a significant amount of time is 
involved in animal care, due to loss of autonomic function, requiring manual voiding of the 
bladder 2-3 times per day.   
 
These models are not without their drawbacks. First, any SCI in an animal will be 
performed under anaesthesia, and animals will not receive the myriad of other drugs often 
required by acute trauma patients. A confounding factor to bear in mind in all of these 
studies is that there is spontaneous regeneration of the CNS in rodents, as well as other 
profound genetic and species differences in the pathology of SCI (Mills et al,. 2001; Basso 
et al, 2006; Kigerl et al., 2006).  
 
Our laboratory has used the compression model of SCI to assess the effectiveness of 
various neuroprotective treatments, such as DHA and EPA (Fig. 2.1; King et al., 2006; 
Huang et al., 2007a, b). Although there are similarities in gross histolopathological 
changes, particularly in the ventral horns and grey matter, the compression model of SCI 
differs from the contusion SCI model in the amount and duration of neuronal loss (Huang 
et al., 2007b) and in some dynamics of the inflammatory response; this is discussed in more 
detail in chapter 5. 
In summary, a substantial body of data supports the use of omega-3 PUFAs and their 
metabolites as neuroprotective and anti-inflammatory agents. The increased understanding 
of the involvement of neuroinflammation after SCI has attracted considerable interest in 
treatments which modulate its effects. It remains to be answered fully, whether treatment 
with omega-3 PUFAs has an impact on the inflammatory response after SCI. The use of 
PUFAs as treatment after SCI will be relatively easy to transfer to the clinic, due to their 
safety and minimal toxicity, but it would be extremely beneficial to have precise knowledge 
of the time course of entry of various inflammatory cells into the injured human spinal cord 
and activation of resident spinal cord cells such as microglia, and of their many actions, 
destructive or beneficial, that affect neural tissue in order to develop second generation, 
more selective treatments.  
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1.6 Aims 
 
Omega-3 PUFAs have significant potential in the treatment of SCI. However, before 
translation to the clinic, and in order to minimise the risk of translational failure, it is 
important to i) gather more information on the impact of these compounds on the very early 
events after injury, a period characterised by complex inflammatory reactions, ii) validate 
the neuroprotective effects in additional species and models of injury and finally also to iii) 
explore in more depth the various regimes of administration that could be considered for 
treatment and/or prophylaxis, and define the optimum compound, 
 
Thus, the studies that follow are divided into four chapters: 
 
I. The characterisation, using immunohistochemistry, of the cellular inflammatory 
response in the spinal cord following rat compression SCI  
II. The assessment of the effects of acute DHA or EPA injection on the acute 
inflammatory response following compression SCI 
III. The assessment of the effects of acute DHA injection in rat contusion SCI. 
IV.  The assessment of the effects of dietary treatment with EPA and DHA in rat 
compression SCI. 
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Chapter 2: Materials and Methods 
 
2.1 Spinal cord injury 
 
All experimental protocols were approved by the Animal Care Committee of Queen Mary, 
University of London, in accordance with the UK Animals Act 1986 and with international 
guidelines on animal use.  
 
Compression SCI (Chapters 3, 4, 6) 
 
Figure 2.1 The compression device. (A) T11 and T13 vertebral processes are clamped in a 
frame and (B) the compression device is lowered onto the surface of T12 (C) followed by 
the addition of a 50 g weight for 5 min (image reproduced from Huang et al. 2007b). 
 
Compression SCI was performed at vertebral level T12, following the methods described 
by Huang et al. (2007b) on adult female Sprague-Dawley rats (200-250 g; Charles-River, 
Margate, UK). Animals were deeply anaesthetized in a fume box with a mixture of 4% 
isoflurane (Meril, Essex, UK) in addition to a mixture of oxygen at a flow rate of 750–1000 
mL ⁄ min. Subsequent anaesthesia throughout the procedure was maintained using 1.5–2% 
isoflurane with oxygen delivered through a nosepiece. After checking for absence of 
hindlimb and corneal reflexes, a midline incision was made with a scalpel through the skin 
and muscle overlying the spinal column. Vertebral level T12 was located by palpation of 
the spine and ribcage: the bottom of T12 is located at the position where the last rib 
intersects the spine. A retractor was put in and all muscle was removed and ligaments 
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incised around the T12 vertebra. A laminectomy was then performed on T12 using micro-
rongeurs. Bone fragment and blood was removed using forceps and cotton buds, leaving 
the dura undisturbed. The T11 and T13 vertebral processes were left intact and clamped in 
a spinal compression frame (Fig. 2.1A), and compression was applied by suspending the 
base of the compression platform (area 2 x 5 mm, Fig. 2.1B) onto the exposed cord, under 
microscopic control. A weight of 50 g was applied statically to the platform for exactly 5 
min. Tail flick confirmed good placement of the platform. The platform and retractor was 
then removed and the injury area checked for the development of a central bruise, or 
enlargement of the dorsal blood vessel (Fig 2.2). Absence of bruising and/or tail flick was 
noted (this could occur if the platform was resting on bone that had not been removed) and 
correlated with hindlimb movement (below). The muscle layers were sutured and the skin 
layers closed with wound clips. Laminectomy, i.e. removal of the T12 vertebral bone only, 
without compression, was performed in control rats. Following surgery, animals were given 
buprenorphine intramuscularly (10-20 mg/kg; Reckitt Benckiser, UK) and 5 ml saline 
(0.9% NaCl w/v) subcutaneously. The PUFA and saline control injections were delivered 
intravenously in a tail vein 30 min after SCI. Animals were checked up to 4 h after SCI to 
confirm absence of hind limb movement and removed from the study if there was extensive 
movement of any joint. For recovery studies longer than 24 h, manual bladder expression 
was performed 2-3 times a day for the first week and at least once daily thereafter, until the 
establishment of reflex voiding. Cages were changed at least every 2 days during the first 
week. Care sheets (Appendix 1) for each animal were kept with a record of their weight and 
bladder recovery throughout each experiment. The rats were given free access to food and 
tap water and maintained on a 12 h light/dark cycle at 21 °C. 
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Figure 2.2 The injury site following compression. Development of a bruise was 
confirmed after each operation. 
 
All of the compression SCI surgery used in this thesis was performed by the author, except 
for the day 14 and day 21 tissue used in the characterisation of the baseline inflammatory 
response (Chapter 3), and the day 7 tissue used for whole section analysis for ED1 (Chapter 
4), which was performed by Dr. Wenlong Huang or Dr. Rachael Ward. The cryosectioning 
and staining of the day 7 tissue used for whole section histological assessment of ED1 was 
done by Dr. Siew-Na Lim and the analysis by Liying-Li. The day 21 tissue was cut by 
Mathuri Sakathinatasan. All surgery, sectioning and analyses were performed blinded to the 
treatment groups.  
 
Contusion SCI (Chapter 5) 
 
28 adult female Sprague-Dawley rats (205–222 g; Harlan, Houston, TX) were anesthetized 
with ketamine (80 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.), and a dorsal laminectomy was 
performed at the T8 vertebral level. Rats then received a moderate spinal contusion injury 
using the Infinite Horizons device (Precision Systems and Instrumentation, Lexington, 
Kentucky, USA) with a preset force of 200 kDynes (actual forces were 200–214 kDynes). 
The muscles overlying the spinal cord were then sutured and the skin was closed by using 
surgical clips. Animals were given 5 ml of saline and placed into warm recovery cages. 
Postsurgical care included 5 days of treatment with antibiotics (gentomicin, 5 mg/kg) and 5 
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ml saline daily for the first week to maintain hydration, and twice-a-day manual bladder 
expression until spontaneous voiding returned. All procedures conformed to NIH and The 
Ohio State University (OSU) animal care guidelines. 
 
The surgery was performed by two surgeons blinded to the treatment groups. The injections 
were delivered intravenously in a tail vein 30 min after SCI by the author. Miss. C. Amy 
Tovar, along with other trained OSU researchers, assisted the author with behavioural 
testing. Tissue was harvested at OSU and sent to our laboratory for histological analysis. 
All researchers, including the author, were blinded to the treatment groups throughout all 
experimental procedures and tissue analysis.  
 
2.2 Treatment with omega-3 PUFAs  
 
Acute i.v. injection 
 
On the day of surgery, solutions of DHA or EPA were prepared in sterile saline (NaCl, 
0.9% w/v) and adjusted to pH 7.4, from 5 μl concentrated stock aliquots kept in light 
sensitive, airtight glass containers (Agilent, Stockport, UK) at -20°C to prevent oxidation. 
The 1 M stock aliquots of fatty acids (Sigma, Dorset, UK) were prepared in a plastic 
airtight atmos bag (Sigma, Dorset, UK) under 100% N2 and were made up in absolute 
ethanol. Glass pipettes and containers were used where possible throughout to prevent 
interaction of fatty acids with, and adsorption onto, plastic surfaces. 
 
Acute DHA/EPA compression study (Chapter 4) 
 
Animals received the following treatments via a tail vein under brief isoflurane anaesthesia 
(2%): an injection of (i) saline (vehicle) (n=46; 0.9% NaCl), (ii) DHA (n=29; 250 nmol/kg), 
or (iii) EPA (n=26; 250 nmol/kg), 30 min after injury. The injection volume was 5 ml/kg. 
Animals were perfused and tissue processed as described below. Treatment was allocated 
randomly and the surgeon was blinded to the treatment groups throughout the surgery and 
the behavioural testing period. 
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Acute DHA contusion study (Chapter 5) 
 
Animals received the following treatments via a tail vein whilst still under ketamine and 
xylazine anaesthesia: an injection of (i) saline (vehicle) (n=10; 0.9% NaCl), (ii) DHA 
(n=10; 250 nmol/kg), (iii) DHA (n=8; 500 nmol/kg) 30 min after injury. The injection 
volume was 5 ml/kg and all researchers were blinded to the treatment group as described 
above. 
 
Dietary enrichment 
 
Prior to beginning the studies, the animal‟s average daily food intake was assessed over a 
two week period by providing 30 g food per day, and weighing how much was left. From 
these observations, the daily intake was 25-30 g. Between one and two weeks prior to the 
start of the studies the animals were weighed and randomly divided into groups, and the 
chow was changed from the standard pelleted form to the ground form, to allow habituation 
to the different food texture. 
The control diet consisted of 5KB3 Certified EURodent diet 14 % (IPS Product Supplies 
Limited, London; Appendix 2). The omega-3 PUFA-enriched diet used in Chapter 6 
consisted of the 5KB3 diet to which oil enriched in DHA or EPA (Incromega DHA700E 
SR; or Incromega SE7010R; both Croda Healthcare, UK) was added. The DHA oil 
contained 70–75% DHA and 10 % EPA. The EPA oil contained 70 % EPA, and 5-10 % 
DHA. The remaining percentages were made up of AA (< 5%) and other fatty acids. The 
volume of DHA or EPA preparation added to the chow calculated correspondingly, so that 
it would result in a target daily dose of 400 mg fatty acid per kilogram of animal body mass 
(Appendix 6). Oil-enriched food was prepared fresh each week under N2 and stored in 
separate bags for each day (-20 °C). The oils used for enrichment were stored at -20 °C and 
each time the bottle of stock EPA was opened, it was flushed with N2 to prevent oxidation. 
Previous measurements in our laboratory confirmed that this method of diet preparation 
retained high concentration of PUFA for several weeks, without oxidation (unpublished, 
Dyall). 30 g was allocated per rat, per day. It was changed daily between 10:00 am and 
12:00 noon, and any left-over food was discarded. Food consumption was monitored before 
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and after SCI. There were 3-4 rats per cage and the experimental groups were mixed. There 
was no significant difference in the amount of diet consumed between any of the 
experimental groups, but animals were found to consume less during the first week 
following SCI (60-70 % less). Therefore, the full dose received was recalculated based on 
these findings. The average amount of food consumed over 28 days after SCI in the EPA 
study dropped to approximately 11-13 g, i.e. a dose of 150-170 mg/kg per day throughout 
the 28 day survival period. In both DHA pretreatment studies animals consumed 
approximately 25 g before SCI (330 mg/kg). In the first DHA study, animals consumed 
approximately 20- 24 g, i.e. 270-320 mg/kg per day after SCI,  respectively.   
2.3 Behavioural analysis  
 
Open field test of locomotion:  
 
The Basso, Beattie, Bresnahan (BBB) score is a way of measuring locomotor function in 
hindlimbs following SCI (Basso et al., 1996). As long as the method is carried out 
consistently, the BBB score can be used to compare results between laboratories and to 
compare the effectiveness of different treatments. The scale ranges from the highest score 
of 21(uninjured animals with normal locomotion) to 0 (complete paralysis). Typically 
following SCI, a curve is obtained which reaches a plateau at various scores, characteristic 
of injury severity. A subscore can further be calculated from the data collected from the 
BBB score (Lankhorst et al., 1999). This can be informative when a BBB recovery curve 
reaches an artificial plateau at the time where stepping and coordination is regained, 
although recovery of finer aspects of paw placement may be overlooked. 
 
Animals were allowed to acclimatise preoperatively to the testing environment in an open 
field, which was a circular plastic enclosure (Fig. 2.3; width 88 cm, depth 30 cm; Water 
Features On-Line, Tyne & Wear, UK). This was considered to be an optimum size for at 
least four continuous steps at the time when the animals began walking, to give an accurate 
assessment of coordination. Animals were introduced to the open field on at least three 
separate occasions, either in cage groups or individually. This was essential for the 
avoidance of fear behaviour (urination, freezing, crouching during locomotion and dragging 
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hind limbs) especially at later recovery time points after SCI, which could give an 
inaccurate assessment of locomotor recovery. During testing, each rat was allowed to walk 
continuously in the open field for 4 min, while characteristics of hind limb movement 
(ankle, knee and hip) were marked on a sheet (Appendix 3). The rat was then removed from 
the open field, which was then wiped with 50 % ethanol solution and allowed to dry before 
the next rat was introduced. This was to help prevent the spread of any urinary infections 
and to remove any „fear scent‟ that might have been present in the urine and could affect 
behaviour of the animal (Basso, 2004). A BBB score was assigned for each hind limb using 
the locomotor rating scale (Appendix 4) and the score for both hind limbs was averaged. 
Following surgery, the animals‟ locomotor function was monitored every day using the 
open field test for the first 7 days and then at 10, 14, 21 and 28 days post-operation. 
 
Figure 2.3 Open field test. Animals were allowed to acclimatise to the testing environment 
before SCI. Each animal was observed for 4 min and movements related to recovery of 
hind limb and locomotor functions were recorded. 
 
2.3.1 Measurement of bladder function 
 
Data on bladder function were collected on the care sheets (Appendix 1). Each day for 7-10 
days following SCI, it was noted whether manual expression was required and whether the 
abdomen was wet, indicating incontinence. Bladder width and length measurements were 
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taken post-mortem after perfusion. The bladder was dabbed with paper towel and 
measurements taken with a ruler. The area was calculated from these. 
 
Ultrasound 
Bladder volume was measured using a high resolution portable digital ultrasound system 
(Sonosite® MicroMaxx®; BCF Innovative Imaging, Livingston, Scotland, UK) with a 
SLA/13-6 MHz 26 mm linear array transducer as described by Al-Izki et al. (2009). The 
ultrasound system acquires a high-resolution two-dimensional image from which 
volumetric calculations were made. For bladder measurements, the abdomens were shaved 
and an ultrasound gel (Alpha tube ultrasound scanning gel; BCF Innovative Imaging) was 
applied. The baseline reading was taken while the animal was anaesthetized preceding the 
SCI surgery. Following SCI, on days 3, 5 and 8, the awake animal was gently restrained, 
and the transducer was first placed longitudinally against the animal to capture the 
maximum bladder length and depth (Fig. 2.4). Next; the transducer was rotated 90° to 
capture the maximum width of the bladder. The volume of bladder urine was automatically 
calculated by the ultrasound imaging software. 
 
     
   
Figure 2.4 Images used to calculate bladder volume. The dotted line indicates the width 
(D
1
) depth (D
2
) and width (D
3
) measurements used to calculate the volume. 
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2.3.2 Measurement of mechanical hypersensitivity  
 
For behavioural assessment of tactile hypersensitivity readings were taken using an 
automated plantar aesthesiometer („von Frey‟: Ugo Basile, Italy). This consists of a 
movable actuator that lifts a blunt probe at a controlled force rate onto the plantar paw 
surface (Fig. 2.5). This rate was set at 1.7 grams/second with a cut off weight of 50 grams 
and latency of 30 seconds. This experimental set-up benefits from the removal of 
observational bias, human error, and variable force applied by the investigator using 
manual von Frey hairs. The mechanical aesthesiometer has greater accuracy (to nearest 0.1 
gram) and the weight incurred on the plantar paw increases at a linear rate from 0 to 50 g, 
whereas manual hair numbers have an exponential force increase, with large force 
differences at higher hair values between adjacent hairs. Rats were acclimatised and a 
baseline reading taken, and then tested post operatively. The probe made contact with the 
same plantar area, and increased force until the foot was voluntarily withdrawn. A positive 
response was determined as a single voluntary flexion withdrawal of the foot, with or 
without foot licking or biting, from the meshed flooring during the increasing weight of the 
probe. Each hind limb was tested 3 times, with an interval of 5 minutes to prevent 
habituation to the stimulus. Post-operative tests were performed on days 7, 14, 21 and 28.  
 
 
Figure 2.5 Behavioural testing of the rat plantar hind paw. Diagram modified from 
Takahashi et al. 2003. The area for mechanical testing is at the border of the L4 and L5 
dermatomes, avoiding paw pads, as indicated by the red circle.  
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2.4 Tissue harvesting for immunohistochemical analysis 
 
 Perfusion fixation and embedding of rat tissue  
 
At specific time points following injury, animals were euthanised using CO2 asphyxiation 
and placed on a plastic board inside a fume hood. Once the absence of corneal or forepaw 
reflexes was confirmed, a midline incision was made along the chest. Scissors were used to 
cut the abdominal wall, from mid abdomen to the xiphisternum. The xiphisternum was then 
grasped with forceps and the diaphragm trimmed away from the ribcage. The ribs were cut 
on either side of the chest cavity, exposing the heart. The sternum and ribs were then held 
back with forceps to allow easy access to the heart. The fixative delivery system was 
gravity-fed and the tap opened slightly to allow a slow flow of saline (0.9% NaCl).  A 
cannula was then inserted into the left ventricle and clamped in place. The tap was opened 
to allow full flow of saline and the right atrium cut. Once all the blood had been washed 
from the animal, judged by the lightening of the liver to a pale red-yellow colour, the tap 
was switched over to allow ~300 mL fixative (4% paraformaldehyde, pH 7.4) to flow 
through.  
 
Tissue was dissected and post fixed for 2 hr, then cryoprotected in 20% sucrose (in 
phosphate buffer, 0.1M pH 7.4) for at least 3 days. A segment of liver tissue of 
approximately 1cm
3 
and 5 mm segments containing the spinal cord lesion site, rostral and 
caudal segments, and the equivalent levels in naїve and laminectomy groups were 
embedded in OCT Embedding Medium (VWR, Lutterworth), frozen on dry ice, and stored 
at −80 ºC for subsequent processing for immunohistochemistry. 
 
Cryosectioning of Embedded Rat Tissue 
 
At least 10 minutes before use, the Leica CM 1900 cryostat (Leica, Milton Keynes, U.K.) 
was set to hold both the chamber and chuck at –12-20 °C and the temperature left to 
stabilise. Tissues were moved from the -80 ºC freezer and left in the cryostat chamber for 5-
10 minutes to warm up to -12-20 ºC before being mounted on the chuck. Rat spinal cord or 
liver sections were mounted onto the chuck using OCT Embedding Medium (VWR, 
Lutterworth, U.K.), which was left to freeze for 5-10 minutes before sectioning. 15 μm 
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thick transverse sections were cut for spinal cord, 10 μm for liver and transferred onto 
Superfrost slides (VWR, Lutterworth, U.K), and left to dry for at least 20 min. Sections 
were cut serially so that each slide contained a selection of sections throughout the lesion 
and were stored in cryoprotectant (120 ml ethylene glycol, 200 ml PBS, and 200 g sucrose) 
at -20 ºC until required for general histological staining or immunohistochemistry (IHC). 
 
2.5 Immunohistochemistry on cryosections 
 
Cryostat spinal cord and liver sections kept in cryoprotectant were removed from the -20 ºC 
freezer and the chosen slides were washed with gentle agitation in PBS (5 x 5 min). After 1 
h incubation in 10% normal donkey serum or normal goat serum, they were incubated 
overnight with the primary antibodies (Table 2.1). Preceding the application of the serum 
and SMI32 antibody, slides were immersed in ice-cold methanol and then washed in PBS.  
The next day, sections were washed and incubated for 1-2 h with secondary antibodies 
tagged either with i) fluorescein isothiocyanate or tetramethylrhodamine isothiocyanate 
(both 1:400), or ii) biotin, amplified with ABC and revealed with the di-aminobenzidine 
(DAB) method. During the course of this research, the protocol was modified slightly to 
include the use of the second generation fluorescence labelled Alexa Fluor® goat anti-
mouse or rabbit 594 or 488 secondary antibodies (1:1000-2000; Invitrogen, Paisley, UK ). 
Slides labelled with NeuN, APC, or JT1 were then counterstained with Hoechst (0.2 μg/ml) 
and then were mounted in glycerol:PBS (1:10) or in DPX after dehydration in the case of 
DAB sections, and cover slipped.  
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Table 2.1: Primary antibodies used 
 
Abbreviation 
 
Concentration 
and species 
 
Distributor 
 
Specificity 
 
ED-1 
 
1:1000 
Mouse 
 
Serotec, UK 
 
CD68 macrophages, monocytes, microglia 
GFAP 1:1000 
Mouse 
Chemicon, UK Glial fibrillary acidic protein in astrocytes         
OX-42 1:500 
Mouse 
Serotec, UK CD11b alpha subunit of Type-3 complement 
receptor (CR3) on resting and activated 
microglia/macrophages/monocytes/neutrophils 
 
Iba1 1:500 – 
1:1000 
Rabbit 
Wako, Germany Allograft Inflammatory Factor-1 (AIF1) or       
ionized calcium-binding adaptor molecule 1- a 
Ca2+-binding peptide produced by activated 
monocytes and microglial cells 
 
OX-1                           1:100
Mouse 
Serotec, UK CD45 or LCA-leukocyte common antigen on 
B lymphocytes  
 
OX19 1:100 
Mouse 
Serotec, UK CD5 molecule on T cells                                      
W3/25                           1:100 
Mouse 
Serotec, UK CD4 molecule on helper T cells  
OX-8 1:100 
Mouse 
Serotec, UK CD8 alpha on T cells, mostly thymocytes and 
majority of NK cells 
 
JT-1 1:1000 - 
1:2000 
Rabbit 
Gift from Prof H. Perry, 
Southampton 
University 
Raised against rat neutrophils 
NeuN  1:1000 
Mouse 
Chemicon.Chandlers 
Ford. U.K. 
Mature neuronal cell bodies 
SMI32 1:1000 
Mouse 
Sternberger Monoclonals, 
Leeds, UK 
Non-phosphorylated neurofilament 
APC 1:200 
Mouse 
Calbiochem, USA Adenomatous polyposis coli tumour 
suppressor protein on oligodendroctyes 
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2.6 Quantification of histological markers 
 
All analyses were performed blinded. Regions from at least three sections per animal were 
used for quantification or measured and data expressed as means ± S.E.M.   
 
Neutrophils  
 
Tissue sections were viewed on a Nikon Eclipse 80i fluorescence microscope using a 40x 
objective. The quantitative analysis of neutrophils in all groups and time points in spinal 
cord tissue was conducted by counting all labelled cells within the field of view in areas of 
the dorsal horn (DH) and ventral horn (VH), dorsal columns (DC) and ventrolateral white 
matter (VLWM; Fig. 2.1). The equivalent spinal cord region was identified on sections for 
each animal for accurate comparison. All cells within and touching the edge of the field of 
view were included. In the liver, a grid was placed over three sections per animal in 
Photoshop; three random areas were selected and then identified under the 20x objective 
and labelled cells counted.  
 
ED1 and Iba1 - macrophages/microglia 
 
Images were taken using a MBF CX9000 camera and Stereo Investigator software. Figures 
were prepared using Adobe Photoshop. For the time course study, the ED1 
immunoreactivity of macrophages/microglia in the epicentre was quantified in the areas of 
the spinal cord shown in Fig. 2.6 using the Q-Win software. A measuring frame (ED1: 360 
x 288 µm; Iba1: 288 x 216 µm) was placed over the area of interest and a binary image 
representing areas of immunoreactivity was then created. Any areas covered by significant 
tears or holes were measured and eliminated from the total area measured. The level of 
immunoreactivity was expressed as the percentage of the area of the measuring frame that 
contained immunoreactivity (field detected area, FDA).  
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dorsal column (DC)
dorsal horn (DH)           
ventral horn (VH)
ventrolateral white matter (VLWM)
 
Figure 2.6 Diagram illustrating areas where ED1 and Iba1 quantitative analysis was 
performed (image outline adapted from Paxinos and Watson, 1997)  
 
Due to the observation of unequal localisation of isolated ED1-labelled clusters of cells, the 
analysis in the subsequent chapters was performed in the epicentre and rostral segments 
with Q-Win using the whole section as shown in Fig. 2.7. An outline was drawn around the 
section, and a binary image created. The level of immunoreactivity was expressed as the 
percentage of the area of the outline that contained immunoreactivity (field detected area, 
FDA). This method has been identified as one of the best to represent the amount of 
macrophages in the injury site after SCI (Donnelly et al., 2009). 
 
 
Figure 2.7 Q-Win whole section analysis of ED1 immunoreactivity. (A) Montages of 
transverse section of the spinal cord labelled with ED1 were created. (B) In the Q-Win 
programme, an outline was drawn around the section and the images converted to a binary 
mode (C) The level of immunoreactivity was set, shown in red, and this information 
converted to the percentage labelling of the image outline.  
 
 
 
69 
 
NeuN neurones and APC oligodendrocytes 
 
Various automated methods were attempted to count NeuN- and APC- labelled cells. 
However, the automated method poorly reflected the numbers from a manual count in the 
boxed areas of interest. A manual method was therefore used. High power images (20 x 
objective) were taken in the areas shown in Fig. 2.6 and 2.8. To maintain consistency with 
previous work in the laboratory, boxes of specific sizes were used. For NeuN:  a 216 x 173 
µm box in the DH and 360 x 288 µm box in the VH (Fig 2.6) was placed over the image as 
shown. For APC: 360 x 288 µm box in the DC, LWM and VWM areas, and a 216 x 360 
µm box in the CST (Fig. 2.8) was used. Inclusion criteria were any NeuN- or APC-labelled 
cells containing Hoechst-stained nuclei within the box or touching the bottom and left hand 
boundary of the box, whereas cells in contact with the other two boundaries were excluded. 
Where possible, counts were expressed as a percentage of the equivalent naïve animal 
tissue counts in the same areas at an equivalent spinal level. 
 
 
Figure 2.8 Quantification of APC-labelled oligodendrocytes. High power images of the 
white matter were taken in the boxed areas shown and counts were obtained of labelled 
cells containing a nucleus. 
 
SMI32 neurofilament 
 
High power images (40 x objective) were taken in specific areas (Fig 2.9A). A 360 x 288 
µm box DC, VWM and VLWM and a 80x80 µm box was placed over the CST (due to the 
different size of particles in this area, see chapter 6) areas. In the Image J programme (Fig. 
2.9 B), these images were converted to a set threshold for all images (Fig. 2.9C) and then 
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counted automatically using the „analyse particles‟ programme. Any sections with high 
background noise to signal ratio were given an altered threshold to best represent the 
staining seen. The treatment groups were blinded until the analysis was complete. 
 
A
 
 
Figure 2.9 Image J analysis of SMI32-labelled axons. High power images were taken in 
the areas shown in (A). In the Image J programme, these images were converted to a set 
threshold for all images (B, C) and then counted automatically using the „analyse particles‟ 
programme.  
 
2.7 Tissue harvesting for protein analysis 
 
Animals were given an overdose of sodium pentobarbital (Euthatal, Merial Animal Health 
Ltd, Essex). This method was used in preference over CO2 asphyxiation, in order to have 
more time for the collection of blood from the animal before death. It was found that blood 
coagulated too quickly when collecting it after CO2 asphyxiation. Once the absence of 
corneal or forepaw reflexes was confirmed, the heart was exposed as described above. 
Blood was collected using a needle (21G) from the left ventricle into a 5 ml syringe 
containing sodium citrate, transferred to a plastic tube and placed on ice until 
centrifugation. A segment of liver of approximately 1cm
3
, and 5 mm tissue segments 
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containing the spinal cord lesion site or equivalent level in naїve animals and laminectomy 
only animals, were rapidly dissected and frozen on dry ice. Blood was spun at 12 000 g for 
15 min at 4°C. The plasma layer was collected and transferred to fresh microfuge tubes and 
stored at -20 °C. Plasma samples were used for cytokine analysis (see below). The red 
blood cell pellets were sent to the University of Stirling (Prof. Gordon Bell) for lipid 
analysis. 
 
Protein Extraction  
The liver tissue and spinal cord epicentres were homogenized on ice in 700 µl lysis buffer 
(1% Nonidet-p40, 200 mM HEPES, pH 7.4, 100 mM NaCl, 100 mM NaF, 1 mM Na3VaO4, 
5 mM EDTA with 1x protease inhibitor cocktail; Roche Diagnostics, Burgess Hill, UK).  
Homogenates were centrifuged for 15 min at 12 000 g  at 4°C and the supernatants were 
retained and assayed for protein content using the bicinchoninic acid (BCA) protein assay 
kit (Pierce, Thermo-Fisher Scientific, Cramlington, UK), against bovine serum albumin 
standards.  
 
Cytokine Multiplex Assay 
 
All reagents were purchased from MesoScale Discovery (MSD, Gaithersburg, USA) unless 
otherwise stated and the assays were performed as described in the manufacturer‟s 
instructions (sensitivity: 12.5 pg/ml). On the day of the analysis reagents were brought to 
room temperature. 25 μl of recombinant calibrators were diluted in Rat Serum Cytokine 
Assay Diluent, to generate a standard curve from 2500 ρg/ml followed by 4-fold serial 
dilution. The same homogenate buffer that was used to prepare the spinal cord and liver 
samples was used to dilute the standards. 25 μl of Rat Serum Cytokine Assay Diluent was 
dispensed into the bottom of each well of a 96-well MULTI-SPOT MSD plate containing 
capture antibodies, in order to cover the entire bottom. The plate was sealed with parafilm 
and incubated for at least 30 minutes with vigorous shaking on an agitator at room 
temperature. 25 μl of either calibrator or sample solution was dispensed into a separate well 
of the MSD plate. The plate was sealed and incubated with vigorous shaking for 2 hours at 
room temperature. The plate was washed 3 times with PBS + 0.05% Tween-20. 150 μl of 
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Read Buffer was added to each well of the MSD plate taking care to avoid bubbles in the 
fluid, which could interfere with reliable reading of the MSD plate. The plate was read and 
analysed on the SECTOR
TM 
Imager. Once the range of the standard curves used for 
calculating relative values was confirmed to be linear for each cytokine/chemokine, raw 
readings were converted to pg/ml of serum or pg/mg total protein for liver and brain. 
 
C-Reactive Protein (CRP) Measurement  
 
The quantitative measurement of CRP in the rat plasma was performed using a commercial 
rat CRP ELISA kit (BD Biosciences, Oxford, UK). Plasma samples were diluted to 1:4000 
and 100 µl of each sample was allowed to react with antibodies coated on specially treated 
microplate wells for 30 min. The wells were then washed to remove unreacted plasma 
proteins, and an enzyme-labeled rabbit anti-rat CRP (conjugate) was then added to react 
with and tag the antigen-antibody complexes for 30 min. The wells were then washed again 
to remove unreacted conjugate. A urea peroxide substrate with tetramethylbenzidine 
(TMB) as chromogen was added to initiate colour development. Development of a blue 
colour indicated a positive reaction while negative reactions appeared colorless or with a 
trace of blue. The reaction was interrupted with a stop solution that turned the blue positive 
reactions to yellow. Negative reactions remained colourless or with a hint of yellow. Colour 
intensity (absorbance) was read at a wavelength of 450 nm on a spectrophotometer. 
Quantification of absorbance was accomplished using a standard curve generated by 
measuring twofold dilutions of the standard provided. 
 
Myeloperoxidase (MPO) Assay 
 
The extent of neutrophil infiltration/activation was estimated by measuring the MPO 
activity. During the first 72 h after SCI, neutrophils constitute the greatest portion of MPO-
positive cells (Taoka et al. 1997; Saville et al. 2002). For measurement of MPO activity, the 
spinal cord homogenates from the tissue collected as described above, were allowed to 
thaw on ice and 25 μl samples from each animal were assayed individually in duplicate in a 
96-well plate. The reaction was started by adding 0.1 ml of sample and 100 μl TMB 
(Sigma, UK). Absorbance was measured at 620 nm at 15 and 60 min and MPO activity was 
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determined by comparing the reaction rate in the samples with the rate of reaction plotted 
against the standard human leukocyte MPO curve from serial dilutions (0-12.5 U/ml in 
homogenate buffer; Sigma, UK). Results are expressed as units per gram of tissue. 
 
2.8 Statistical Analysis 
 
All statistical tests were performed using GraphPad Prism version 5 (GraphPad Software 
Inc., San Diego, CA, USA). The data are presented as means and standard error of the 
means. BBB data were analyzed using one-way or two-way analysis of variance (ANOVA) 
with Tukey‟s or Bonferroni‟s post hoc comparisons, or independent t tests. Differences 
were considered significant when p < 0.05. The Fisher Exact Test was performed using a 
Fisher Exact Test online calculator. 
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Chapter 3: Results I. Characterisation of the cellular inflammatory 
response following compression spinal cord injury 
 
 3.1 Introduction 
 
One of the first characterisations of the inflammatory response in the CNS following injury 
was made by Perry et al. in 1987, where a comparison was made between the responses of 
the optic nerve in the CNS versus the sciatic nerve in the PNS, to a forceps crush injury. 
The contribution of the inflammatory response to axonal pathology began to be questioned 
at this point and the idea of inflammation as a bystander event was challenged. The debate 
over the relevance of the role of the immune system in recovery after CNS injury began to 
take shape in the 1990‟s and has become more and more complex, with the emergence of 
divergent roles, particularly attributed to macrophages.  
  
Most descriptive characterizations of the inflammatory response have been carried out in 
rodent models of SCI such as crush or contusion (Popovich et al., 1997; Zhang et al., 1997; 
Sroga et al., 2003). It quickly became clear that the inflammatory response following SCI 
involves a dynamic interaction between endothelium, blood vessels, neurones and glia, as 
well as the infiltration of blood-derived (haematogenous) monocytes. More recently, the 
mobilisation of blood-derived cells from the bone marrow has been shown to be influenced 
by a systemic response to injury in the liver and enhanced by signalling from the injury 
epicentre (Campbell et al., 2003, 2005). Differences were discovered between species and 
even between strains of the same species, primarily in the timing of the entry and 
composition of cell types in the injury epicentre at acute and chronic time points after SCI. 
Specifically, neutrophils accumulate within the lesion over the course of hours to days, and 
in most species are rapidly cleared during the first week post-injury. In mice, elevated 
numbers of neutrophils may persist in the lesion for months (Kigerl et al., 2006). In rats, 
lymphocytes start to infiltrate the lesion alongside monocytes 3-7 days post-injury. In 
contrast, lymphocyte entry is delayed in humans and mice, with peak numbers evident after 
a delay of months post-injury (Sroga et al., 2003; Kigerl et al., 2006). Unique to mice is the 
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formation of a dense connective tissue matrix in the lesion in parallel with lymphocyte 
accumulation (Popovich et al., 1997; Fleming et al., 2006; Kigerl et al., 2006; Sroga et al., 
2003; Donnelly et al., 2007). We need to understand the importance of these differences 
and the relative contributions of each cell type in order to develop effective treatments.  
 
3.1.1 The acute neutrophil response (minutes to hours) 
 
There appears to be agreement between laboratories that following SCI there is an 
immediate up regulation of pro-inflammatory cytokines and chemokines, e.g. TNFand 
IL-1by damaged neurones and glia at the injury epicentre, followed by the rapid entry of 
neutrophils (Bartholdi and Schwab, 1997; Bareyre and Schwab, 2003; Aimone et al., 2004). 
The molecular cytokine and chemokine response will be covered in more detail in the next 
chapter. Neutrophils are important for the removal of debris but regarded as cytotoxic 
following CNS injury. Perhaps due to this, their actions are short-lived and most 
neutrophils undergo programmed cell death within 48 h (Lawrence et al., 2002). Several 
laboratories have attempted to block neutrophil infiltration with the use of nitrogen mustard 
(Taoka et al.,  1997), or antibodies directed against integrins such as CD11d (Bao et al., 
2004, 2005; Fleming et al., 2008, 2009) or adhesion molecules such as P-Selectin (Taoka et 
al.,  1997). Such molecules are expressed by neutrophils and aid in their diapedesis of the 
blood-brain-barrier. All of these studies found reduced neutrophil infiltration along with 
improved motor outcome. The consensus seems to be that reducing neutrophil infiltration is 
advantageous after SCI. 
 
3.1.2 The chronic macrophage/microglial inflammatory response (hours to days) 
 
The infiltration of neutrophils is followed by the delayed entry of monocytes in the injured 
parenchyma around 3 days, where they differentiate into macrophages and numbers peak 
between 7 and 14 days (Popovich et al., 1997; Trivedi et al., 2006). Macrophages persist at 
the site of injury and are functionally heterogeneous and diverse in their response to injury. 
Their actions in non-neuronal tissues are usually self-limiting and have been considered to 
play a beneficial role, which includes triggering the initiation of resolution of inflammation 
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by suppressing pro-inflammatory signalling (Serhan and Savill 2005). Interestingly, it has 
been demonstrated that implantation of activated macrophages that have been exposed to 
peripheral nerves leads to regrowth of the transected optic nerve and partial recovery from 
spinal transection (Lazarov-Spiegler et al., 1996; Rapalino et al., 1998). These experiments 
originated from the theory that early and robust invasion by macrophages may be one of the 
reasons why axonal regeneration is more effective in the PNS than in the CNS. It has been 
shown in pre-clinical models of SCI that blocking or reducing acute macrophage 
accumulation at the injury site using chlodronate or integrin antibodies is beneficial to 
functional recovery (Blight et al., 1994; Popovich et al., 1999; Gris et al., 2004; Bao et al., 
2004, 2005; Fleming et al., 2008, 2009). 
 
The divergent effects of the experiments described above can be explained in part by 
manipulation of different macrophage subsets. It has recently been shown that neurotoxic 
“classically-activated” pro-inflammatory (M1) macrophages dominate the lesion within one 
week following SCI and that these cells overwhelm a comparatively smaller and transient 
“alternatively-activated” (M2) macrophage response (Kigerl et al., 2009).  The M1 
macrophage phenotype persists at the injury site for several weeks. One possibility is that 
depletion or alteration of the M1 subset is responsible for the improved recovery reported in 
some studies. In vitro, the M1 and M2 macrophages exert distinct effects on neurone 
survival and axon growth. In the presence of media conditioned by M1 or M2 macrophages 
(MCM), dorsal root ganglion (DRG) neurones exhibit distinctive growth characteristics. 
M1 macrophages stimulate a sprouting growth response that is often associated with pain in 
vivo, whereas M2 macrophages stimulate long distance axon growth. The mechanisms that 
control these divergent macrophage functions at sites of injury are not understood (Kigerl et 
al., 2009). 
 
Microglia, the resident macrophages of the CNS, have been shown to respond immediately 
to SCI and migrate rapidly to the injury site (Banati et al., 1993; Kettenmann, 2007). It has 
also been shown that infiltrating monocytes from bone-marrow differentiate into microglia 
(Soulet and Rivest, 2008). Microglia express multiple phenotypes with corresponding 
different functions in tissue repair and/or damage (Schwartz and Yoles, 2006). In the adult 
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CNS, they show three main phenotypes: 1) “resting”, with ramified processes extending in 
all directions from the soma; 2) activated, slightly larger, with retracted processes; and 3) 
reactive, or phagocytic, with swollen cell bodies and short cytoplasmic extensions (Flaris et 
al., 1993; Popovich et al., 1997). As mentioned previously, in the latter phenotype, 
microglia become difficult to distinguish from infiltrating macrophages (Popovich et al., 
1997; Schnell et al., 1999). Thus, it is not clear what the ratio is of blood-derived versus 
resident macrophages that remain in the epicentre and spread above and below the initial 
injury site at later time points. Also, their exact contribution to toxicity or to wound healing 
remains to be fully understood.  
 
Attempts have been made to isolate the haematogenous derived macrophages from resident 
microglia/macrophages. Recently, Schecter et al. (2009) used irradiation-induced bone 
marrow chimeric mice, with GFP-labelled bone marrow specific to monocytes. This 
allowed labelled blood-derived leukocytes to be identified at later time points after SCI. 
They found that the spatial organization of the infiltrating myeloid progenitor cells around 
the lesion site has a direct impact on functional recovery. In another study, this group have 
shown that infiltrating monocyte-derived cells mediate a function essential for repair that 
cannot be provided by resident microglia during SCI (Shechter et al., 2009). It is clear that 
the macrophage response after SCI is heterogeneous, and that a more in-depth analysis will 
be required when assessments of the impact of treatments on the SCI inflammatory 
response are made.  
 
3.1.3 The chronic lymphocyte immune response  
 
Research in multiple sclerosis has consistently shown the pathological potential of 
neuroantigen-reactive T and B lymphocytes, particularly those that recognize and mount 
reactions against myelin proteins (e.g. myelin basic protein; MBP). These are autoimmune 
responses which amplify the CNS macrophage response, resulting in blood-brain barrier 
injury, toxicity to oligodendrocytes and neurones and loss of function (Benveniste et al., 
1997; Schroeter and Jander, 2005; Donnelly et al., 2007). There is a growing body of 
evidence in animal models and human SCI supporting the idea that traumatic or ischemic 
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CNS injury can trigger pathological autoimmunity (Popovich et al., 1996a; Jones et al., 
2002; Fee et al., 2003; Gonzalez et al., 2003; Ankeny et al., 2006). Using transgenic mice 
and rats vaccinated to expand MBP-reactive T cells, Jones et al. (2002) have shown that 
autoimmune reactions exacerbate demyelination and axonal pathology, increasing the size 
of the contusion lesion and causing loss of supraspinal neurones. Mice and rats without T-
lymphocytes (RAG knockout and athymic nude rats) have attenuated neuropathology after 
TBI and SCI (Fee et al., 2003; Potas, et al., 2006). Also, antibody-mediated blockade of 
lymphocyte chemokines inhibits T cell infiltration and attenuates secondary injury after 
SCI (Gonzalez et al., 2003). In parallel to T cell activation in the adaptive immune 
response, there is usually activation of B cells and both generate antibodies. Some of these 
are autoantibodies against CNS antigens. The presence of autoantibodies directed against 
CNS antigens has been confirmed in human serum samples from chronic SCI individuals 
(Hayes et al., 2002) and in a mouse model of contusion SCI (Ankeny et al., 2006). 
Schwartz and colleagues have challenged the view that autoreactive T cells are destructive 
to neurones, stating that autoreactive T cells, specifically those responding to myelin 
proteins, have the potential to control the pathological immune response following CNS 
injury, but do so inefficiently (Moalem, et al., 1999; Hauben et al., 2000a; Schwartz and 
Kipnis 2001, 2002). They have supported this concept by demonstrating that passive or 
active immunization with autoimmune T cells directed against the MBP antigen limits 
secondary neurodegeneration in injured optic nerve (Moalem, et al., 1999 and contused 
spinal cord (Hauben et al., 2000a). As a result, they propose therapeutic vaccines to treat 
SCI and TBI (Schwartz, 2001; Donnelly et al., 2007). Clearly, our understanding of 
lymphocyte functions in the injured nervous system is incomplete. 
 
Most studies on the inflammatory response following SCI have been in the hemisection, or 
contusion models of SCI. Differences have been found between strains of rat and mouse, 
and between models. For example, the peak timing of the accumulation of macrophages 
varies from 3 to 7 days in a hemisection or contusion model in the rat (Table 3.1), whereas 
the peak of neutrophil infiltration remains similar at 1 day. There are further differences in 
the timing of lymphocyte infiltration (Table 3.1). Therefore, it is essential that a 
characterisation is carried out in our model of SCI, in order to establish a „baseline‟ for 
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infiltration of inflammatory cells and define the optimum time line in which to assess the 
effects of fatty acids. 
 
Table 3.1 Timing of infiltration of inflammatory cells to the spinal cord after SCI in different 
models 
    dpi peak:  
                         
study species model neutrophils 
macrophages/ 
microglia lymphocytes 
 
Kigerl (2006)* 
 
mice           
(4 strains) 
 
T9 contusion 
 
7 
 
14&42 
 
14&42 
Bao (2005) rats (Wist) T4 clip 
compression 
1 3 - 
Carlson (1998) rats           
(L.E.) 
T10 contusion 1 2 - 
Dusart & Schwab 
(1994) 
rat T9 dorsal 
hemisection 
1 3 3 
Popovich 
(1997)** 
Rat              
(SD & Lew) 
T8 contusion - 7 7 (SD), 3 (Lew) 
Schnell (1999) mice 
(C57/BL6) 
T8 dorsal 
hemisection 
1 4 2 
Sroga (2003) rat (Lew) & 
mice 
(C57/BL6) 
T8 contusion 
T9 contusion 
- 
- 
7 
7 
1 
56 
Zhang (1997) rat (SD) T8 crush 1 3 - 
*One strain of mouse had a significantly more reduced and delayed lymphocyte & macrophage infiltration 
than the 3 other strains.                                                                                                                                        
** The Lewis strain had a prolonged increase in macrophages/microglia at 28dpi AND 4-8 mm rostral and 
caudal to the epicentre, when the amount dropped in the SD strain at the same time points.  
dpi: days post SCI; Wist: Wistar; L.E.: Long Evans; SD: Sprague Dawley; Lew: Lewis; (-) not 
quantified. 
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3.1.4 The systemic response following SCI 
 
In parallel to the inflammatory response at the site of SCI, there is also a significant 
systemic influence from increased levels of proinflammatory cytokines such as IL-1, IL-6 
and TNF-α in the circulation, which are collectively termed acute-phase proteins (APPs) 
and are secreted by hepatocytes in the liver. The changes that are influenced by these APPs, 
such as leukocyte mobilization, fever, and changes in serum levels of glucocorticoids and 
cytokines, are part of the acute-phase response (APR) (Parham, 2000; Campbell et al., 
2003). As a result, post-trauma recovery may be impeded by the development of multi-
organ dysfunction syndrome and chronic disease (Campbell et al., 2003, 2005; Davis et al., 
2005; Gris et al., 2008).   
After SCI or brain injury in the rat, the production of certain chemokine APPs such as 
CINC-1 and CCL2 is found to enhance the response to injury, increasing leukocyte 
recruitment. Blocking this response using chemokine antagonists has been shown to lead to 
a corresponding decrease in the numbers of leukocytes recruited to the injured spinal cord 
or brain. This has challenged the dogma that local chemokines at the site of injury attract a 
circulating population of phagocytes from the blood up a concentration gradient (Campbell 
et al., 2005). Although the hepatic chemokine response may not be specific to CNS injury, 
it opens the possibility for a new target for therapeutic intervention. It will be interesting 
therefore, to also explore the systemic response in our model of SCI and changes after 
treatment with omega-3 PUFAs. 
81 
 
3.1.5 Aims 
 
The aims for this chapter were to characterize the inflammatory response in our 
compression model of SCI over several time points and to compare our findings to the 
published literature. We hoped to identify the most accurate methods of quantification of 
various parameters of the inflammatory response in order to assess the effects of fatty acid 
treatment on SCI inflammation in subsequent chapters. This would help us to identify 
specific actions of fatty acids and also help us understand the contribution of the 
inflammatory response to recovery after SCI. 
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3.2 RESULTS 
 
 3.2.1 Neutrophils infiltrated the epicentre 4 h after SCI  
 
The most commonly used way to quantify neutrophils is to use a general cellular 
marker/stain, for example cresyl violet and to identify and count cells containing a lobed 
nucleus, characteristic of these leukocytes. However, this stain marks all cell nuclei and it is 
difficult to obtain an accurate estimate. Alternatively, the amount of myeloperoxidase 
(MPO) released by neutrophils in the tissue can be quantified by western blot. This is a 
good indicator of neutrophil activity; however it may not be the most accurate 
quantification or specific for CNS neutrophils in a heterogeneous homogenate.  We have 
been able to obtain a more specific polyclonal rabbit antiserum against murine neutrophils, 
generated in Professor H. Perry‟s laboratory. The epitope has not yet been characterized but 
has the same staining characteristics as MBS-1 (Cunningham, et al., 2005; Teeling et al., 
2007). Western blot analysis on spinal cord homogenates consistently reveals a dominant 
band of 65kDa (Fig 3.1).  
   
65 kDa
naïve    lami SCI
 
GAPDH
 
Fig. 3.1 Western blot analysis of the JT1 antibody in the SCI epicentre at 24 h. There 
was a dominant band of 65 kDa, which increased in density following SCI. 
 
In order to validate this neutrophil marker (JT1), high power confocal images were taken to 
distinguish between cells with lobed nuclei or cells with a rounded, single nucleus. Fig. 3.2 
shows neutrophils in blood vessels in a section of the spinal cord 4 h after SCI (A, C) and 
penetrating the meningeal layer and parenchyma at the site of SCI (D). 
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The JT1 antibody was optimised using a biotinylated secondary antibody, ABC 
amplification and the DAB method, and similar profiles of neutrophils were seen in 
adjacent sections labelled with immunofluorescence (IF). However, in 4 h and 1 d tissue, 
because of haemorrhage into the injury epicentre from damaged blood vessels, the presence 
of red blood cells made it very difficult to distinguish them from the slightly larger 
neutrophils (Fig. 3.2B). Therefore, the immunofluroescence method was chosen and 
quantification was performed on tissue labelled with JT1. 
 
Figure 3.2 Neutrophils in the epicentre at 4 h. Only cells with lobed nuclei are labelled 
with JT1 (green, arrows, A), whereas other mononuclear cells are labelled with the 
macrophage marker ED1 (red, A). Using the DAB method it was difficult to distinguish 
labelled neutrophils (arrows) at this time point from red blood cells in the background (B). 
Using immunofluroescence, neutrophils were seen attached to blood vessels (C) and 
traversing into the injury site (D). Scale bar = 5 μm (A), 20 μm (B), 100 μm (C, D). 
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Examples of representative sections of SCI and sham laminectomy control tissue in the 
ventral horn area of the epicentre are shown in Fig. 3.3A-D. The inset in Fig. 3.3C shows 
an example of a typical neutrophil with multilobed nucleus. Detailed quantification of 
neutrophils in the epicentre (Fig. 3.4) revealed a significant influx of neutrophils to the 
dorsal horn and dorsal columns within 4 h, spreading to the ventral horns within 1 day, the 
response reaching a peak at 1 day. Only 1 or 2 neutrophils were found 7, 14, 21 and 28 days 
after SCI, as well as in control laminectomy or naïve tissue. 2 way ANOVA revealed a 
significant time (F=23.64) but not region (F=1.67) effect.  
 
Figure 3.3 Neutrophil infiltration in the ventral horn. (A) A sham control section of the 
spinal cord, with absence of neutrophils (JT1 staining) representative of all time points. (C) 
Neutrophils distributed extensively in the same area of the spinal cord at 24 h. Inset shows 
high power confocal image of a neutrophil (JT1, green) with characteristic multilobed 
nucleus (HO-Hoechst, blue). (B & D) show respective Hoechst-labelled nuclei on the same 
sections as A & C. Scale bar = 100 μm. Figure reproduced from Hall et al., (in submission).  
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Figure 3.4 Time course of neutrophil infiltration.  Detailed quantitative analysis of 
neutrophils in the epicentre. At 4 h neutrophils were seen mostly in the dorsal horns and 
dorsal columns (Δ p<0.05 compared to VH and VLWM and all other timepoints).  
Maximum infiltration was at 24 h in the dorsal columns and grey matter (* p<0.05 
compared to all other time points; # p<0.05 compared to VLWM). Numbers returned to 
control levels at 7 days. Results are expressed as mean ± SEM of the number of animals; 
n=3-4 per group. Data reproduced from Hall et al., (in submission). 
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3.2.2 Macrophages filled the epicentre 7 – 28 days after SCI 
 
ED1 (CD68) is an intracellular marker, packaged in vesicles and labels monocytes, 
activated and phagocytic macrophages/microglia. It is one of the most commonly used 
antibodies to label macrophages. Fig. 3.5 shows infiltration of DAB labelled ED1 
monocytes into the injury epicentre and accumulation of macrophages over several time 
points. ED1 labelling was negligible or absent in laminectomy control tissue (not shown). 
Disruption of the blood brain barrier was highlighted by the presence of red blood cells 
(RBCs) seen in 4 h and 1 day tissue (* in Fig. 3.5). There were no RBCs present in spinal 
cord tissue at 7 days 
 Detailed quantitative analysis of the epicentre revealed only 1 or 2 labelled cells infiltrating 
the injured epicentre within the first 24 h (Fig. 3.6). By 7 days and up to 28 days a 
significant increase in ED1 labelled macrophages were distributed throughout the grey and 
white matter covering 7-12% of the measured fields. 2 way ANOVA revealed a significant 
time (F=19.89) and region (F=5.53) effect. Overall, comparatively fewer macrophages 
were seen in the ventrolateral white matter but this was only significant at 14 days 
compared to the dorsal columns and ventral horns. There was a significant drop in the 
amount of macrophages in the dorsal columns at 14 days. Levels of ED1 staining in the 
grey matter of the dorsal and ventral horns reflect areas that were found at later time points 
to contain large cystic cavities filled with macrophages (shown later, Fig. 3.12).   
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Figure 3.5 Time course of macrophage (ED1) infiltration. At 4 and 24 h, macrophages were absent or small and few in  number, 
but this was masked by the presence of red blood cells from ruptured blood vessels (shown by *). Macrophages initially appeared in 
the dorsal half of the cord (24 h) but over 7-28 days became swollen and filled the entire area of the section. In some cases, cavities 
were also visible. Scale bar = 100 μm.
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Figure 3.6 Quantification of macrophage (ED1) infiltration.  Detailed quantification 
revealed no or few macrophages at 4 and 24 h. Maximal amounts were found at 7 to 28 
days after SCI (* p<0.05 compared to 4 h; # p<0.05 compared to 24 h). Highest levels 
were seen in the dorsal columns and grey matter. A relatively smaller amount was seen 
in the ventrolateral white matter at all time points but this was only significant at 14 
days (Δ p<0.05 compared to dorsal columns and $ p<0.05 compared to ventral horn). 
Results are expressed as mean ± SEM; n=3-4 per group. 
 
3.2.3 Activated microglia/macrophages were visible 7-28 days after SCI 
 
OX42 (CD11b) and Iba1 (ionized calcium binding adaptor molecule 1) are two 
antibodies commonly used to identify resting and activated microglia in rat CNS tissue. 
Both antibodies showed similar labelling of cells in laminectomy control tissue at all 
time points, with uniform labelling of cells in the white and grey matter (Fig. 3.7A, B). 
However, in injured tissue OX42 showed low signal to noise ratio using either DAB or 
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immunofluorescence methods and poor detection of ramified processes (Fig. 3.7C), 
whereas the Iba1 antibody labelled both ramified microglia and rounded cell types in 
grey and white matter (Fig. 3.7D). Therefore, in subsequent chapters the Iba1 antibody 
was used to detect resting and activated microglia.  
 
Figure 3.7 Microglial markers. (A, B)  Ramified microglia (OX42, Iba1) in the dorsal 
horn and dorsal column of adjacent sections of laminectomy control spinal cord 
representative of all time points analysed (red dotted line marks the boundary between 
white  and grey matter; (*) denotes the grey matter side). Labelling was uniform in the 
white and grey matter regions. (C, D) Swollen microglia in the ventral horn and 
ventrolateral white matter of adjacent sections of injured spinal cord 28 days after SCI 
(OX42, Iba1). Iba1 labelled more cells than OX42 in the white matter of all sections.  
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Figure 3.8A-E shows representative Iba1-labelled sections of SCI and sham 
laminectomy control tissue in the dorsal horn area of the epicentre at several time points. 
Iba1 labelling on 4 and 24 h tissue appeared to be less than in sham tissue, possibly due 
to loss of signal or a higher signal to noise ratio. However, 7 and 28 day tissue revealed 
a substantial increase in size and number of Iba1 cells.  The two insets (Fig. 3.8A, E) 
show examples of the different phenotypes of microglial cells mentioned in the 
introduction; i) small, with elongated processes (Fig. 3.8A) and ii) enlarged and rounded 
(Fig. 3.8E). Detailed quantification (Figure 3.8F) confirmed the histological 
observations of low signal at 4 and 24 h and a significant increase of microglial labelling 
at later time points. 2 way ANOVA revealed a significant time (F=19.89) and region 
(F=8.19) effect. There was no remaining tissue available at the 14 and 21 day time 
points for Iba1 analysis. Laminectomy (sham) tissue was taken from all time points (n = 
2-3 per group) and pooled, since there was no significant difference between time 
points. 
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Figure 3.8 Time course of microglia response. Images show representative microglia 
(Iba1) labelling in the dorsal horn (A-E). Cells became swollen and filled several areas 
of the epicentre. Insets (A and E) show high power confocal images of microglia 
labelled with Iba1 and Hoechst. Scale bar = 100 µm. (F) Detailed quantitative analysis 
of Iba1 supports a significant microglial reaction seen at 7 and 28 days. Results are 
expressed as mean ± SEM; n=3-4 per group.$*# p<0.05, compared to sham, 4 h and 24 
h. + p<0.05 compared to 7 day VLWM, Δ p<0.05 compared to 7 day DC. 
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3.2.4 Infiltrating and resident macrophages (microglia) share the same phenotypic 
markers 
 
ED1 and Iba1 both label resident phagocytic or activated microglia as well as infiltrating 
macrophages. This means that once blood-derived (haematogenous) macrophages 
occupy the epicentre, it is not possible to distinguish between them and resident 
microglia. It has not been documented to date, whether all Iba1 labelled cells co localise 
with ED1, or vice versa, or if a percentage of each marker co-localise as a proportion of 
total macrophages. Using confocal microscopy, we found a heterogeneous population of 
microglia at 28 days: some that were Iba1+/ED1+ and others that were Iba1+/ED1- (Fig. 
3.9). Several apparent hypertrophic Iba1+/ED1+ cells were discovered that were larger 
(15-20 µm) than the ED1 cells seen at 1 day. Some of the Iba1+ cells also showed 
punctate ED1 labelling localised on the cellular processes.  
 
 
Figure 3.9 Microglia/macrophages 28 days after SCI. Large, swollen cells were 
labelled with both ED1 (red) and Iba1 (green) in the epicentre. Scale bar = 5µm. 
 
93 
 
 
Figure 3.10 Time course of ED1/Iba1 microglia/macrophage staining. Iba1 single labelled cells were predominantly 
visible at 1 day. At 7 days, Iba1 labelled cells were mostly distinct from the rounded ED1 labelled cells. At 28 days many 
large, Iba1 and ED1 double labelled cells were seen. Scale bar = 20 μm.
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Figure 3.10 shows in more detail how the two cell types varied over time. At 1 day after 
SCI, Iba1-labelled microglia were dominant. At 7 days, the two populations were quite 
distinctive and Iba1 cells were mostly separate from rounded ED1 labelled cells, although 
there was co-localisation of some cells. At 28 days a mixture of large, Iba1 and ED1 cells 
was observed. 
 
3.2.5 Lymphocyte numbers were negligible after SCI 
 
Using the cell surface markers CD4, CD8, CD45 and CD5 to identify B and T 
lymphocytes, validation of the specificity of these markers was first performed in spleen 
tissue. CD45 labelled cells in germinal zones typical of B lymphocytes (Fig. 3.11A) 
whereas CD4, CD8 and CD5 labelled T cells in areas surrounding arterioles. In the spinal 
cord epicentre, only one or two B cells were seen in one or two animals 7 d after SCI 
(Fig. 3.11B). Low numbers of CD4, CD8 and CD5 T cells were seen at 7 d and they were 
associated with blood vessels (Fig. 3.11C). T lymphocytes were absent in a preliminary 
assessment of 28 day tissue. 
 
3.2.6 Reactive astrocytes formed a boundary around macrophages 
 
Using an antibody that labels glial fibrillary acidic protein in astrocytes (GFAP), a 
comparison was made between laminectomy and injured spinal cord tissue (Fig. 3.12A, 
B). Laminectomy tissue showed GFAP labelling of astrocytes throughout the grey and 
white matter, whereas 28 days after SCI an astrocytic barrier was found to wall off intact 
white matter from an area filled with macrophages and reactive microglia (Fig 3.12C).  
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Figure 3.11 Lymphocytes (A) B lymphocytes (CD45, green) in a germinal zone found in 
naïve spleen tissue. Nuclei of other cells are visible in blue (Hoechst) and vascular 
labelling is in red (GAP43). Scale bar = 100 µm. (B) Spinal cord epicentre 7 days: a 
neutrophil (red) and a B lymphocyte (CD45, green, arrow). (C) At 7 days a few T 
lymphocytes (CD5, green) were seen in the epicentre grey matter associated with a blood 
vessel. Scale bar = 10 μm. 
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Figure 3.12 Astrocytes (A) Astrocyte (GFAP) labelling in the spinal cord after 
laminectomy. (B) 28 days after SCI, an astrocytic (GFAP) barrier walls off an area in the 
epicentre. (C) An adjacent section showing that the walled-off area is filled by 
macrophages (ED1). Scale bar represents 90µm (A-C). 
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3.2.7 The inflammatory response expands beyond the injury epicentre 
 
As work progressed during this doctoral study, it was found that in experiments assessing 
chronic inflammatory markers, tissue in the epicentre contained several cavities. In sets 
of tissue where there were cavities, it was not possible to obtain an accurate 
quantification of inflammatory, neuronal or other non-neuronal cell markers at the 
epicentre. Therefore, in some cases, we analysed tissue rostral to the epicentre, where 
there were fewer cavities and there was spared tissue.  
 
Since neutrophils were found to be largely absent in the epicentre from 7 days, we used 
primarily ED1 and Iba1macrophage/microglia markers to explore the inflammatory 
response at times of 7 days and beyond.  
  
Figure 3.13A-C shows representative transverse sections of tissue from the epicentre and 
sections spanning 5 mm directly rostral and caudal to the epicentre. Due to the 
unpredictable variation in the location of areas of ED1 staining in rostral and caudal 
sections, the analysis made was based on % ED1 labelling of the whole section and an 
average of three sections was used for each animal (Fig. 3.13D). As expected, the highest 
amount of ED1 labelling was seen in the epicentre and about half of that amount in the 
rostral tissue, but this was not significant (p>0.05). There was also staining in caudal 
regions, but this was significantly less (p<0.05) and will therefore not be considered in 
the following chapters. 
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Figure 3.13 Distribution of ED1 labelling rostral and caudal to the injury epicentre 
at 7 days. Analysis of the whole transverse section was carried out, as described in the 
Methods chapter. There was significantly less ED1 labelling in the caudal segment 
compared to the epicentre (* p<0.05). Results are expressed as mean ± SEM; n=5 per 
group.  
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3.2.8 The systemic inflammatory response to compression SCI 
 
Neutrophils were recruited to the liver 4 h after SCI 
 
Parallel to the inflammatory events observed in the spinal cord after SCI, activation of 
resident macrophages and infiltration of neutrophils was studied in the liver (examples 
shown in Fig. 3.14). This is because we planned to assess the effects of omega-3 PUFAs 
delivered systemically and it is possible that they have effects on cytokines or leukocytes 
involved in the acute phase response in the liver.  
 
Figure 3.14 Inflammatory response in the liver after SCI. (A) Kupffer cells (ED1, 
red) in the liver and (B) neutrophils (JT1, green) in the same representative section 
following compression SCI. Scale bar = 15 µm. Figure reproduced from Hall et al., (in 
submission). 
 
Quantification (Fig. 3.15) revealed that a few neutrophils were found scattered 
throughout the liver of naïve animals. One way ANOVA and post-hoc tests revealed that 
4 and 24 hours following SCI, the amount of neutrophils found infiltrating the liver 
tripled significantly (F=11.06, p<0.05). In laminectomy control tissue there was a similar 
significant trauma related increase in hepatic neutrophils (p<0.05). At 28 days following 
SCI, neutrophil numbers remained elevated in SCI and this also appeared to be the case 
in laminectomy tissue (it was only possible to quantify two animals in the laminectomy 
group at this time point).  
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ED1 Kupffer cells were also seen in the liver (Fig. 3.14A). Their morphology was not 
rounded, as that of mature monocytes and macrophages found in the spinal cord, but 
elongated and probably located in the lumen of sinusoids, anchored to the sinusoidal 
endothelium of hepatic lobules. After several attempts, using various protocols, we found 
that the labelling of these cells with ED1 was inconsistent between animals and we 
therefore did not assess this marker in subsequent work.  
 
Figure 3.15 Time course of liver neutrophil infiltration. Detailed quantification 
revealed low numbers of neutrophils in naive liver tissue.  Following sham surgery or 
SCI there was a significant increase in hepatic neutrophils compared to the naïve group 
and the numbers remained elevated 28 days after SCI (* p<0.05). Results represent mean 
± SEM. n = 2-4 animals per group. Data reproduced from Hall et al., (in submission). 
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3.3 DISCUSSION 
3.3.1 Neutrophils acutely infiltrated the injury epicentre 
Following compression SCI there was an acute infiltration of neutrophils to the epicentre 
at 4 h and 24 h. The observation of peak neutrophil infiltration to the spinal cord at 1 day 
correlates with that reported by other laboratories, summarised in Table 3.1 (Dusart and 
Schwab, 1993; Zhang et al., 1997; Carlson et al., 1998; Schnell et al., 1999).  We 
observed initial infiltration of neutrophils to the dorsal horns and dorsal columns, 
spreading at the peak to all areas of the injured parenchyma. A similar regional analysis 
has not been carried out (Popovich et al., 1997; Sroga et al., 2003), or was quantified in a 
different plane, so a comparison cannot be made (Zhang et al., 1997; Schnell et al., 1999). 
The methods used to quantify neutrophils also varied between studies. For example, 
MPO activity was used by Carlson et al. (1998), a general H & E stain was used by 
Zhang et al. (1997), and an in-house marker - HB 199 by Schnell et al. (1999). Bao et al. 
(2005) used an antibody for gp91
Phox
, a membrane component of the enzyme NADPH 
oxidase expressed by phagocytes. However, this marker is also expressed by 
macrophages. We saw negligible numbers at later time points, in contrast to observations 
in mouse tissue where numbers persisted up to a month after contusion SCI (Kigerl et al., 
2006). However, in a mouse hemisection model the numbers declined after 1 day 
(Schnell et al., 1999). Again, in these two studies different antibodies were used to label 
the neutrophils. It is possible that the JT1 antibody used here did not label the entire 
neutrophil population, but after comparison with other commercially available antibodies 
and histological images in the literature it was the most favourable choice. A preliminary 
analysis was made using this antibody on epicentre homogenates by Western blot. A 
consistent band was found, at 65 kDa, which increased in density at 4 and 24 h after SCI. 
It will be essential in future to fully characterise the epitope, in order to gain more 
information as to the nature of the cellular component detected. In particular, it appears to 
be localised to the cell surface and some cells were labelled less intensely than others. 
This could be due to down regulation of a receptor which could be representative of a 
functional characteristic such as release of myeloperoxidase, or initiation of phagocytosis, 
which could help to identify important intra-cellular signalling pathways. It would be 
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extremely useful in future, when assessing anti-inflammatory treatments, if we could 
distinguish between different neutrophil phenotypes and subpopulations.  
3.3.2 Macrophages/microglia dominated the injury epicentre at later time points 
The macrophage/microglia response was delayed, in comparison to the neutrophil 
response, not peaking until 7 days and remained elevated in the gray matter until 28 days. 
Our observations are similar to reports that have been published of the morphology of 
large cells, containing abundant lipid vacuoles, in sites of tissue destruction (Klusman 
and Schwab, 1997; Sroga et al., 2003). The results from the quantification of ED1 
macrophages/microglia from 7 days after compression SCI were difficult to interpret, due 
to large variations between animals and areas analysed. It appeared that the response in 
the dorsal columns was reduced by half at 14 days. A drop in the overall amount of ED1 
labelled cells in the epicentre has been reported elsewhere after 7 days, but this was 
followed by a plateau in the amount of ED1, not another increase as seen here. A similar 
extensive analysis in the different areas of the spinal cord has not been quantified (Dusart 
and Schwab, 1994; Zhang et al., 1997; Carlson et al., 1998; Sroga et al., 2003; Bao et al., 
2005; Popovich et al., 2007). 
Carlson et al. (1998) and Popovich et al., (1997) reported the highest density of 
macrophages in the grey matter and dorsal funiculus of the injury epicentre and we also 
saw highest levels of macrophages in these areas. This regional specificity of macrophage 
location occurred alongside similar areas of breakdown/permeability of the blood-brain 
barrier to horseradish peroxidase observed by Schnell et al. (1999) after SCI. They 
reported widespread blood-brain barrier breakdown at one day, continuing up to 14 days 
in a smaller region, which appeared to be confined to the grey matter and dorsal 
funiculus. Also relevant, is the fact that there is a larger microvascular network within the 
spinal gray matter, relative to the white matter (Popovich et al., 1997) and almost twice 
the number of veins entering the spinal cord, from where leukocytes are recruited, 
compared to arteries (Koyanagi et al., 1993). There are also differences in expression of 
adhesion molecules (Schnell et al., 1999) and chemokines, which may contribute to the 
regional characteristics of cellular infiltration and localisation described here (Popovich 
et al., 1997). 
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The Iba1 macrophage/microglia quantification cannot be compared directly with the ED1 
macrophage/microglia quantification since the levels of immunoreactivity and image 
analysis will vary for each antigen. In particular, the Iba1 epitope labels an antigen on the 
cell surface, whereas ED1 labels a cytoplasmic antigen. Some authors have attempted to 
correct for this limitation by using a „fill target‟ function (Popovich et al., 1997), but this 
was not considered necessary for the purposes of the analysis made here. Our aim was to 
obtain a quantitative estimate of changes in the magnitude of the cellular infiltrate. This 
method does not necessarily reflect changes in cell number. So an increase in ED1 
immunoreactivity may not necessarily reflect changes in actual cell numbers but does 
indicate an increased state of activation for the cell types under investigation in this study.  
Despite the technical issues, the Iba1 signal in the injury epicentre followed a similar 
pattern to the ED1 time course. Thus, the increase in Iba1 labelling was delayed 
compared to neutrophils and was elevated at 7 and 28 days. The amount of Iba1 labelling 
in the boxed area at 7 days appeared to be double the percentage of ED1 labelled cells. 
This could reflect the additional labelling of the population of resident microglia along 
with the infiltrating cells. At 28 days, the amount of Iba1 staining was similar to the 
levels of ED1 labelling in the epicentre at this time point. This reflects what was seen 
histologically, that nearly all macrophages/microglia in the epicentre at 28 days were 
large, rounded cells and there were few or no „resting‟ microglia present. Activated 
microglia have been quantified by others, using immunohistochemistry, already by the 
first day after SCI, increasing in number by 7 days, then plateauing between 2 and 4 
weeks (Popovich et al., 1997; Trivedi et al., 2006). The increase at 1 d was not obvious in 
our model and may be partly due to limitations in the sensitivity of the method of 
quantification. At these earlier timepoints, there was an increased amount of background 
noise compared to the signal (i.e. decreased signal to noise ratio), which therefore made it 
difficult to detect the thickening of the fine processes of microglia. Other methods have 
been used to quantify macrophages/microglia, such as Western blot analysis (Bao et al., 
2005). However, this method means it is not possible to observe the location of the 
macrophages in the spinal cord. In other studies, counts have been carried out of 
macrophages/microglia (Roggendorf et al., 1996; Felts et al., 2005). However, it would 
not have been possible here, since it was difficult to visualise individual cells in dense 
clusters in the areas of damage after SCI. A comparison of various methods to quantify 
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macrophages by Donnelly et al. (2009) concluded that the least variable and most time 
efficient way of analysing macrophages/microglia after SCI was to use a densitometric 
thresholding method, similar to that used here.  
In future work, it will be interesting to see if there are also differences between ED1 and 
Iba1 staining in tissue rostral to the injury epicentre. In addition, in SCI models it might 
yield more meaningful data if an analysis is done in areas where there is tissue sparing, 
rather than where there is already extensive tissue destruction and cavitation. Here, a 
comparison was made between ED1 labelling in sections rostral and caudal to the 
epicentre. A considerable amount (half of that seen in the epicentre) of macrophages was 
found to spread by 7 days as far as 5 mm above the epicentre, fewer below, and was 
found to be concentrated in one or two discrete areas, such as the dorsal funiculus, 
presumably in areas containing degenerating fibre tracts, as seen by Popovich et al., 
(1997). Macrophages can persist in areas of Wallerian degeneration for several months 
(Dusart and Schwab, 1994; Schwab and Bartholdi, 1996). Since our exploration of the 
tissue sections rostral and caudal to the epicentre revealed a heterogeneous distribution of 
macrophages, with both isolated clusters and widespread scattering of macrophages of 
different morphologies and sizes, this led us to critically evaluate our method of 
quantification. The method used in the epicentre, restricting measurement to specific 
discrete regions of the cord, meant that it was possible to miss the small areas of 
accumulations of macrophages. Although balanced by a slight loss in resolution quality, 
we found that to get a more accurate representation it was necessary to measure the 
immunoreactivity of the entire section.  
Easily distinguishing between infiltrating and resident macrophages remains a challenge 
at present. The data reported here have shown that not all Iba1 labelled microglia stain for 
the ED1 marker. One study has compared ED1 with OX42 labelling, another marker of 
activated microglia (Popovich et al., 1997). A higher amount of OX42 labelling than ED1 
labelling was found at all time points, the peak of OX42 slightly preceding ED1 at 7 days 
in Sprague-Dawley and Lewis rats, compared to 14 days post-SCI. Another study has 
compared ED1 and Iba1 in contusion SCI (Wu et al., 2005). According to their analysis, 
there was less Iba1 than ED1 overall. Co localisation staining was performed, similar to 
what was observed here, but quantification was not performed.  
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Macrophages have been found to persist for several months to years in the injury site 
after SCI in human (Fleming et al., 2006). Unlike neutrophils, macrophages do not 
undergo apoptosis in the first 1-2 days after entry to the injury site (Parham, 2000). In 
models of inflammation that reach resolution, the phagocytosis of neutrophils and debris 
by macrophages reduces the inflammatory reaction, which terminates upon their 
departure from the site of injury (Serhan and Savill, 2005). It is possible that blood 
derived macrophages infiltrate the spinal cord after SCI, departing in the same process as 
described above and that the macrophages found at chronic time points in the spinal cord 
are, in fact microglia that remain in an activated state. However, there are several 
experiments that found blocking the infiltration of leukocytes to the injury site was 
beneficial, which would suggest that blood-derived macrophages do accumulate in the 
epicentre. The beneficial effect of blocking macrophage infiltration is challenged by the 
research of Schechter et al. (2009), who found that the hematogenous derived 
macrophages perform an essential role that microglia are unable to carry out alone.  The 
above observations could reflect differing phenotypes in a similar way to the M1 and M2 
phenotypes described by Kigerl et al. (2009). Although the markers have not been 
characterised in rat tissue, it may be possible to use markers such as CD86 and iNOS that 
have been used to define the M1 population, and arginase 1 and CD206 for the M2 
population, in combination with a pan-CNS macrophage marker. A heterogeneous 
population of microglia has also been demonstrated based on the Toll-like receptors 
(TLRs) present on their cell surfaces (Flaris et al., 1993). 
 
Importantly, alongside the increase in macrophages/microglia in the epicentre, there 
appears to be an inverse correlation with locomotor recovery. The behavioural analysis 
was not included in this chapter, but in our model of SCI, locomotor function improves 
dramatically in the first 10 days post-SCI and then reaches a plateau, without full 
recovery. This means that recovery can occur despite the progression of the early 
inflammatory response, but at the later time points full recovery might not be reached due 
to the persistence of activated macrophages/microglia. Since full recovery is possible in 
the spinal cord in smaller, less severe lesions, it is possible perhaps, that „boosting‟ the 
beneficial part of the inflammatory response after severe SCI towards the reparative 
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phenotype and towards a resolution of the inflammatory reaction is required in order for 
full recovery to be obtained.  
 
3.3.3 Astrocytes walled off damaged areas of tissue 
We found extensive astroctye labelling in uninjured as well as injured spinal cord tissue 
where, at later time points, they appeared to “wall off” cystic cavities containing 
macrophages. Astrocytes support neurones in the brain tissue and release several factors, 
including AA, DHA, and prostaglandins. During ischemic injury, deprivation of oxygen 
induces activation, proliferation, and hypertrophy of microglial cells and astrocytes 
(Farooqui et al., 2007b). After SCI astrocytes upregulate inhibitory molecules such as 
chondroitin sulphate proteoglycans (CSPGs) which are repellent to neurite outgrowth 
(Bareyre and Schwab 2003; Profyris et al., 2004). Both activated microglial cells and 
activated peritoneal macrophages have been shown to have striking morphological effects 
on astrocytes (Fitch et al., 1999). Therefore, the presence of macrophages may have 
prevented the entry of astrocytes into the necrotic injury site. Since it was not possible to 
define and study subpopulations of astrocytes, their roles in the inflammatory response as 
a whole remains to be fully investigated. 
3.3.4 Lymphocyte numbers were negligible 
 
We found very few lymphocytes in the epicentre at any of the time points investigated 
after compression SCI. Reports of infiltration of B and T lymphocytes to the injury site 
have been made after rat (Dusart and Schwab, 1994) or mouse hemisection (Schnell et 
al., 1999) and rat or mouse thoracic contusion (Hauben et al., 2000a; Sroga et al., 2003; 
Ankeny et al., 2006). In mice there appears to be a more robust and protracted response at 
later time points (14-56 days) (Kigerl, 2006; Sroga) than in rats, where there appears to 
be an early recruitment (1-7 days) in low numbers (Popovich et al., 1997; Sroga et al., 
2003, Dusart and Schwab, 1994). The fact that neither B lymphocytes nor CD4 and CD8 
phenotypes of T lymphocytes have been quantified in rat tissue in the literature to date, 
must illustrate their sparse appearance (Popovich et al., 1997; Sroga et al., 2003). Our 
observations are in agreement with Fleming et al., (2006) who found very low numbers in 
human spinal cord following SCI.  
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Attempts were made to optimize the lymphocyte markers used here by increasing their 
concentration or using amplification with tyramide but it may be that the strain and 
species differences that are found in the time course of lymphocyte infiltration meant that 
the optimal time points were missed. Therefore, we would need to look in future at 
further time points. For the purposes of this doctoral study, the numbers were considered 
too low to make an extensive analysis possible.  
 
In classical immunology, the presence of lymphocytes is an indication of activation of the 
adaptive response of the immune system and has important implications for autoimmune 
disorders. It has been suggested that there are sufficient numbers of autoreactive 
lymphocytes to CNS antigens to create an autoimmune response (Ankeny et al., 2006). 
Activated T cells can modulate macrophage function and antibody production by B 
lymphocytes and others believe that they modulate wound healing through the release of 
cytokines, e.g. TGF-β and/or neurotrophins (Moalem et al., 1999; Hauben et al., 2000a). 
Together with the conflicting reports describing the role of lymphocytes after SCI it is 
clear that it would be important to follow up this part of the inflammatory response in 
future work (Shwartz and Hauben, 2002; De Caterina and Massaro, 2005; Ankeny et al., 
2006). 
 
3.3.5 Systemic response 
We found that compression SCI is accompanied by a hepatic response. Evidence reported 
by Davis et al. (2005) and Campbell et al.(2003, 2005) demonstrates that the APR of the 
liver stimulates additional recruitment of leukocytes to the injury site following a mild 
compression SCI at thoracic level 8, and exacerbates damage. Such observations open up 
the possibility of reducing the inflammatory response and damage to the CNS by 
blocking the APR response in the liver. An increase in neutrophils was found at all time 
points considered after SCI, partly supporting the work reported in the literature. 
Interestingly, no difference was found in the number of neutrophils recruited to the liver 
after injury compared to laminectomy surgery alone, indicating that the APR response of 
the liver is not specific to injury of the spinal cord in our model and is a generic response 
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to tissue trauma. The APR response of a laminectomy group was not described in the 
studies described above (Campbell et al., 2005; Davis et al., 2005).  
 
3.3.6 Conclusions 
 
The results in this characterisation study demonstrate that the inflammatory response to 
compression injury is very similar to the response reported in contusion injury. 
Neutrophils are dominant in the injury epicentre at one day and then disappear, to be 
replaced at later time points (7-28 days) by macrophages/microglia, surrounded by an 
astrocytic barrier. There were very few lymphocytes present in the cord at the time points 
studied. There was a systemic response to trauma and compression SCI, marked by 
elevation in neutrophil numbers in the liver.  From 7 days, there was a spread of 
macrophages to specific areas rostral and caudal to the epicentre of the spinal cord. The 
distinct timings and location of the different cell types are probably related to levels of 
cytokines/chemokines released from damaged blood vessels and cells in the injury site. 
An analysis of cytokines/chemokines will be described in the following chapter. 
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Chapter 4: Results II. Comparison of the effects of the acute 
intravenous injection of DHA and EPA on the early inflammatory 
response 
 
4.1 Introduction 
 
There have been several promising approaches to the treatment of SCI that target the 
acute inflammatory response but none are yet used clinically. The literature to date 
reflects that it is widely believed by many researchers that the initial inflammatory 
response after SCI, i.e. the increase in pro-inflammatory signalling, along with infiltration 
of activated neutrophils, is detrimental to recovery from SCI. However, there is also 
evidence to the contrary, and this controversy is discussed in more detail later. If 
inflammation is damaging, reducing this early component of the inflammatory response 
would improve outcome. The cellular inflammatory response after SCI has already been 
introduced in chapters 1 and 3.The following introduction will expand on the 
cytokine/chemokine inflammatory response described in chapter 1 and consider why 
current acute anti-inflammatory treatments have not been successful. The remainder of 
the chapter will explore the effects of acute treatment with omega-3 PUFAs on the early 
CNS inflammatory response. 
 
4.1.1 The inflammatory cytokine/chemokine response after SCI 
 
The entry of inflammatory cells to the injury site after SCI is not random. As noted in the 
previous chapter, neutrophils enter earliest, followed by monocytes. One theory 
explaining the selective leukocyte entry into CNS regions of inflammation is that it is 
influenced by the prior differential expression of specific cytokines (Glabinski et al.1995, 
1996a, b; Adams and Lloyd, 1997; Ransohoff, 1997; Ransohoff and Tani, 1997; 
McTigue, 1998)(refer to Table 1.1 of cytokines/chemokines in the general introduction, 
Chapter 1).  
 
Cytokines are immunomodulating signalling molecules and are classified into five major 
groups: interleukins, growth factors, interferons, chemokines, and tumor necrosis factor 
110 
 
(TNF). IL-6, IL-1β and TNFα are the most well-documented and have been found in 
most cell types at the CNS injury site, at 3 and 6 h after injury (Bartholdi and Schwab, 
2007). IL-1β and TNF-α have been shown to stimulate reciprocally their secretion (Pan et 
al., 2002), their amount reaching a peak several hours after injury but becoming 
negligible by 24 h. IL-1β, IL-6 and TNF-α are known to be mediators of inflammation 
and sustained elevations of TNF-α and IL-1β cause neuronal and oligodendrocyte death 
(Hermann et al., 2001; Shamash et al., 2002; Cai et al., 2003). Over-expression of IL-6 in 
the spinal cord enhances leukocyte infiltration, decreases axonal growth and impairs 
locomotor recovery (Lacroix et al., 2002). 
 
Chemokines are a specific family of small cytokines (approximately 8-10 kilodaltons), or 
chemotactic cytokines. Their name is derived from their ability to induce directed 
chemotaxis in nearby responsive cells. They are classified according to shared structural 
characteristics, such as the presence of four cysteine residues in conserved locations that 
are key to forming their three-dimensional shape.  One major subgroup is known as α-
chemokines, including human interleukin-8 (IL-8). These are typically chemoattractive 
activators for neutrophils (Adams and Lloyd, 1997; Rollins et al., 1997). The expression 
of chemokines is regulated by the inflammatory cytokines TNF-α, IL-1β and interferon-γ 
(Hurwitz et al., 1995; Majumder et al., 1996; Ping et al., 1996; Sun et al., 1997; Streit et 
al., 1998). Cytokine-induced neutrophil chemo-attractant 1 (CINC-1) is the rat equivalent 
of IL-8 and growth-regulated oncogene (GRO) protein in humans. Elevated expression of 
the CINC proteins has been reported in the rodent CNS following stroke (Yamagami 
1999). Blocking the interaction of chemokines such as macrophage inflammatory protein 
(MIP) with its receptor by using an infusion of the antagonist vMIPII (Ghirnikar et al., 
2000) has been shown to limit the inflammatory response and provide significant 
neuroprotection after contusion SCI in the rat (Eng and Lee, 2003 for review). 
 
Not all cytokines are neurotoxic. A growing number of cytokines have been found to 
exert beneficial effects on neurones and oligodendrocytes in vitro and in vivo (Lindholm 
et al., 1987; Martinou et al.,1990; Schwartz et al., 1991; Hama et al., 1991; Ikeda,et al., 
1996; Kossmann,et al., 1996).Thus, a better understanding of the production of these 
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factors in the injured CNS is needed if we want to exploit this process with the aim to 
improve neurone survival after injury.  
 
C-reactive protein (CRP) is an extensively studied marker of systemic inflammation in 
humans and rats. It is an acute-phase protein produced in the liver, thought to be 
regulated by IL-6, IL-1 and TNF-α and binds specifically to phosphocholine (Thompson 
et al., 1999), a component of microbial capsular polysaccharide, and participates in the 
innate immune response. Previous studies indicate that a chronic low-grade inflammation 
is involved in the pathogenesis of atherosclerosis, and an elevated CRP level is a risk 
factor for coronary artery disease (Ridker, 2003; Sattar et al., 2003).  Elevated levels in 
adults with chronic SCI have been reported and provide evidence suggesting a state of 
chronic inflammation post-SCI (Manns et al., 2005; Gibson et al., 2008). 
 
4.1.2 Acute anti-inflammatory strategies for SCI 
 
Some of the anti-inflammatory strategies being explored to date, such as minocycline and 
integrin antibodies, have been introduced in Chapter 1. There are additional anti-
inflammatory strategies currently being researched. 
 
Cyclooxygenases (COX), lipoxygenases (LOX) and iNOS exert detrimental effects after 
SCI. COX enzymes exacerbate the inflammatory response by synthesising 
proinflammatory eicosanoids. Many studies have reported that a decrease in iNOS and 
COX leads to neuroprotection. Administration of selective inhibitors for iNOS and COX 
inhibitors has been tested in a model of SCI (Resnick et al., 1998; Hains et al., 2001) 
alone or in combination with grafts of olfactory ensheathing cells, and the results showed 
that treatment with COX and iNOS inhibitors improved locomotor ability and led to 
tissue sparing (López-Vales et al., 2006).  
 
Blocking the proinflammatory cytokines TNF-α or IL-1β confers neuroprotection in 
rodent models of SCI (Nesic et al., 2001; Sharma et al., 2003; Genovese et al., 2005) and 
traumatic brain injury (Sanderson et al., 1999). Systemic treatment with the anti-
inflammatory cytokine IL-10 limits secondary neurodegeneration and improves 
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locomotor recovery in some but not all SCI studies in rodents (Bethea et al., 1999; 
Brewer et al., 1999; Takami et al., 2002). Taurine is an organic acid and can act as an 
osmoregulator, antioxidant, inhibitory neuromodulator, and regulator of intracellular   
Ca
2+
 flux. Injecting taurine intraperitoneally within 30 min after SCI decreases IL-6 and 
myeloperoxidase (MPO) activity, and significantly decreases motor dysfunction 
compared to controls (Nakajima et al., 2010). 
 
Statins are the most commonly prescribed class of lipid-lowering drugs, and recently, it 
has been recognized that statins also have powerful immunomodulatory and anti-
inflammatory effects. Treatment with simvastatin and atorvastatin appeared to offer 
remarkable improvements histologically and behaviourally (Pannu et al., 2005; 2007). 
Although initial results were promising, administration of simvastatin and atorvastatin 
after thoracic spinal cord contusion injury by an independent laboratory failed to replicate 
the effect when given with a 1 h delay (Mann et al., 2010). Discrepancies of efficacy 
between these two laboratories may be at least in part due to the different models used, 
severity and segmental level of SCI. 
 
The time and expense needed to establish de novo pharmacological or biological 
therapies for acute SCI has encouraged the development of neuroprotective treatments 
based on drugs that are already in clinical use, like most of those described above. They 
offer the advantage of a well-characterized safety and pharmacokinetic profile in humans. 
Omega-3 PUFAs are well tolerated compounds and have potent neuroprotective effects. 
They are therefore, a good candidate for translation into SCI clinical trials. 
 
4.1.3 PUFAs, SCI and neuroinflammation  
 
Apart from their important structural and physiological roles, after injury, omega-6 and 
omega-3 PUFAs are important potential regulators of the onset and resolution of the 
inflammatory response (Farooqui et al., 2007b; Serhan et al., 2008), as described in 
Chapter 1. 
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After SCI, the enzyme phospholipase A2 is up-regulated in microglia, neurons and 
oligodendrocytes (Liu et al., 2006). This enzyme releases free fatty acids (FFA; Anderson 
and Hall, 1993) from cellular membranes. Arachidonic acid (AA), an omega-6 PUFA, is 
highly enriched in the membrane phospholipids of neurones and is one of the major 
species of fatty acids released (Demediuk et al., 1985a, b, 1989; Murphy et al., 1994). 
Cyclooxygenases and lipoxygenases play a key role in converting precursors of omega- 6 
PUFAs such as AA to proinflammatory eicosanoids such as prostaglandins, 
thromboxanes and leukotrienes (Smith and DeWitt, 1996), leading to further 
proinflammatory signalling of cytokines and chemokines which enhance vascular 
permeability and attract leukocytes to the injury site. Omega-3 fatty acids such as EPA 
act as a competitive substrate for cyclooxygenases and generate less inflammatory 
eicosanoids such as 3-series prostaglandins and  thromboxanes, 5-series leukotrienes, as 
well as anti-inflammatory metabolites such as resolvins and protectins (for review, see 
Calder 2009). Conversion of DHA by a lipoxygenase-like enzyme produces anti-
inflammatory and pro-resolving chemical lipid mediators collectively called docosanoids 
(Serhan, 2006). DHA and EPA metabolites have been shown to antagonize the effects of 
proinflammatory eicosanoids, decrease proinflammatory cytokine production in glial 
cells and attenuate neutrophil migration and tissue injury in peritonitis and ischemia-
reperfusion injury models (Hashimoto et al., 1999; Hong et al., 2003; Marcheselli et al., 
2003; Serhan et al., 2004; Spite et al., 2009). 
 
Work in other laboratories has shown that DHA is a potent inhibitor of lymphocyte 
adhesion to endothelial cells. DHA and EPA can inhibit the NFκB signalling system (De 
Caterina and Massaro, 2005; De Smedt-Peyrusse et al., 2008), in turn preventing the 
expression of pro-inflammatory cytokines including TNF-α and IL-1α and β and 
modulating leukocyte trafficking. Thus, evidence suggests that the generation of omega-3 
fatty acid metabolites from EPA and DHA may provide potent anti-inflammatory 
protective mechanisms for preventing neuronal damage after trauma. 
 
Work in our laboratory has shown that the omega 3 polyunsaturated fatty acids (omega-3 
PUFAs) possess potent neuroprotective effects. In particular, DHA injection alone and in 
combination with DHA dietary intervention leads to a significantly improved outcome 
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after SCI (Huang et al. 2007a; King et al., 2006). We also have some evidence that 
another omega-3 PUFA, eicosapentaenoic acid (EPA), could be neuroprotective when 
given as an acute bolus treatment following SCI (Lim et al., in press). Macrophage 
infiltration and cyclooxygenase-2 protein levels at the epicentre were reduced by DHA 
(Huang et al. 2007a). Therefore, it is possible that part of the neuroprotective effect of 
these agents is due to their anti-inflammatory properties. Their effect on the acute 
infiltration of other leukocytes such as neutrophils has not yet been characterised after 
SCI.  
 
4.1.4 Aims 
 
In this chapter we will explore the effects of an early (30 min post-SCI) DHA or EPA 
bolus injection on neutrophil (4 and 24 h) and macrophage (7 days) infiltration in the 
spinal cord and in the liver. In addition, we will measure cytokines and chemokine in the 
injury epicentre and systemically, and make an assessment of the impact of DHA or EPA 
bolus injection on their levels. 
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4.2 RESULTS 
 
The three experimental groups used in this chapter will be referred to as the following: 
 
Saline/vehicle – one bolus intravenous injection of saline (0.9 % NaCl, pH 7.4) 
injection, 30 min after compression SCI 
DHA (250 nmol/kg) – one bolus intravenous injection, 30 min after compression SCI 
EPA (250 nmol/kg) – one bolus intravenous injection, 30 min after compression SCI 
 
4.2.1 DHA, but not EPA, significantly reduced neutrophil infiltration at the 
epicentre 
 
In the previous chapter we found that high levels of neutrophils influx into the injury 
epicentre at 4 and 24 h after SCI.  Therefore, in this study we evaluated the effects of 
intravenous omega-3 PUFA injection on neutrophil infiltration at 4 and 24 h. There 
appeared to be fewer neutrophils in the ventral horns following DHA injection. 
Representative immunohistochemical labelling of neutrophils in the epicentre 24 h after 
SCI and intravenous injection of saline, DHA or EPA is shown in Figure 4.1. Detailed 
quantification of JT1 cells in specific areas of the epicentre revealed a significant 
decrease in the ventrolateral white matter (VLWM) at 4 h following DHA injection 
compared to saline injection (-71%, *p<0.05; Fig. 4.2A). There was a similar trend 
towards a decrease in neutrophil infiltration in the dorsal columns 4 h after DHA and 
EPA treatment, but this was not significant. At 24 h after SCI, the number of neutrophils 
in the epicentre increased three to twenty-fold in the saline group compared to 4 h, and 
there were significantly fewer neutrophils in the ventral horns of the DHA-treated group 
than the saline treated group (-40%, *p<0.05; Fig 4.2B). There was a trend towards a 
reduction in the number of neutrophils in most areas of the injury epicentre after 
treatment with EPA but this did not reach significance.  
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Figure 4.1. Representative immunohistochemical labelling of JT1 neutrophils in 
specific areas of the epicentre 24 h after SCI and one intravenous injection of saline, 
DHA (250 nmol/kg) or EPA (250 nmol/kg) 30 min after SCI. There appeared to be 
fewer neutrophils (arrows) in the ventral horns following DHA injection, and this was 
confirmed by quantitative analysis (Fig X). Dorsal columns (DC), dorsal horns (DH), 
ventral horns (VH), ventrolateral white matter (VLWM). Scale bar = 50 μm. Figure 
reproduced from Hall et al., (in submission). 
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Figure 4.2. Quantification of neutrophils in specific areas of the injury epicentre, 4 h 
and 24 h after SCI and one intravenous injection of DHA (250 nmol/kg), EPA (250 
nmol/kg), or vehicle (veh) 30 min after SCI. (A) JT1 immunostaining revealed that 
there was a significant increase in neutrophils in the dorsal columns (DC), dorsal horns 
(DH) and ventrolateral white matter (VLWM) of the vehicle group compared to sham 
(#p<0.05). There were significantly fewer neutrophils in the VLWM of the DHA-treated 
group than the vehicle group (*p<0.05). There was a trend towards a reduction in the DC 
following treatment with DHA and EPA but this was not significant.  (B) 24 h after SCI 
the number of JT1 immunoreactive neutrophils in the epicentre increased three to twenty-
fold in the vehicle group compared to 4 h and was significantly greater than sham 
(#p<0.05). There were significantly fewer neutrophils in the ventral horns of the DHA 
treated group than the vehicle treated group (*p<0.05). There was a trend towards a 
reduction in the number of neutrophils in most areas of the injury epicentre after 
treatment with EPA, but this did not reach significance. Results are mean ± SEM number 
of animals in brackets. Data reproduced from Hall et al., (in submission). 
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4.2.2 Myeloperoxidase activity  
 
In parallel with the reduction of neutrophils in the DHA-treated group we quantified the 
levels of myeloperoxidase (MPO) activity, an enzyme released by neutrophils, in the 
injury epicentre, to see whether they were also reduced. MPO activity (Fig. 4.3) was 
significantly increased 2-3 fold (#p<0.05) at 4 and 24 h after SCI compared to animals 
that received laminectomy surgery, but was not attenuated by treatment with DHA or 
EPA (Fig. 4.3).  
 
Figure 4.3 Quantification of MPO in the epicentre, 4 h and 24 h after SCI and one 
intravenous injection of DHA (250 nmol/kg), EPA (250 nmol/kg), or vehicle (veh) 30 
min after SCI. MPO activity was significantly increased (#p<0.05) in the injury 
epicentre after SCI compared to sham but was not attenuated by treatment with DHA or 
EPA. Values are the mean ± SEM of 4 and 24 h sham (both n=4); 4 h vehicle and EPA 
(n=5), 4 h DHA (n=4); 24 h vehicle, DHA and EPA (all n=5). Data reproduced from Hall 
et al., (in submission). 
 
4.2.3 Cytokine and chemokine changes in the injury epicentre  
 
 
Since it was the first time that cytokine and chemokines were to be measured in spinal 
cord tissue using the electrochemiluminescence method in our laboratory, a preliminary 
validation study was carried out on a 7-plex plate using a 24 h plasma sample. The only 
cytokine/chemokine 7-plex plate available at the time for rat tissue contained the 
following antibodies: IFN-γ, IL-1β, IL-4, IL-5, IL-13, KC/GRO/CINC, TNF-α. Levels of 
most of these factors were undetectable or at very low levels in plasma one day after SCI. 
Some of the wells on the plate were used to measure levels in spinal cord tissue. A 
significant increase (p<0.001) was detected in all 7 of the cytokines and chemokines in 
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the epicentre after SCI compared to naive and sham groups (data not shown). Following 
these preliminary results, we designed a custom 4-plex plate containing a select group of 
factors: IL-6, KC/GRO/CINC, IL-1β and TNF-α, which are reported to be increased after 
SCI and are related to neutrophil infiltration (Bareyre and Schwab, 2003; Bartholdi and 
Schwab, 1997; Aimone et al., 2004; Tonai et al., 2001; Streit et al., 1998; McTigue et al., 
1998; Pan et al., 2002). 
 
Following measurement of spinal cord, liver and plasma samples on the 4-plex plates 
detailed above we found that SCI led to a significant increase (p<0.001; Fig. 4.4) in the 
levels of IL-6, KC/GRO/CINC, IL1-β and TNF-α in the epicentre 4 h after SCI. 
Cytokines and chemokines returned to baseline levels at 24 h. Treatment with DHA (Fig. 
4.4) or EPA (Fig. 4.5) did not affect the increase in levels of these cytokines and 
chemokines after SCI. The data for EPA and DHA in the spinal cord is shown separately 
because the two treatments were assessed in a separate set of animals, with new controls 
and separate plates for each experiment.  
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Figure 4.4.Quantification of cytokines/chemokines in the injury epicentre 4 h and 24 
h following SCI and one intravenous injection of DHA (250 nmol/kg) treatment 30 
min after SCI. (A-D) SCI led to a significant increase (**p<0.01, ***p<0.001) in the 
levels of IL-6 (A), KC/GRO/CINC (B), IL1-β (C) and TNF-α (D) in the epicentre 4 h 
after SCI compared to naïve and sham control. Cytokines and chemokines returned to 
baseline levels at 24 h. Treatment with DHA did not affect the levels of any of these 
cytokines and chemokines after SCI. Results are mean ± SEM number of animals (n=4-7 
per group). Data reproduced from Hall et al., (in submission). 
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Figure 4.5 Quantification of cytokines/chemokines in the injury epicentre 4 h and 24 
h following SCI and one intravenous injection of EPA (250 nmol/kg) 30 min after 
SCI. (A-D) Treatment with EPA did not alter the levels of IL-6 (A), KC/GRO/CINC (B), 
IL-1β (C) or TNF-α (D) after SCI. Results are mean ± SEM number of animals (n=5-6 
per group). Data reproduced from Hall et al., (in submission). 
 
4.2.4 Effects of acute omega-3 PUFA injection on systemic inflammatory markers  
 
4 h and 24 h after SCI and laminectomy surgery there was a trauma-related increase in 
the number of neutrophils recruited to the liver (Fig. 4.6A). Treatment with DHA or EPA 
did not reverse this increase.  
 
The same 4-plex plates detailed in the previous section were also used to measure 
cytokines and chemokines in liver tissue and circulating levels in the plasma. Circulating 
plasma (Fig. 4.6B) and hepatic levels (Fig, 4.6C) of KC/GRO/CINC were significantly 
increased 4 h following laminectomy and compression SCI (p<0.05 and p<0.01, 
respectively). Levels returned to baseline 24 h after surgery. Treatment with DHA or 
EPA did not reverse this increase. A similar pattern was apparent for IL-6, IL1-β and 
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TNF-α, but the levels in many samples were close to the limit of detection (data not 
shown).  
 
Figure 4.6 Quantification of systemic neutrophils, cytokines and chemokines after 
SCI and one intravenous injectionof DHA (250 nmol/kg), EPA (250 nmol/kg), or 
saline 30 min after SCI. (A) 4 and 24 h after SCI there was a trauma related increase in 
the number of neutrophils recruited to the liver. Treatment with DHA or EPA did not 
reverse this increase. Results are mean ± SEM of naïve (n=3); 4 and 24 h sham (both 
n=4); 4 h vehicle (n=11); 24 h vehicle (n=7); 4 and 24 h DHA (both n=8); 4 h EPA (n=6); 
24 h EPA (n=9).Circulating plasma (B) and hepatic levels (C) of KC/GRO/CINC were 
significantly increased 4 h following compression SCI compared to naive levels 
(***p<0.001) and additionally in the sham group (***p<0.001).  Levels returned to 
baseline values 24 h after surgery. Treatment with DHA or EPA did not reverse this 
increase. Results are mean ± SEM number of animals (n=3-7 per group). Figure 
reproduced from Hall et al., (in submission).   
 
C - reactive protein (CRP) 
 
Control levels of CRP in the 4 h plasma samples from sham or naïve animals were 384 ± 
32 μg/ml (Fig. 4.7). Following SCI, there was a significant increase in the vehicle (saline)  
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treated group to 471 ± 20 μg/ml. DHA significantly reduced the CRP levels to control 
levels (392 ± 10 μg/ml; p<0.05), whereas EPA had no significant effect (507 ± 23 μg/ml; 
p>0.05). 
 
 
Fig. 4.7 CRP plasma levels 4h after SCI and one intravenous injectionof DHA (250 
nmol/kg), EPA (250 nmol/kg), or saline 30 min after SCI. ELISA revealed a 
significant increase in the vehicle (saline) treated group (p<0.05). DHA significantly 
reduced the CRP levels to control levels (p<0.05), whereas EPA had no significant effect 
(p>0.05). Data reproduced from Hall et al., (in submission). 
 
4.2.5 Effects of acute EPA injection on macrophage infiltration 
 
Our laboratory has previously assessed the effect of DHA injection on macrophage 
infiltration. A significant reduction was found at 7 and 28 days (Huang et al., 2007a). 
Detailed quantification in the rostral, epicentre and caudal sections revealed a trend 
towards a reduction of 28% in the epicentre of ED1 labelled macrophages at 7 days 
following acute EPA injection (Fig. 4.8B). However, this did not reach significance (P > 
0.05).  Similarly, in rostral and caudal sections there was no statistically significant 
decrease in the amount of macrophages in the EPA treated group (P > 0.05).  
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Figure 4.8 ED1 labelling of macrophages and activated microglia 7 days following 
SCI and one intravenous injection of EPA (250 nmol/kg), or saline 30 min after SCI.  
Following treatment with EPA, there appeared to be a decrease in the amount of ED1 
labelling in the epicentre (Ae versus Ab). Detailed quantitative analysis (B) revealed a 
trend towards a decrease in the amount of ED1 labelled macrophages in the epicentre. 
However, this did not reach significance (P > 0.05). Similarly, in rostral and caudal 
sections (Ad versus Aa; Af versus Ac) there was no significant decrease in the amount 
of macrophages in the EPA treated group (P > 0.05). Data represents mean ± SEM; n=4 
or 5 in each group. Figure reproduced from Lim et al., 2010 but created and data analysed 
by JH. 
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4.3 DISCUSSION 
 
In the current chapter, we have explored the effects of DHA and EPA injection on the 
acute local and systemic inflammatory response following compression SCI. An i.v. 
injection of DHA (250 nmol/kg), 30 min after SCI, significantly reduced the amount of 
neutrophils in some areas of the injury epicentre, whereas the EPA (250 nmol/kg) 
injection had no significant effect, although there was a trend towards a reduction. 
Further experiments showed a robust increase in the injury epicentre of MPO and 
cytokines and chemokines and CRP in the plasma, at 4 h after SCI. DHA significantly 
returned CRP levels to control values, whereas EPA did not. DHA and EPA did not 
change the myeloperoxidase (MPO) activity in the tissue epicentre, nor did they reduce 
the levels of pro-inflammatory cytokines and chemokines, systemically or locally, 
associated with neutrophil migration. 
 
4.3.1 Effects of DHA and EPA on the local neutrophil response to compression SCI 
 
A reduction in the number of neutrophils of 71% in the ventrolateral white matter 
(VLWM) at 4 h and 40% in the ventral horns at 24 h was found in the injured epicentre 
after treatment with DHA. DHA could be targeting events in the endothelia, preventing 
chemotaxis and extravasation of neutrophils, as demonstrated by others (Sperling et al., 
1993; Lee et al., 1985). It is not clear why the effect of DHA was confined to only two 
regions of the epicentre. We cannot directly compare the impact of treatment on 
neutrophils to the work of Fleming et al. (2008, 2009) since their quantification was not 
based on a cell count, but the percentage of immunoreactivity of MPO positive 
neutrophils. Also, a much larger sample box (0.5 cm x cord width) than ours was 
analysed on longitudinal sections. The improved behavioural and sensory outcome that 
they observed following their clip compression model of SCI was correlated with at least 
a 50% reduction in neutrophil infiltration at 3 days, but no improvement was seen after 
delayed treatment and a reduction of only 36%. Despite a decrease in our model of up to 
71 % in the VLWM at 4 h, the smaller reduction in other areas of the epicentre would 
dilute the effect if the counts were pooled to reflect a larger total area and there would 
have been a modest reduction overall. It is therefore very unlikely that the behavioural 
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improvement associated with omega-3 injection found elsewhere (Lim et al., in press; 
King, et al., 2006; Huang, et al. 2007a) is solely due to the modest reduction seen in 
neutrophil numbers.  
 
DHA and EPA have been reported to differ in their regulation of inflammatory processes. 
For example, DHA is more effective than EPA in reducing acute inflammatory processes 
such as infiltration of lymphocytes and expression of cytokines (Tomobe et al., 2000), 
whereas others suggest the opposite (Sierra et al., 2008; Terano et al., 1987). Some of 
these differences can be attributed to the different inflammation models used, such as 
controlled in vitro models of inflammation with activation of specific receptors such as 
toll-like receptor 4 (TLR) 4 by lipopolysaccharide. There are further differences in the 
amount, delivery and form (free fatty acid or ester) of PUFAs used. The concentration of 
DHA required for some of these reported effects is beyond the physiological range of 
DHA, which can reach for example 6.7 μM in murine serum in animals fed on a diet 
enriched with fish oil (Kim et al., 2010). Furthermore, studies that reported a 
modification in the composition of fatty acids in leukocyte membranes after fatty acid 
intake were based on chronic dietary enrichment (Sperling et al., 1993; De Deckere et al., 
1999; Healy, et al., 2000; Wang et al., 2006; Bousquet et al., 2008).  
 
A reduction in neutrophil number has usually been found to be associated with a parallel 
MPO decrease (Bao et al., 2004; Fleming et al., 2008) which was not the case here. It is 
possible that any effect on MPO in our study was masked as a result of analyzing a mixed 
homogenate from the entire epicentre section. The neutrophil quantification was carried 
out on specific areas, so was possibly a more sensitive analysis. Although samples are 
measured against a standard curve created using purified MPO, it is not clear whether the 
assay is specific for MPO or in fact measures all endogenous peroxidase activity. The 
increase in MPO that was seen here at 4 and 24 h correlates with the work of Bao et al. 
(2004), who looked at 6, 24, 72 h and 1 week and  found elevated levels up until 72 
hours, with a return to control levels at 1 week. The amount of MPO that they found is 
not directly comparable with our results due to the differences in SCI model, assay 
protocol, storage of samples, activity between the purified MPO standard, use of TMB 
substrate and plate to plate variation, but it would appear that we found considerably 
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more activity in our samples at 24 h (100 fold; 0.1 U/μg compared to our 10 U/μg). 
Taoka et al. (1997) found a larger peak of MPO activity (~0.7 U/μg) at 3 h after SCI, in 
male Wistar rats. In addition, Xu et al. (2009) reported a significant increase at 24 h (0.5 
U/μg), but these were both still a lower activity than what we found. We did encounter 
some technical difficulties with the assay while optimising the standard curve and 
thought that the enzyme activity was lower than expected. Therefore, we increased the 
concentration of the enzyme for the standard curve, but this should not have affected the 
detection of enzyme activity in the samples.  
 
We chose to examine the effects of omega-3 fatty acid injection during the peak of the 
neutrophil response, at 4 and 24 h after SCI. It is possible that the effects of treatment on 
neutrophil numbers and MPO activity at these time points were masked by saturation of 
the response. Typically, neutrophils undergo programmed apoptosis around 24 h after 
entering inflamed tissue (Gallin and Snyderman, 1999) and metabolites of DHA and EPA 
can enhance the removal of neutrophils and resolution of inflammation (discussed below; 
see also Serhan and Savill, 2005). It would be interesting to examine whether DHA or 
EPA accelerate this process after SCI. In our model, the timing of peak neutrophil 
infiltration (one day) correlates with doubling of neuronal (NeuN) loss from 43% at 1 day 
to 73% at 3 days. The death of neurones at 3 days is unlikely to be due to the initial injury 
alone (Huang et al., 2007b). Whether the number of neutrophils in the epicentre remains 
high at 3 days, or if they undergo apoptosis at this time point has not yet been examined 
in our model.  
 
A reduction in neutrophils is not always associated with improved outcome. Stirling et al. 
(2009) found that treatment with an antibody against Ly6G (a major antigen on mature 
neutrophils) 2 and 24 h after SCI in mice, reduced circulating neutrophils by >90%, but 
this was accompanied by reduced spared white matter and worsened behavioural 
outcome. The authors alluded to a novel hypothesis, that neutrophils after SCI might be 
involved in the wound healing response by promoting the astrocyte response. Reactive 
astrocytes help seal off and isolate the necrotic core of the lesion site, help to re-establish 
the integrity of the blood-brain barrier, and detoxify molecules such as free radicals and 
glutamate (Sofroniew, et al., 2005). This scar formation provides a barrier for axonal 
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regeneration, however recent studies have found that reducing astroctye activity and 
astrogliosis after SCI worsened functional outcome (Faulkner et al., 2004; Herrmann et 
al., 2008; Renault-Mihara et al., 2008). Clearly, further work is needed to confirm this 
hypothesis of a beneficial role of neutrophils after SCI.  
 
4.3.2 Effects of DHA and EPA on the cytokine/chemokine response to compression 
SCI  
 
In parallel with the effects of the DHA injection on neutrophil infiltration, we considered 
whether there might be a related effect on signalling molecules associated with SCI 
pathology and neutrophil infiltration. Active tissue invasion by inflammatory cells 
requires appropriate adhesion molecules and chemokines, such as cytokine-induced 
neutrophils chemoattractant-1 (CINC-1), or IL-8 to attract cells to their targets. It has 
already been mentioned above that the use of omega-3 PUFAs has been associated with a 
reduction in the amounts of these molecules.   
 
Until recently, it has only been possible to measure one protein at a time using enzyme-
linked immunosorbent assay (ELISA). Another widely used method to quantify levels of 
cytokines is to measure mRNA levels using reverse transcriptase polymerase chain 
reaction (RT-PCR). However, changes in mRNA levels will only have an impact if the 
increases in transcription result in changes in the levels of the encoded bioactive proteins. 
Recent technology has now made it possible to measure multiple molecules at a time in 
one sample. We designed a custom plate containing a select group of factors: IL-6, 
KC/GRO/CINC, IL-1β and TNF-α, related to SCI pathology and neutrophil infiltration.  
Discussion with the manufacturer helped avoid the use of a combination of 
cytokines/chemokines whose amounts could cover entirely different ranges. We saw a 
robust increase at 4 h in all of these factors followed by decrease to control levels at 24 h, 
in agreement with the report on the mRNA expression of these cytokines in contusion 
SCI by Streit et al. (1998) and by others (Yakovlev and Faden, 1994; Wang et al., 1997; 
Lee et al., 2000). It would be expected that mRNA changes would precede protein levels, 
and if we had looked at additional time points between 4 and 24 h this might have been 
elucidated. We also might have seen further differences such as a slightly later peak of 
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IL-6 (6 h, Streit et al., 1998) compared to TNF-α and IL-1β (1 h). Elevated IL-1β and 
TNF-α mRNA have also been detected in the injured spinal cord within 1 hr post-injury 
(Yakovlev and Faden, 1994; Wang et al., 1997; Lee 1999). Levels remained high at day 
1, returned to low levels by day 3, and were not detected by day 5. Similar dynamics 
were seen in rat brain in stroke models (Taupin et al., 1993; Wang et al., 1998), along 
with increased CINC concentration (Yamagami et al., 1999) but a smaller increase in IL-
6 and TNF-α and a smaller, later increase of IL-1β was seen in axotomized facial nerve 
(Streit et al., 1998). Delayed and reduced infiltration of leukocytes to the brain has been 
associated with the delayed increase in cytokine levels (Schnell et al., 1999).We found no 
difference in the levels of pro-inflammatory cytokines and chemokines in the epicentre 
after DHA or EPA injection. This was surprising, since treatment with omega-3 PUFAs 
has been shown to indirectly reduce a variety of inflammatory cytokines in other models 
of inflammation (Tomobe et al., 2000; De Caterina and Massaro 2005), possibly by 
blocking activation of NF-ĸB (De Smedt-Peyrusse et al., 2008).  
 
The antibodies were attached to the bottom of each well, rather than coating the entire 
surface of the well as in the ELISA method, which can reduce noise/background levels. 
Using the method of electrochemiluminescence detection rather than the ELISA method 
also meant that background signals were minimal, because the stimulation mechanism 
(electricity) is decoupled from the signal (light). We did not find significant well to well 
variation between replicates and therefore measuring samples in duplicate was sufficient. 
It is the first time that spinal cord homogenates have been measured using this method 
and the increase in cytokines/chemokines in all treatment groups at 4 h compared to the 
control group would suggest that the method was satisfactory.  
 
The short duration of cytokine/chemokine increase after SCI, indicates a self-limited 
process. It is likely that the early increase in levels of cytokines/chemokines originates 
from cells endogenous to the spinal cord, probably astrocytes or microglia, since these 
cells have been shown to produce IL-6 in vitro and monocytes do not infiltrate the 
epicentre until later time points (Sawada et al., 1992; Suzumura et al., 1996;). In addition, 
IL-6 knockout mice show marked attenuation of glial cell activation (Klein et al., 1997). 
Multi-labelling analysis has revealed that microglia and astrocytes, 30–45 minutes post 
SCI in the mouse, were the two major sources of IL-1β and TNF-α at these times (Pineau 
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et al., 2007). Colocalization studies revealed that all populations of CNS resident cells, 
including neurones, synthesized cytokines between 3 and 24 hours post-SCI. In addition, 
Pineau et al. (2009) demonstrated that astrocytes distributed throughout the spinal cord 
initially contributed to early neuroinflammation by rapidly synthesizing monocyte 
chemoattractant protein-1 (MCP-1), KC, and MIP-2, from 3 up to 12 h post-SCI. 
 
The early transient expression also suggests that these cytokines/chemokines play a 
primary role in the acute phase of the injury response, and that they are not directly 
involved in causing additional, secondary tissue damage. Dramatic upregulation of IL-1β 
and TNF-α transcripts does not occur following CNS injuries in which the blood-brain 
barrier remains intact, i.e., the axotomized facial nucleus (Streit et al., 1998). It is 
therefore likely that breakdown of the blood-brain barrier, which is a common occurrence 
in traumatic and ischemic injuries, contributes to the induction of the transcription of 
these cytokines. It has been reported that direct injection of IL-1β or TNF-α into normal 
CNS caused widespread leukocyte margination, but little or no diapedesis, suggesting 
that the normal CNS is resistant to leukocyte diapedesis (Andersson  et al., 1992). 
 
Our treatment with omega-3 PUFA did not attenuate the increase in 
cytokine/chemokines. This would suggest that the reduction in neutrophil number by 
DHA was independent of the cytokine/chemokines that we measured, although it could 
be that the modest effect we saw was diluted by analysing the entire spinal cord 
homogenate. Methylprednisolone and dexmedetomidine treatment have been shown to 
significantly decrease TNF-α and IL-6 levels at 24 h along with a reduction in neutrophils 
(Can et al., 2009). Also, Xu et al. (2009) found that in combination dexamethasone and 
aminoguanidine reduced TNF-α or IL- 1β increase along with a neutrophil reduction 
(measured by MPO assay), but did not have this effect when given separately. 
Application of antiserum to TNF-α locally following an incision of the dorsal horn at 
T10/11was neuroprotective, but the time points of intervention were not clinically viable 
(30 min preceding injury, and up to 10 min post-SCI) (Sharma et al., 2003). Etanercept is 
a TNF blocker and used to treat inflammatory disorders. It has not been shown to 
improve locomotor outcome but can reduce the development of neuropathic pain 
(Marchand et al. 2009). Blocking cytokines/chemokines in a limited number of studies 
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has led to improved locomotor outcome, but these treatments have not progressed to 
clinical trials. It could be that manipulating these molecules is not as effective compared 
to changing the levels of those molecules involved in the physical mechanisms of 
leukocyte transmigration, such as the integrins, which appear to have had more success 
preclinically.  
 
4.3.3 Effect of omega-3 PUFA injection on systemic inflammatory markers 
 
Injury causes a systemic inflammatory response syndrome (SIRS) that is clinically much 
like sepsis (Bone et al., 1992) and consists of the acute phase response (APR), where 
cytokines and chemokines such as IL-6 and Il-1β are manufactured by the liver and 
released into the circulation. Evidence reported by Davis et al. (2005) and Campbell et al. 
(2003; 2005) demonstrates that the acute phase response (APR) of the liver stimulates 
additional recruitment of leukocytes to the injury site following a mild compression SCI 
at thoracic level 8, and exacerbates damage (Campbell et al., 2005). 
 
We found that compression SCI was accompanied by a sustained systemic response, 
marked by accumulation of neutrophils and resident macrophages in the liver and pro-
inflammatory cytokine and chemokines in circulating plasma and the liver. Our results 
partly support the work of Campbell et al. (2005), although the response of a 
laminectomy group was not described in that study. We found no difference in the 
number of neutrophils recruited to the liver after SCI or after laminectomy surgery alone, 
indicating that the APR of the liver is not specific to SCI in our model and is a generic 
response to tissue trauma. Cellular injury can release endogenous „damage‟-associated 
molecular pattern molecules (DAMPs) that activate innate immunity (Matzinger, 1994; 
Zhang et al., 2010) and can elicit neutrophil-mediated organ injury. However, it remains 
unclear why the increase in neutrophil number in the liver persists at 28 days. Our 
hypothesis was that omega-3 PUFA treatment by i.v. injection could influence the 
systemic response and therefore open the possibility of a parallel therapeutic benefit. 
However, neither DHA nor EPA injection had an impact on this systemic response. 
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Interestingly, there were differences between the effects of EPA and DHA on CRP levels 
in the plasma. DHA significantly reduced levels of CRP in the plasma after SCI, whereas 
EPA did not. The amount of CRP in plasma in the control group fell within the range 
reported by other studies, which is a much higher constitutive level in the rat than in 
humans (350-400 mg/l vs. 1.1-1.5 mg/l; Madsen et al., 2003). Elevated CRP levels have 
been measured in adults with chronic SCI (>3 mg/l) (Manns et al., 2005; Gibson et al., 
2008) but have not been documented acutely after SCI. There is no direct interaction that 
has been proposed for PUFA with CRP, but it is likely to be an indirect mechanism. In 
some studies of healthy individuals, there have been reports in the literature, mainly 
correlative, where an inverse relationship has been found between the intake of omega-3 
PUFAs and levels of CRP (Madsen et al., 2001; Niu et al., 2006; Poudel-Tandukar et al., 
2009).  
 
We found relatively higher levels of KC/GRO/CINC and IL-6 in plasma compared to the 
liver samples at 4 h.  This indicates that the peak of their production, if this was in the 
liver, would have occurred at an earlier time point between <1-4 h. However, it might be 
that local production of these markers at the injury site, where higher levels were found in 
this case, was more important in contributing to their elevated levels at this time point. 
We found very low levels of TNF-α and IL-1β, close to the limit of background levels in 
plasma and liver samples (not shown here). Wang et al., (1996) could not detect TNF in 
the CSF or serum collected from rats both with and without SCI. However, this was 
measured using a cytotoxic assay and cannot be directly compared with our results. The 
authors suggested that TNF is produced locally in the spinal cord following traumatic 
injury, in agreement with our findings.  
 
4.3.4 EPA injection showed a trend towards reducing macrophage infiltration at 7 
days 
 
Treatment with DHA (250 nmol/kg) after compression SCI has been shown previously in 
our laboratory to reduce the amount of macrophage infiltration to the epicentre, 7 days 
and 6 weeks after injury (Huang et al., 2007a). However, another study using a 
hemisection model of SCI found that there was no difference in the macrophage levels 
between the DHA (250 nmol/kg) and saline treated groups 7 days after SCI (King et al., 
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2006). Here, despite a strong trend towards a reduction, along with significant neuronal 
and oligodendrocyte protection and improved behavioural outcome (not shown here, Lim 
et al., in press), the same dose of EPA did not significantly alter the levels of 
macrophages at 7 days. The low numbers in each group limited the power of statistical 
analysis in this case, and it is probable that increasing group size could have led to a 
significant difference. It is clear from our collection of data that there is not a 
straightforward relationship between the presence of tissue macrophages in the epicentre 
(identified with the ED1 marker) and behavioural outcome.  
 
It was obvious from looking at the tissue sections in all groups that the injury epicentre 
was extensively damaged and perhaps saturated with the accumulation of inflammatory 
cells. We therefore also analysed sections rostral or caudal to the epicentre, to explore 
whether some differences between the two groups in the amount of macrophage 
infiltration would be seen along with increased sparing of tissue. However, although the 
amount of macrophages was less overall and there was still a trend towards a reduction, 
there was still no statistically significant effect of the EPA treatment. Phagocytic 
microglia are also labelled by ED1, but it would be useful to extend the analysis to 
include activated as well as phagocytic microglia. This could be done using Iba1 and 
would label additional activated microglial cells that might not have been picked up by 
the ED1marker alone. 
 
Reducing numbers of macrophages after SCI may not be an ideal intervention. A 
significant number of findings show that immunosuppression caused by trauma itself sets 
in days to weeks after the injury. A greater loss of immune function after SCI could 
seriously compromise recovery. High dose methylprednisolone has been criticised for 
causing widespread and prolonged effects on monocytes/macrophages and neutrophils, 
that lead to extended suppression of monocyte/macrophage function and prolonged 
actions of intraspinal neutrophils (Dayyani et al., 2003) due to the lack of clearing by 
macrophages. The immune response following SCI has been shown to be important for 
aiding regeneration (Schwartz et al., 1999). Implantation of macrophages (Lazarov-
Spiegler 1996; Rapalino, 1998) and passively transferred activated T cells specific to a 
CNS antigen, myelin basic protein (MBP; Moalem, et al., 1999) have been shown to 
protect neurons from secondary degeneration. Therefore, it may be more desirable to 
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preserve or enhance the neuroprotective properties of macrophages and the infiltration of 
T cells at later time points following SCI.  
 
4.3.5 The omega-3 PUFA injection may be converted into active anti-inflammatory 
metabolites or directly interact with cellular targets 
 
It is not yet clear what proportion of the free DHA and EPA that is injected in our 
experiments is simultaneously incorporated into phospholipids, taken up by binding 
proteins, directly bound to intracellular or extracellular receptors, or rapidly converted 
into anti-inflammatory metabolites, thus indirectly influencing recruitment of neutrophils. 
Proinflammatory eicosanoids derived from AA such as the 2-series prostaglandins and 
thromboxanes, and 4-series leukotrienes stimulate the production of lipoxins (Levy et al., 
2001), also derived from AA which are significantly involved in reducing the entry of 
new neutrophils to sites of inflammation (Serhan et al., 1995) and reperfusion injury 
(Chiang et al., 1999) and macrophages to ingest and clear apoptotic neutrophils (Takano 
et al., 1998; Godson et al., 2000). These events coincide with the biosynthesis of less 
inflammatory products from EPA, the 3-series prostaglandins and thromboxanes, and 5-
series leukotrienes, and from both EPA and DHA, the anti-inflammatory and pro-
resolving metabolites such as the resolvins of the E and D series, respectively, which are 
actively involved in the resolution of inflammation (for review, see Serhan et al. 2005, 
2008; Farooqui et al., 2007b; Calder 2010). At nanomolar levels, one of the metabolites 
of EPA, resolvin E1, dramatically reduces dermal inflammation, peritonitis, dendritic cell 
migration, and interleukin IL-12 production (Arita et al. 2005). These metabolites have 
been shown to antagonize the effects of AA-derived prostaglandins and thromboxanes, 
decrease proinflammatory cytokine production and attenuate neutrophil migration and 
tissue injury in peritonitis and ischemia-reperfusion injury models (Hashimoto et al., 
1999; Serhan et al., 2002; Hong et al., 2003; Marcheselli et al., 2003; Spite et al., 2009). 
The D resolvins derived from DHA decrease leukocyte–endothelial interactions in vivo 
and neutrophil recruitment by direct modulation of leukocyte adhesion receptor 
expression. In addition, they block TNF-α-induced interleukin (IL)-1β transcripts and are 
potent regulators of neutrophil infiltration in brain (Serhan et al. 2004; Spite et al., 2009). 
The pro-resolving metabolites derived from EPA and DHA are a log order more potent 
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than their parent compounds, and interestingly, there is some indication that protectin D1  
may have overall a better pro-resolving  profile than resolvin E1 (Serhan et al., 2006, 
2008). The conversion of DHA and EPA into their metabolites may occur very fast. It has 
been shown that both long chain omega-6 and omega-3 fatty acids have a rapid 
disappearance in plasma (Zhou et al. 2002; Rapoport et al 2007). After intravenous 
injection, the fatty acids will very likely be rapidly incorporated into phospholipids, but a 
fraction of the injected dose could be converted into metabolites. It will be interesting to 
quantify the metabolites of DHA and EPA such as resolvins and protectins in future 
work.  
 
Since we have found a rather modest effect of DHA on the acute inflammation after SCI, 
we need to consider other mechanisms to account for the previously documented 
neuroprotective effects of omega-3 PUFAs (King, et al., 2006; Huang et al., 2007a) 
One possibility may involve action on retinoid X receptors (RXRs), one of several 
members of the retinoic acid receptor family. These ligand-regulated transcription factors 
are required to mediate the retinoic acid signalling cascade and are activated and 
expressed by microglia after spinal cord contusion injury (Mey et al., 2005). Minor 
changes were observed in the quantitative expression of retinoid receptors after SCI, but 
their cellular location appeared to move from the cytosol of motoneurones and glia in 
uninjured tissue, to the nucleus of macrophages and surviving neurones close to the 
injury site (Schrage et al., 2006). A recent paper has demonstrated that fenretinide, a 
semisynthetic analogue of retinoic acid, significantly reduced tissue damage, 
proinflammatory gene levels and improved locomotor recovery when administered after 
SCI. Interestingly, this was accompanied by a significant decrease in AA and increase in 
DHA levels in plasma and injured spinal cord tissue (López-Vales et al., 2010). It is 
possible that the DHA bolus could modulate retinoid signalling after SCI.  
 
DHA and EPA also bind to and activate a second group of transcription factors, called 
peroxisome proliferator-activated receptors (PPARs).Three isoforms have been 
described, PPARα, PPARγ and PPAR-β/δ. All possess anti-inflammatory activity and are 
known to occur in neural tissues (Drew et al., 2005). PPARα was demonstrated to           
be involved in recovery in a murine knockout model of lung inflammation (Cuzzocrea et 
al., 2008). PPARγ has been shown to regulate inflammatory signalling in neural cells 
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(Park et al., 2003; Welch et al., 2003). Furthermore, PPAR-β/δ agonists reduce 
inflammatory activity and exert beneficial effects in a mouse model of SCI (Ding et al., 
2006; Paterniti, et al. 2010).  
 
Another possible target is the potassium channel TREK-1, which is a key component in 
shaping the characteristics of neuronal excitability. TREK-1 is mechano-sensitive and can 
also be activated by PUFAs, including DHA. Models of epilepsy and ischemia have 
shown that the marked neuroprotection induced by omega-3 PUFAs is abolished in mice 
with a disrupted TREK-1 gene (Lauritzen et al., 2000; Heurteaux et al., 2004). TREK-1 is 
not directly involved in inflammation. Since we have found modest or no effect of DHA 
and EPA on acute inflammation after SCI, it is possible that activation of TREK-1 could 
account for the neuroprotective effects of omega-3 PUFA previously documented (King, 
et al., 2006; Huang et al., 2007a). The involvement of all these specific targets could be 
tested in future experiments using selective antagonists and transgenic animals. 
 
4.3.6 Conclusions  
 
The purpose of the work in this chapter was to focus on the early phase of inflammation 
after SCI and to assess whether it is affected by an acute administration of omega-3 fatty 
acids. A modest reduction in neutrophil number was seen in the epicentre after DHA, but 
the reduction did not reach significance after EPA treatment. No other parameter was 
affected by the fatty acids. The dose of fatty acid that we used in this study confers strong 
histological protection and markedly improves locomotor recovery (Huang et al. 2007a; 
King et al., 2006). The role of inflammatory processes in the outcome and recovery 
following SCI is controversial. It remains to be established, using other markers, whether 
omega-3 PUFAs have a major impact on the specific early inflammatory response after 
SCI, and to what extent the modulation of inflammation is a determinant of their 
neuroprotective effect.  
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Chapter 5: Results III. The effects of the acute intravenous 
administration of DHA in a contusion model of SCI in the rat 
 
5.1 Introduction 
 
The models that are considered most clinically relevant for spinal cord injury are the 
compression and contusion models, rather than the laceration-type injuries (Tetzlaff et al., 
2010). The contusion device was first described by Allen (1911) as a simple weight that 
is dropped from a varying height. This basic method has now been optimized through 
precision controlled devices such as the MASCIS/NYU impactor, designed by Wise 
Young, John Gruner, and Carl Mason at New York University Medical Centre in 1991, 
the Ohio State University (OSU) electromagnetic SCI device (Stokes et al., 1992), which 
is a displacement-driven model, and the force-driven Infinite Horizons Contusion (IHC) 
device (Scheff et al., 2003; Precision Systems and Instrumentation, Lexington, KY).  
 
5.1.1. Comparison between the contusion and compression models of SCI 
 
The NYU impactor precisely measures the movement of a 10-gram rod onto the dorsal 
surface of the thoracic cord. The height of the rod dropped can be accurately controlled. 
After impact, a computer readout gives information on impact trajectory, impact velocity, 
cord compression distance and time. The OSU device is used frequently for mouse 
experiments (Jones et al. 2002; Sroga et al. 2003; Ankeny et al., 2006; Basso et al., 2006; 
Kigerl et al., 2006). The IHC instrument enables the application of standard-force injuries 
through electronically controlled impaction, and force levels can be varied accordingly. 
The IHC device is usually applied to the lower thoracic spinal levels (T8-T10). However, 
the device has also been used to create a cervical hemicontusion injury (Siriphorn et al., 
2010). By altering the impact force, a force of 150 kDyne in rats relates to a moderate-
mild SCI, with a plateau to a recovery of locomotor function of 15 on the BBB test 
(Rabchevsky et al., 2003; Cao et al., 2005). This equates to consistent plantar stepping 
and coordination but with some dragging of the hindlimbs. 
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Development of the contusion model of SCI was carried out with the NYU impactor 
device, alongside the establishment of the open field test of locomotion (BBB score; 
Basso et al., 1996). The OSU device was characterised in the mouse (Ma et al., 2001) and 
the IHC device was characterised by Scheff et al. (2003) and Cao et al. (2005), along with 
the development of the mouse open field test of locomotion (BMS score; Basso et al., 
2006). A comparison was made between the NYU and IH contusion devices by 
Rabchevsky (2003), where a similar amount of gray matter damage was found, while the 
NYU device rendered a greater loss of white matter, reflected in more severe hind limb 
functional deficits. 
 
The main difference between the contusion and compression models of SCI, is the initial 
impact force, which is less, but more prolonged following compression. Contusion is 
likely to cause greater and immediate shear stress at the site of injury and possibly more 
cell death. Maximal neuronal loss after contusion SCI has been shown to occur at 8 h 
after injury (Liu et al., 1997), with no further loss at later time points (Grossman et al., 
2001). In contrast, following compression SCI there is a protracted period of neuronal 
loss, which extends rostral and caudally to the injury site up to a month after the injury, as 
shown in our laboratory (Huang et al., 2007b). These differences may be due to the 
pathogenesis of the secondary insults such as ischemia, inflammation and free radical 
production.  
 
The inflammatory response follows a similar pattern in the contusion and compression 
models of SCI and has been discussed in the previous chapters. In both models in the rat, 
there is an initial (within 24 h) infiltration of neutrophils, followed by the chronic 
accumulation of phagocytic macrophages/microglia at later time points (within 7 days), 
spreading above and below the initial injury site. 
 
5.1.2 Treatments that have been assessed in more than one model of SCI 
 
Several promising preclinical treatments in SCI have failed to be translated successfully 
to the clinic. In order to increase the probability of successful translation to the clinic, it is 
important to show efficacy in more than one species and/or model of SCI and ideally to 
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replicate the success of the treatment in more than one independent laboratory. Although 
this is an important exercise, it is done at the expense of a study that might not be 
published. The "Facilities of Research-Spinal Cord Injury" is part of a recent NIH 
initiative which supports the independent replication of published studies and some of 
these will be described below. 
 
Targeting myelin inhibition, or Nogo, is one of the longest-studied therapeutic strategies 
in SCI. The anti-Nogo (IN-1) antibody, developed in Martin Schwab‟s laboratory has 
been tested in rat and primate species using more than one model of SCI (Schnell and 
Schwab, 1990; Thallmair, 1998; Merkler et al., 2001). Intrathecally applied anti-Nogo 
IgG treatment has been demonstrated to stimulate regeneration/sprouting of axons and 
lead to functional improvements (Liebscher et al., 2005; Freund et al., 2007, 2009; 
Wannier-Morino et al., 2008). Another approach is the intrathecal or subcutaneous 
injection of the competitive antagonist of the Nogo receptor with a synthetic Nogo-66 (1-
40) peptide (Nogo extracellular peptide, residues 1-40, or NEP1-40). Histological 
improvements, i.e. stimulation of sprouting/regeneration of axons and modest behavioral 
improvements have been demonstrated with acute intervention (Grandpre et al., 2002; 
Atalay et al., 2007; Cao et al., 2008) and with a delay of treatment up to 7 days post-SCI 
(Li and Strittmatter, 2003). Together, the two approaches have provided compelling 
evidence to support the pursuit of their translation but the majority of investigation has 
resided within single laboratories. A formal, NIH-funded replication study failed to 
reproduce the significant benefits of NEP1-40, although there was a weak suggestion that 
NEP1-40 „„created a situation that was slightly more conducive to axon regeneration‟‟ 
(Steward et al., 2008). There is need for further investigation to characterize the 
robustness of this intervention. The anti-Nogo antibody treatment has not undergone a 
similar replication study, possibly due to commercial intellectual property issues, but has 
been translated into human clinical trials, with a European and Canadian trial being 
initiated in 2007. 
 
Minocycline has been evaluated relatively extensively in thoracic contusion SCI (Lee et 
al., 2003; Teng et al., 2004; Festoff et al, 2006), balloon compression (Saganová et al., 
2008), clip compression (Wells et al., 2003), and transection models (Stirling et al., 2004; 
Labombarda et al., 2006; Gonzalez et al., 2009). A range of doses was administered, the 
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most common dose used was 90 mg/kg, given intraperitoneally immediately after, or 
within 1 h of SCI and led to improved locomotor outcome. Non-behavioural outcomes 
included tissue sparing, decreased cytochrome c release, decreased caspase 3 positive 
oligodendrocytes, and macrophages/microglia. Pinzon and colleagues (2008) made an 
NIH-sponsored attempt to reproduce the positive effects of minocycline that had been 
demonstrated by others in contusion SCI, but failed to reveal any benefit to either 
intraperitoneally or intravenously administered minocycline at the 90mg/kg dose with no 
clear explanation for the contradictory results from this attempted reproduction. 
Intravenously administered minocycline is however, under evaluation as a 
neuroprotective compound for the management of SCI in a phase I/II pilot study in 
Calgary, Alberta. 
 
Erythropoietin is another example of a promising treatment for SCI that has been studied 
in more than one model of SCI. Neuroprotective effects have been reported after 
unilateral hemisection (King at al., 2007) and improved behavioural outcome after 
thoracic contusion SCI, when delivered within 30-60 min (Gorio et al., 2002; Boran et al., 
2005). However, Mann and colleagues (2008) examined both erythropoietin and 
darbepoetin, a more bioavailable version of EPO, but found neither to have any 
neuroprotective efficacy. An NIH-sponsored study by Pinzon and colleagues (2008) 
failed to reproduce the positive effects of EPO described previously, particularly the 
studies by Gorio and colleagues. Like minocycline, it is unclear how to interpret these 
contradictory reports on the efficacy of EPO in acute SCI. 
 
5.1.3 Aims 
 
Our laboratory has demonstrated so far the neuroprotective effect of DHA in the 
hemisection and compression models of SCI, and more recently, in a mouse model of 
compression SCI (Lim, et al., in press). The aim of the study presented in this chapter 
was to assess in a pilot study the effect of an acute i.v. administration of DHA in a rat 
contusion model of SCI.  We carried out a T8 contusion SCI (200 kDyne force) and we 
used the same treatment paradigm as that used in compression SCI (Huang et al., 2007a). 
We studied the effect of the treatment on locomotor function and also on tissue injury 
markers.  
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5.2 RESULTS 
 
5.2.1 Locomotor recovery 
 
The control group recovered to a BBB score of 10 ± 0.3 by day 14, where the majority of 
the group regained occasional weight supported plantar steps, but no forelimb-hindlimb 
coordination (Fig. 5.1). All groups recovered to a BBB score of 11 by 28 days (saline: 
11.1 ± 0.1; DHA 250 nmol/kg: 11.2 ± 0.3; DHA 500 nmol/kg: 11.4 ± 0.3). A 2 way RM 
ANOVA revealed that there was no significant effect of treatment (F=2.024; p>0.05) and 
time (F=315.5; p>0.05). The subscore analysis at 28 days following SCI showed a 
difference between groups, with the DHA 500 nmol/kg group having the highest score 
(4.9 ± 1.03) compared to the control group (2.7 ± 0.82), but this was not statistically 
significant (one way ANOVA; p>0.05; Fig. 5.2).  
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Figure 5.1 Effect of the acute administration of DHA on the BBB score after rat 
contusion SCI. Animals received i.v. saline, 250 or 500 nmol/kg DHA, 30 min after SCI, 
and were tested for 28 days post-injury. There was no significant difference between the 
three treatment groups. Error bars represent SEM, n = 8-10 animals per group. 
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Figure 5.2 Effect of the acute administration of DHA on the BBB subscore after rat 
contusion SCI. Animals received i.v. saline, 250 or 500 nmol/kg DHA 30 min after SCI, 
and were tested post-injury. There was no significant difference between the three 
treatment groups. Error bars represent SEM, n = 8-10 animals per group. 
 
 
When the groups were analysed based on the frequency of stepping at 28 days post-SCI, 
there was a clear difference between the groups, with 30 % of the control saline-injected 
group stepping frequently/consistently compared to 60 % in the DHA 250 group and 88 
% in the DHA 500 nmol/kg group. Statistical analysis using the Fischer‟s exact test 
revealed that the DHA 500 nmol/kg, but not the DHA 250 nmol/kg group, had 
significantly more frequent/consistent steppers than the saline-injected group (p<0.05; 
Table 5.1). 
 
Number of frequent or consistent steppers 
 
 Group    # frequent/consistent steppers 
 
 
 Saline      3/10 
 DHA 250     6/10 
 DHA 500     7/8 
  
Table 5.1 Effect of the acute administration of DHA on the recovery of stepping 
function after rat contusion SCI. Animals received i.v. saline, 250 or 500 nmol/kg 
DHA 30 min after SCI. Significantly more rats in the DHA 500 nmol/kg treated group 
recovered frequent or consistent stepping compared to the saline-treated group (p<0.05).  
n = 8-10 animals per group. 
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5.2.2 Histology 
  
5.2.2.1 Epicentre 
 
Similar to compression SCI tissue, contusion produced a central area of tissue destruction 
at the epicentre, with a spared peripheral rim (Fig. 5.3A, B). Because of the limited time 
available, only 7-8 animals from the saline and DHA 500 nmol/kg groups were used for 
tissue analysis.  
 
Figure 5.3 Effect of the acute administration of DHA on ED1 staining at the injury 
epicentre after rat contusion SCI. Animals received i.v. saline or 500 nmol/kg DHA 30 
min after SCI and the tissue was analysed 28 days post-injury. The analysis of the area 
covered by macrophages (ED1) revealed no significant difference between groups. 
Results represent mean ± SEM; n = 7-8 animals per group. Scale bar = 200 μm. 
 
 
Macrophages/microglia  
 
A large cystic cavity filled with macrophages was observed in regions previously 
occupied by the gray matter. Macrophages also occupied the rim of preserved tissue 
surrounding the cystic cavity (Fig. 5.3A, B). The quantitative analysis showed this to be 9 
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± 1.6% of the whole transverse section in the control saline-injected group; Fig. 5.3). 
There was no significant difference in the amount of macrophages (ED1) present in the 
saline and DHA 500 nmol/kg groups (p>0.05).  
 
Neuronal survival 
 
A small region of gray matter was spared in the dorsal horns of the injury epicentre, but 
only in a minority of animals (Fig. 5.4). Therefore, quantitative analysis of neurones was 
extended to a region 5 mm rostral to the injury epicentre (Figs. 5.7 and 5.8 below). 
 
 
Figure 5.4 Effect of the acute administration of DHA on NeuN staining at the injury 
epicentre after rat contusion SCI. Animals received i.v. saline or 500 nmol/kg DHA 30 
min after SCI, and the tissue was analysed 28 days post-injury. There was little 
preservation of neurones in the grey matter of the injury epicentre. A few neurones could 
be seen in the dorsal horns (red arrow). Scale bar = 200 μm. 
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5.2.2.2 Rostral 
 
Macrophages/microglia 
 
The tissue was relatively intact 5mm rostrally, compared to the injury epicentre. 
Macrophages (ED1) were found confined to the dorsal columns, as well as scattered 
throughout the white matter (Fig. 5.5A-B). Quantification confirmed a smaller amount of 
macrophages at this distance compared to the epicentre (1.6 ± 0.2 % compared to 9 ± 1.6 
% in the control group in the epicentre; Fig. 5.5C). However, there was no significant 
difference in the amount of macrophages between the saline-injected and the DHA 500 
nmol/kg treated groups (p>0.05).  
 
Figure 5.5 Effect of the acute administration of DHA on ED1 staining rostral to the 
injury epicentre after rat contusion SCI. Animals received i.v. saline (A) or 500 
nmol/kg DHA (B), 30 min after SCI, and the tissue was analysed 28 days post-injury. 
Quantification (C) revealed that there was no significant difference (p>0.05) between the 
saline and DHA 500 nmol/kg treated groups. Results represent mean ± SEM; n = 7-8 
animals per group. Scale bar = 200 μm. 
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Both microglia/macrophages of the phagocytic/activated phenotype, as well as the 
resting/ramified phenotype were labelled with the Iba1 antigen (Fig. 5.6). There was an 
area of phagocytic/activated microglia/macrophages confined to the dorsal columns, 
similar to the ED1 labelled cells, with additional Iba1-labelled cells displaying the 
resting/ramified phenotype throughout the remainder of the section. Quantification was 
performed on the phagocytic/ activated phenotype in the dorsal columns (6.8 ± 0.9 % of 
the analysis box in the control group; Fig. 5.6B) and on the resting/ramified phenotype in 
the dorsal horns (3.0 ± 0.45 % of the analysis box in the control group; Fig. 5.6C). There 
was no significant difference between the saline and DHA-treated groups in either of 
these areas (p>0.05 %), therefore the analysis was not extended to further areas. 
 
Neuronal survival 
 
Quantification of neurones was carried out by counting NeuN labelled cells in specific 
areas of the grey matter as described in the Methods chapter (Fig. 5.7A-C). Compared to 
counts on uninjured control tissue at approximately the T10/11 level (see Chapter 6), 
there was little neuronal loss at approximately the T7/8 level after T9 contusion (17.5 % 
in the dorsal horn and 6.7 % in the ventral horns, data not shown). There was no 
significant difference in the amount of neuronal survival at this level between the saline- 
and DHA-treated groups in either the dorsal horns (p>0.05; Fig. 5.7C), or ventral horns 
(p>0.05; Fig. 5.8C).  
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Figure 5.6 Effect of the acute administration of DHA on the microglia/macrophages 
(Iba1 staining) rostral to the injury epicentre after rat contusion SCI. Animals 
received i.v. saline or 500 nmol/kg DHA 30 min after SCI, and the tissue was analysed 28 
days post-injury. Quantification of microglia (Iba1) in the dorsal columns (red box and 
graph, B) and dorsal horns (yellow box and graph, C) revealed that there was no 
significant difference between the saline-injected and DHA-injected groups (p>0.05). 
Results represent mean ± SEM; n = 7-8 animals per group. Scale bar = 100 μm.  
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Figure 5.7 Effect of the acute administration of DHA on NeuN staining in the dorsal 
horns rostral to the injury epicentre after rat contusion SCI. (A-B) Representative 
sections showing NeuN labelled neurones in the dorsal horn. Animals received i.v. saline 
(A) or 500 nmol/kg DHA (B), 30 min after SCI, and the tissue was analysed 28 days 
post-injury. The same sections are counterstained with Hoechst on the right. Scale bar = 
100 μm (C) Quantification revealed no significant difference in the amount of neuronal 
survival at this level between the two groups (p>0.05). Results represent mean ± SEM; n 
=7-8 animals per group. 
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Figure 5.8 Effect of the acute administration of DHA on NeuN staining in the 
ventral horns rostral to the injury epicentre after rat contusion SCI. (A-B) 
Representative sections showing NeuN labelled neurones in the ventral horn. Animals 
received i.v. saline (A) or 500 nmol/kg DHA (B), 30 min after SCI, and the tissue was 
analysed 28 days post-injury. The same sections are counterstained with Hoechst on the 
right. Scale bar = 100 μm. (C) Quantification revealed no significant difference in the 
amount of neuronal survival at this level between the two groups (p>0.05). Results 
represent mean ± SEM; n =7-8 animals per group. 
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White matter pathology 
 
Using the non-phosphorylated neurofilament marker SMI32, an analysis was carried out 
on immunoreactivity in specific areas of the white matter (Fig 5.9). Following SCI, 
swollen particles of various sizes were seen in a haphazard distribution (Fig. 5.9). In the 
control and DHA (500 nmol/kg) groups (Fig. 5.10), the numbers of SMI32-labelled 
particles in the areas analysed were: DC (732 ± 46 vs.856 ± 131), CST tract (417 ± 45 
vs.442 ± 32), VWM (1202 ± 70 vs.1233 ± 35) and VLWM (1053 ± 80 vs. 1021 ± 39) 
respectively. There was no significant difference between the two treatment groups 
(p>0.05). 
Normal, uninjured spinal cord at a similar thoracic level was not available for this study. 
However, in the subsequent chapter, SMI32 labelling in uninjured spinal cord tissue can 
be seen as numerous, regular-sized punctate particles which were evenly distributed (see 
Fig. 6.14 in Chapter 6).  
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Figure 5.9 Effect of the acute administration of DHA on the SMI32 staining rostral 
to the injury epicentre 28 days after rat contusion SCI. (A-I) Representative sections 
showing SMI32 labelling in the DC (A, B), CST (C, D), VWM (E, F) and VLWM (G, 
H). SCI-animals received vehicle (i.v. saline, A, C, E, G) or 500 nmol/kg DHA (B, D, F, 
H), 30 min after SCI. Scale bar = 50 μm. 
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Figure 5.10 Effect of the acute administration of DHA on the SMI32 staining rostral 
to the injury epicentre after rat contusion SCI. (A-D) Animals received i.v. saline or 
500 nmol/kg DHA 30 min after SCI, and the tissue was analysed 28 days post-injury. 
Quantification in the DC (A), CST (B), VWM (C) and VLWM (D) revealed no 
significant difference between the two treatment groups. Results represent mean ± SEM; 
n = 7-8 animals per group.  
153 
 
5.3 DISCUSSION 
 
In this study we have shown that an i.v. injection of DHA, delivered within 30 min of 
contusion SCI, leads to a significant improvement in the recovery of stepping, but not in 
the BBB score or sub score. We saw no differences between control and DHA 500 
nmol/kg-treated animals in markers of neuronal survival, axonal integrity, or in the 
microglia/macrophage presence at the injury site or rostral to the epicentre.  
 
The T8 contusion injury revealed some differences in the functional outcome as well as 
in the histopathology compared to our T12 50 g static compression model. The force of 
200 kDyne was chosen to lead to a similar injury severity as that obtained in our 
compression model. Locomotor recovery reached a plateau of a BBB score of 11 at 28 
days post-contusion, compared to a slightly higher score of 12-13 in the compression SCI 
(King et al. 2006; Huang et al., 2007a). This could be an important difference in injury 
severity, since it represents the start of coordinated walking.  
 
Previously in the compression model, we found that 250 nmol/kg DHA was an effective 
dose which led to significant functional and histological improvement (Huang et al., 
2007a). Here, the dose of DHA 500 nmol/kg, but not the dose of 250 nmol/kg led to a 
significant improved locomotor outcome, i.e. recovery of frequent/consistent stepping. 
However, DHA did not affect the main BBB score. There have been other studies which 
found no difference in BBB score, but improvement in other aspects of locomotor 
recovery. For example, in their macrophage depletion study, Popovich et al. (1999) 
reported a significant and continuous improvement in more refined parameters of the step 
cycle after treatment, which was not evident in the BBB scale. The different dose 
efficacies in the two SCI models could reflect the differences in the severity, as 
mentioned above, and the differences in the evolution of the injury and tissue pathology 
between the two models. For example, if the neuroprotection effect derived from the 
DHA injection is mainly associated with a reduction in apoptotic or necrotic cell death 
(King et al., 2006; Huang et al., 2007a) and there is more cell death in the first 24 h 
following contusion than compression SCI, this may explain the need for a higher dose of 
DHA following contusion SCI, and therefore a shift to the right of the dose-response 
curve. This will be further explored in more extensive dose-response studies in future.   
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5.3.1 Histology 
 
Cavitation and macrophages/microglia 
 
A notable difference between the contusion and compression injury epicentres was that 
rather than several large, cystic cavities following compression SCI, such as those seen at 
28 days by Huang et al. (2007 a, b), there was one large central cavity in the contusion 
epicentre, filled with macrophages. Interestingly, contusion injuries delivered by the 
NYU impactor have been shown to result in multiple cavities in the rat, with septa or 
fibrous bands of tissue in-between them (Basso, et al., 1996). The relevance of these 
differences is unknown, but the septa could provide a supportive substrate to spared 
axons and explain the better locomotor outcome in compression SCI. A very simple 
analysis method was used to estimate the area of cavitation after contusion injury. A more 
accurate method to measure the area of cavitation, volume, or in fact the amount of tissue 
sparing, would be to collect sagittal or horizontal sections spanning the injury site and to 
label spared white matter, with a myelin stain such as eriochrome cyanine. Serial sections 
could then be measured throughout the injury epicentre and expressed as the amount of 
myelin as a percentage of the total area (Han et al., 2010).  
 
Greater motor deficits are related to greater SCI severity and less tissue sparing (Noble 
and Wrathall, 1989; Basso et al., 1995, 1996; Fehlings and Tator, 1995; Kloos et al., 
2004).  Thus, better tissue sparing may lead to better locomotor outcome. Consistent 
plantar stepping has been shown to depend on 10% white matter sparing, whereas 
coordination requires 25% white matter sparing (Kloos et al., 2005). It could be that the 
DHA 500 nmol/kg treatment, which led to significantly more frequent stepping, may 
have protected the tissue more, but this was too subtle to be detected using the approach 
used here, especially with the markers we used, and this was not quite enough to preserve 
the amount of tissue required for coordination. Central pattern generators (CPG) are 
important for the rhythmic generation of stepping movements; this is also the case in 
humans. However, in humans, supraspinal control is also essential for the performance of 
locomotion (Edgerton et al., 2001; van Hedel, et al., 2010). It is thought that recovery of 
forelimb–hindlimb coordination is dependent upon communication between the cervical 
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and lumbar enlargements (Ankeny et al., 2004), i.e., axonal regeneration or improved 
conduction across the lesion site. It is unknown whether communication across the lesion 
was improved here. 
 
The amount of macrophages in the epicentre cannot be compared directly to the 
compression model in the study by Huang et al. (2007), due to differences in the method 
of analysis. In addition, the macrophage distribution in the epicentre looked notably 
different here compared to the study by Huang et al. (2007). Here, the macrophages filled 
the grey matter area in the epicentre, whereas in the compression study, there were 
multiple cavities and macrophages seemed to be distributed primarily in the white matter 
surrounding the grey matter, and were very sparse in the grey matter. However, in rostral 
segments, as seen by Popovich at al. (1997), the macrophage distribution in contusion 
tissue appeared similar to compression tissue (see Chapter 6), i.e. it was confined 
primarily to the dorsal columns, but also scattered throughout the white matter.  No 
differences were found in the amount of macrophages/microglia between treatment 
groups after contusion in the epicentre or the rostral segment, in contrast to what was 
found by Huang et al. (2007a), who reported a significant decrease in ED1-labelled 
macrophages after DHA bolus treatment in specific areas of the epicentre at 6 weeks in 
the compression SCI model. The significance of this is not clear. Interestingly, no 
difference was seen in the amount of macrophages after acute i.v. DHA treatment in 
another, rat hemisection model of SCI at 7 days, despite a marked reduction in the lesion 
size and a significant improvement in locomotor function (King et al., 2006). These 
differences reflect the complexity of the inflammatory response after SCI and likely the 
limitations of assessment of this response using the ED1 staining as index. In future, it 
will be necessary to analyse the response of macrophages in much more detail. For 
example, it would be more informative to look at a change in the amounts of the various 
phenotypes of macrophages, such as the M1 or M2 types, as documented by Kigerl et al. 
(2009) and mentioned in Chapters 1 and 2. For example, if it can be assumed that the 
same markers used in mouse tissue would apply in the rat following SCI, one could look 
at an increase in arginase or CD206 expression, which is characteristic of the M2 
phenotype, whereas CD86, CD16/32 or iNOS are indicative of the M1 phenotype and has 
been demonstrated to dominate the lesion core at later time points (Kigerl at al., 2009). 
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Also, it is important to be able to assess the functionality of macrophages, such as their 
expression of proinflammatory cytokines/chemokines such as TNF-α and IL-1β after 
activation. This could be performed in an in vitro assay on isolated macrophages (see 
Future work section, Chapter 7).  
 
Neuronal survival 
 
In the epicentre, we observed a small region of spared gray matter in the superficial 
dorsal horns, as characterised before in rat contusion injured tissue using the NYU 
impactor (Basso et al., 1996). There appeared to be more survival of neurones in the grey 
matter of the epicentre after compression SCI. Huang et al. (2007a, b) noted 
approximately 10 % survival of neurones in the ventral horns and 30 % in the dorsal 
horns of the epicentre at 6 weeks compared to uninjured tissue. Also in contrast to 
contusion tissue, more loss and therefore spread of damage to the grey matter (20 % vs. 
18 % in the dorsal horn and 40 % vs. 7 % in the ventral horns, see chapter 6) was seen 5 
mm rostral to the injury site after compression SCI than contusion SCI, in agreement with 
Huang et al., (2007b), who documented a protracted neuronal loss after compression SCI 
compared to contusion SCI. This might mean that the analysis in the rostral location here 
was outside the zone of neuronal loss surrounding the epicentre and could explain why 
there was no difference between the two groups.  
 
It has been suggested that NeuN might not reflect neuronal loss (McPhail et al., 2004), 
but rather a down regulation of the antigen in intact neurones. However, Huang et al 
(2007b) performed counts of ventral horn neurons stained with toluidine blue, which 
showed a very similar pattern of loss, suggesting that the NeuN loss seen after the 
compression injury does represent actual neuronal loss. It would be interesting to analyse 
other markers for neurones in the grey matter such as the microtubule associated protein-
2 (Map-2), which forms part of the cytoskeletal network and is specific for neurones and 
their dendrites (Bernhardt and Matus, 1984; Bloom et al., 1985; Binder et al., 1986; 
Matus, 1994). This marker has been shown to be down-regulated in the epicentre after 
compression SCI (Ward et al., 2010), the loss of MAP-2 extending a substantial distance 
(approximately 3 mm) rostrally and caudally from the injury site (Springer et al., 1997).  
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White matter pathology 
 
In order to examine axonal pathology, a neurofilament marker was used (SMI32). The 
neurofilament protein is a component of the cytoskeleton and is present in neuronal cell 
bodies and axons in its phosphorylated and non-phosphorylated form. Ward et al., (2010) 
showed a decrease in the non-phosphorylated component following compression SCI. A 
loss of non-phosphorylated neurofilament compared to uninjured control was not 
quantified after contusion in this study since tissue was not available at the same thoracic 
level. However, compared to uninjured spinal cord at approximately T10/11 (not shown), 
there was an apparent overall loss after SCI, and the greatest loss appeared to be in the 
dorsal columns. There was no significant difference between treatment groups, which is 
in contrast to what was seen after the DHA 250 nmol/kg bolus injection in the 
compression model at the injury epicentre (King et al., 2006; Huang, et al., 2007a; Ward 
et al., 2010). Again, this difference could be due to the difference in injury severity 
between the two models (discussed above). The method of quantification was also 
performed slightly differently, although images were taken at the same magnification and 
similar areas. A manual count was performed previously. The different size of particles 
was obvious in the contused tissue here, and a gross count of all particles may not be as 
informative as a more extensive analysis based on particle size. If the larger particles are 
likely to be swollen, dystrophic axons, it might be interesting to set a cut off point and see 
if the treatment had any effect on the amount of abnormal axons of a certain diameter. 
This could be performed upon reanalysis of the sections, using the Image J software, this 
time collecting the raw data on particle size for each section. A programme can then 
divide the data for each section into bins of different sizes and then once collated, the data 
could be analysed for a shift in particle size. 
 
5.3.2 Mechanisms 
 
As discussed in the previous chapter, it is likely that the acute DHA injection is targeting 
early events such as reducing oxidative stress and lipid peroxidation (King et al., 2006; 
Huang et al. 2007a), which occur after SCI (Hall and Braughler,1986; Xu et al., 2005) 
and lead to dysfunction of mitochondria and subsequent neuronal death (Sullivan et al., 
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2005). DHA might also reduced glutamate-induced excitotoxicity (Hogyes et al., 2003; 
Wang et al., 2003), which is known to be one of the triggers of apoptosis after SCI (Xu et 
al., 2004). The dose of DHA remains in a physiological range and is compatible with the 
affinity of this fatty acid for targeting of TREK-1 channels or retinoid receptors, which 
may be activated by the free DHA (de Urquiza, et al., 2000).  DHA has anti-inflammatory 
actions and has been shown to reduce COX-2 expression after SCI (Huang et al., 2007a). 
The DHA in the injection may have had some anti-inflammatory effect, such as a 
reduction in the amount of neutrophil infiltration to the injury site as shown in the 
previous chapter, although this remains to be determined after the contusion injury. Also, 
the injected DHA may have led to production of anti-inflammatory downstream 
metabolites such as neuroprotectin D1 (Mukherjee et al., 2004). Finally, a small 
percentage of DHA might have been retro-converted to EPA, which can inhibit pro-
inflammatory signalling directly, or through its downstream metabolites such as resolvin 
E1.  
 
Various laboratories have attempted to validate alternative strong candidates for 
translation such as erythropoietin, minocycline and the anti-Nogo antibody in more than 
one model of SCI (For review, see Chapter 1 and Kwon et al., 2010). All have shown 
efficacy in more than one model of SCI and despite problems with one or two replication 
studies (Pinzon et al., 2008a, b; Steward et al., 2008), have demonstrated sufficient 
potential to be carried forward to SCI clinical trials.  
 
In conclusion, this pilot study in contusion injury demonstrated that a higher dose of 
DHA (500 nmol/kg) injection was required compared to compression SCI for improved 
locomotor outcome (stepping function). There was no significant effect on the markers of 
tissue damage.  As was concluded in the previous chapter, a higher and/or prolonged dose 
of the long-chain omega-3 PUFA may be necessary in contusion SCI, in order to see 
significant changes in the tissue response to injury and especially in the inflammatory 
markers after SCI. However, the improved functional outcome in the animals at the 
highest dose of DHA we have tested suggests that, in absolute terms, neuroprotection in 
this model of higher SCI severity is not unrealistic. 
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Chapter 6: Results IV.The effects of dietary PUFA on the response to  
compression SCI 
 
6.1 Introduction 
 
Sir David Cuthbertson recognised that the inflammatory response is a key central player 
in the metabolic response to injury and discussed the future of parenteral and enteral 
nutrition (1982).  He suggested that artificial nutrition could be used to modulate the 
activity of the immune system, anticipating the current situation of a range of nutrient 
components that are used in parenteral nutrition, including various lipids, although the 
optimisation of those components still remains uncertain today.  
 
Addition of EPA or DHA to the diet is a way of increasing endogenous omega-3 PUFA 
levels, thus changing fatty acid composition in cell membranes and, indirectly, modifying 
signaling events, including those underlying anti-inflammatory effects. From our 
experience with DHA in rat compression SCI, boosting levels of DHA in the diet after 
the injury appears to enhance the neuroprotective effects of the bolus injection (Huang et 
al., 2007a). Pilot observations also indicated that an EPA bolus i.v. injection after SCI 
also shows some neuroprotective effects (Lim et al., in press); although overall they 
appear to be more modest than those of DHA.  The effects of an EPA-enriched diet after 
SCI have not yet been explored. Therefore, this chapter will first provide a review of the 
treatments that have been given as dietary supplementation after SCI. This will be 
followed by an investigation of the effects of an EPA enriched diet after SCI. The chapter 
will close with our observations on the dietary prophylactic supplementation with DHA 
prior to injury.  
 
6.1.1 Dietary alterations and SCI  
 
It is considered that the present average Western diet does not include a sufficient intake 
of omega-3 PUFAs (Calder et al., 2009 for review). The typical American consumes 0.7-
1.6 g of omega-3 PUFA per day, equivalent to approximately 0.2-0.7% of total calories 
(Kris-Etherton et al., 2000). Most of this is as ALA, the plant omega-3 PUFA. Intake of 
fish-derived long chain omega-3 PUFA (i.e., EPA and DHA) is reported to be less than 
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0.1-0.2 g per day. In comparison, the Greenland Inuit were reported to consume levels of 
6–14 g/day, which corresponds to 2.7–6.3% of daily energy (Feskens et al., 1993). 
Similarly, traditional Japanese diets contain 1–2% of daily energy as long chain omega-3 
PUFA (Okuyama et al., 1996; Nagata et al., 2002). With respect to physiological 
relevance, this range is similar to that seen in human clinical studies with these 
compounds, i.e. 1-9 g/day (0.45-4% of calories) of omega-3 PUFA, mainly in the form of 
EPA and/or DHA (Kelley et al., 1998; Kelley et al., 1999; Thies et al., 2001; Rees et al., 
2006). Clinical studies have found that increased consumption of long-chain omega-3 
PUFA either in the form of oily fish or fish oil supplements, compared to omega-6 PUFA 
is beneficial for coronary heart disease (Stone et al., 1996; Bucher et al., 2002), cancer 
(Caygill et al., 1995; Augustsson et al., 2003), immune disease (Mehta et al., 2009) and 
prevention or management of neurological disorders such as Alzheimer‟s disease (Calon 
et al., 2004; Cole et al., 2004).  
 
Although there is a wealth of data looking at the long-term benefits of various diets on 
overall health and prevention of neurological diseases such as stroke, as well as reduction 
in risk for neurodegenerative disorders such as dementia, and alleviation of inflammatory 
conditions such as rheumatoid arthritis, there have been few studies that have looked at 
the neuroprotective effects of dietary modifications after SCI.  
 
Questionnaires given to adults with chronic SCI have found evidence of inadequate 
dietary intake (Walters et al., 2009). Although the percentages of daily energy for men 
and women were within an acceptable macronutrient distribution range, inadequate 
intakes for men and women were found for vitamin A, magnesium, folate, zinc, vitamin 
C, thiamine, vitamin B12, riboflavin and vitamin B6. Another questionnaire collated by 
Opperman et al., (2010) recorded dietary intake, including supplements in people with 
SCI. 71% of the sample reported using supplements at least once, with 50.6% being 
classified as consistent supplement users. The top three supplements consumed were 
multivitamins (25%), calcium (20%) and vitamin D (16%). It is important to be aware of 
the use of supplements in the SCI community when treating chronic SCI.  
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Some SCI studies have looked at the impact of dietary intervention on muscle strength 
and bladder activity. Nash et al. (2007) found that whey and carbohydrate ingestion for 
five consecutive days immediately following a walking to fatigue test increased 
ambulation distance, time, and caloric expenditure in patients with incomplete SCI. 
Dietary glycine (1% to 3%) has been shown to inhibit bladder and urethral activity, and 
improve detrusor hyperreflexia and detrusor-sphincter dyssynergia in rats, following 4 
weeks supplementation, commencing after SCI (Miyazato et al., 2005). It has been shown 
that rats fed for 4 weeks with a creatine supplemented diet before undergoing a moderate 
spinal cord contusion had a reduction in the spread of secondary injury (Hausmann et al., 
2002).  
 
It is well-established that dietary restriction (DR) increases longevity across many 
species, even if started in adulthood (Weindruch andWalford, 1982). Interestingly, 
therapeutic DR started after SCI has been shown to provide neuroprotection, anatomical 
plasticity and improve functional recovery (Plunet et al., 2008). The authors suggested a 
broad spectrum effect, and found that blood β-hydroxybutyrate levels, a ketone known to 
be neuroprotective, were increased 2–3-fold on the fasting days. In addition, Davis et al. 
(2008) found that fasting animals for 24 hr, but not 48 hr, after traumatic brain injury, 
resulted in a significant increase in tissue sparing, a decrease in biomarkers of oxidative 
stress and calcium loading, and increased mitochondrial oxidative phosphorylation in 
mitochondria isolated from the site of injury. Again, they showed that the underlying 
mechanism appeared to involve ketosis rather than hypoglycaemia.  
 
6.1.2 Dietary enrichment with omega-3 PUFAs affects the cells involved in the 
inflammatory response  
 
Fish oil, rich in long chain omega-3 PUFAs, is widely used as a dietary or nutritional 
supplement for its anti-inflammatory effect, for conditions such as atherosclerosis (Mori 
and Beilin, 2004). In the Western diet there is a high ratio of omega-6: omega-3 PUFAs, 
believed to be quite different from that of our ancestors (Simopoulos, 1999).   
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Fatty acids that are delivered in the diet are known to be incorporated into the cell 
membrane phospholipids of the liver, brain and leukocytes in a time- and dose-dependent 
manner (Salem et al., 2001; Calder et al., 2003, 2004, 2009; Bailes et al., 2010). Time-
course studies have indicated that the incorporation of EPA and DHA into human 
immune cells reaches its peak within 4 weeks of commencing increased dietary intake 
(Healy et al., 2000; Yaqoob et al., 2000; Thies et al., 2001; Rees et al., 2006) and dose-
response studies indicate that incorporation occurs in a manner that is highly correlated 
with the amount of the fatty acid consumed (Healy et al., 2000; Rees et al., 2006). Based 
on an example by Sperling et al. (1993), where omega-3 PUFAs supplements (9.4 g EPA, 
5 g DHA,) were delivered to healthy volunteers for 10 weeks, fatty acids are taken up by 
the major classes of phospholipids including phosphatidylinositol, phosphatidylcholine 
and phosphatidylethanolamine, by 3 weeks. 
 
Once fatty acids have been taken up into cell membranes, the composition may affect the 
balance of various biochemical reactions. For example, EPA and DHA inhibit AA 
metabolism due to direct competition for the same enzymes such as COX2. Thus, 
production of AA-derived eicosanoids is decreased by these long chain omega-3 fatty 
acids. This process can lead to changes in the expression of pro-inflammatory genes and 
the availability of pro-inflammatory lipid mediators, thus modulating the intensity and 
duration of neuroinflammation (Calder et al., 2009). In addition, as mentioned previously, 
EPA is also able to act as a substrate for both cyclooxygenase and 5-lipoxygenase, giving 
rise to eicosanoids with a slightly different structure to those formed from AA. Thus, fish 
oil supplementation of the human diet has been shown to result in increased production of 
LTB5, LTE5 and 5-hydroxyeicosapentaenoic acid by inflammatory cells, which play roles 
in the chemotaxis of neutrophils and monocytes (Goetzl & Pickett, 1980; Lee et al., 1984, 
1985; Kragballe et al.1987; Endres, et al., 1989; Sperling et al., 1993). Through their 
effects on membranes, cell signalling, gene expression and lipid mediator profiles, 
omega-3 fatty acids influence aspects of innate immunity (Calder et al., 1990), and alter 
the production of inflammatory cytokines by endothelial cells, monocytes and 
macrophages (see Table 6.1). Omega-3 PUFAs have been shown to affect the 
inflammatory signalling of microglia in culture by inhibiting MMP 9 production (Liuzzi 
et al., 2007)  
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Table 6.1 Anti-inflammatory effects of dietary treatment or pre-treatment with omega-3 PUFA 
Study Inflammatory model Species PUFA Effects 
Lo et al., 1999 LPS-stimulated 
macrophage cell line 
mouse EPA pre-stimulation 
incubation 
↑ COX-2 mRNA & protein expression                                       
↓ PGE2 production 
Novak et al, 2003  LPS-stimulated 
macrophage cell line 
mouse Omega-3 emulsion 
(DHA + EPA) pre-
stimulation incubation 
Inhibited IκB, ↓NFκB                                                         
↓ TNFα mRNA and protein expression 
Zhao et al., 2004 Hypercholesterolemic 
subjects 
human ALA diet ↓ CRP, ↓ ICAM-1, ↓ VCAM-1, ↓ E-selectin 
de Caterina et al., 1994a, b Subjects with chronic 
renal disease 
human 6 week DHA + EPA   
TG or ethyl ester diet  
Both ↓ platelet generated thromboxane B2          
prolongation of the bleeding time from ethyl esters 
de Caterina et al., 1994 IL-1, TNF, IL-4 or LPS 
stimulated endothelial 
cells 
human DHA or EPA DHA ↓ ICAM-1,VCAM-1, E-selectin, IL-6 &IL-8 
and ↓ adhesion of monocytes  
Renier et al., 1993 LPS-stimulated 
macrophages from 
atherosclerosis-
susceptible mice 
mouse 6 & 15 week fish oil 
diet (DHA + EPA) 
↓ TNFα & IL-1β mRNA expression at both time 
points                                                                               
↓ prostaglandin production 
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Table 6.1 Anti-inflammatory effects of dietary treatment or pre-treatment with omega-3 PUFA (continued) 
Study Inflammatory model Species PUFA Effects 
Endres, et al., 1989  Endotoxin stimulated 
peripheral-blood 
mononuclear cells 
human 6 week fish oil diet 
(DHA + EPA) 
↓ IL-1β synthesis 
Babcock et al., 2002  LPS-stimulated 
macrophages 
mouse Omega-3 emulsion 
(DHA + EPA) pre-
stimulation incubation 
↓ TNFα protein production 
Abbate et al., 1996 LPS-stimulated 
mononuclear cells 
human 18 week omega-3 
PUFA ethyl ester diet 
(DHA + EPA) 
↓ procoagulant activity 
↓ IL-6 
Trebble, et al., 2003a Peripheral blood 
mononuclear cell 
human 4 week fish-oil diet 
(DHA + EPA) 
↓ TNFα & IL-6 production 
Trebble, et al., 2003b Lymphocytes human 4 week fish-oil diet 
(DHA + EPA) 
↓ PGE2 production                                                             
↑ IFN-γ production & lymphocyte proliferation  
Wallace et al., 2003 LPS-stimulated 
mononuclear cells 
human 12 week fish-oil 
capsules (DHA + EPA) 
↓ IL-6 production                                                             
no difference in TNFα, IL-1β, IL-2, IL-4, IL-10 or 
IFN-γ 
Liuzzi et al., 2007 LPS-stimulated microglia rat  Fish oil (DHA + EPA) 
incubation simultaneous 
to activation 
↓ MMP-9 production                                                              
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Table 6.1 Anti-inflammatory effects of dietary treatment or pre-treatment with omega-3 PUFA (continued) 
Study Inflammatory model Species PUFA Effects 
Lee et al., 1984 Ionophore-activated 
neutrophils 
human EPA or DHA EPA ↓ LTB4, DHA did not 
Sperling et al., 1993 LTB4, PAF, zymosan or 
calcium ionophore-
stimulated neutrophils 
human 3-10 week DHA + 
EPA tablets 
↓ LTB4- stimulated IP3 formation                                                                  
↓ calcium ionophore-stimulated LTB4 & LTB5                
↓ LTB4- & PAF- stimulated chemotaxis 
Ly et al., 2006 Anti-CD3 and anti-CD28 
stimulated splenic 
CD4(+) T-cells 
mice 14 d DHA or EPA diet DHA & EPA ↓ proliferation                                                                    
EPA but not DHA ↑ CTLA-4 
Tomobe et al., 2000 Contact hypersensitivity 
reaction in the ear 
sensitized with 2,4-
dinitro-1-fluorobenzene 
mice DHA or EPA ethyl 
ester diet 
DHA, not EPA ↓ ear swelling, infiltration of CD4+ T 
cells, IFN-γ, IL-6, IL-1β, and IL-2 mRNA expression 
Mickleborough et al., 
2009 
LPS-stimulated asthmatic 
alveolar macrophages 
human DHA or EPA pre-
stimulation incubation 
EPA & DHA ↓ TNFα & IL-1β mRNA expression,                       
↓ LTB4, PGE2, TNFα & IL-1β production               
The EPA reduction was significantly more than DHA 
Terano et al., 1987 Patients with various 
thrombotic diseases 
human 16 week EPA diet ↓ thromboxane formation, platelet aggregation, 
retention & whole blood viscosity                                                                          
↑ red blood cell deformation & prolongation bleeding  
ICAM- intercellular cell adhesion molecule, VCAM - vascular cell adhesion molecule, TG – triglycerides, LTB4 - leukotriene B4, PAF - 
platelet-activating factor, IP3 – phosphoinositide, CTLA-4 - cytotoxic T-lymphocyte antigen 4
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Clinically, in patients with septic shock in the intensive care unit (ICU) given an omega-3 
emulsion enriched in EPA and DHA intravenously for a 5 or 10 day period there was 
modulation of several inflammatory events (Mayer et al., 2003a, b). Stimulation of 
neutrophils (Mayer et al., 2003a) or monocytes (Mayer et al., 2003b) from the septic 
patients, ex vivo, demonstrated the generation of less inflammatory 5-series leukotriene 
production and suppression of the proinflammatory cytokines TNF-α, IL-1β, IL-6, and 
IL-8. In addition, studies of an enteral feed including fish oil in combination with γ-
linolenic acid given to acute respiratory distress syndrome (ARDS) patients for 4-7 days, 
showed a reduction in IL-8 in bronchoalveolar lavage fluid and higher than normal levels 
of oxygenation, measured by increased partial pressure of oxygen in Arterial Blood / 
Fraction of Inspired Oxygen (Pacht et al., 2003). Clinical improvement such as fewer 
days of ventilatory support, reduction of organ failure and decreased length of stay in the 
intensive care unit was seen in patients with ARDS or acute lung injury who were given 
an infusion of EPA with gamma-linolenic acid (GLA) for 4-7 days (Gadek et al., 1999; 
Pontes-Arruda et al., 2006; Singer et al., 2006). The above benefits were seen within 
days. 
 
Sperling et al. (1993) isolated neutrophils and monocytes from eight healthy volunteers 
for biochemical investigation 4 weeks before starting dietary supplementation with 
omega-3 PUFA, and after 3 and 10 weeks of supplementation with 20 g of „Super-EPA‟ 
(Phenmacaps, Elizabeth, NJ, USA) daily, providing 9 g EPA and 5 g DHA. Increases in 
the EPA content of all the major phospholipids of neutrophil membranes, including the 
phosphocholine, phosphoethanolamine, and phosphatidylinositol pools, were observed 
after 3 and 10 weeks of dietary omega-3 PUFA supplementation. In parallel, the AA 
content of the phosphocholine and phosphoethanolamine pools of neutrophil membranes 
declined substantially, with the exception of the phosphatidylinositol pool. The number 
of neutrophils did not change significantly but chemotaxis was significantly inhibited.  
 
Since fatty acids given in the diet are also incorporated into monocytes, it is possible that 
there are influences on macrophage activation and phenotype. The view that 
macrophages could aid in recovery after SCI has been supported by the demonstration 
that macrophages in in vitro and in vivo models of inflammation switch to an anti-
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inflammatory phenotype, through down regulation of pro-inflammatory signals such as 
TNF-α and IL-1β and up regulation of anti-inflammatory signals such as TGF-, 
secretion of growth factors and neurotrophic factors such as BDNF, GDNF, NGF and 
NT-3 (Elkabes et al., 1996; Kerschensteiner et al., 1999; Nakajima et al., 2001; Huynh, et 
al., 2002; Nakajima and Kohsaka, 2004; Hashimoto et al., 2005b). It is possible therefore, 
that chronic treatment with PUFAs either by i.v. infusion or in the diet could have a 
dramatic influence on the inflammatory cell composition, also modifying the 
inflammatory environment in which macrophages become activated and function after 
SCI.  
 
6.1.3 Dietary effects of PUFA after trauma and SCI 
 
There is already evidence that lipid emulsion preparations enriched in omega-3 fatty 
acids have beneficial effects in critically ill patients (Calder, 2003). A study in which a 
mixed group of over 650 patients received parenteral nutrition containing fish oil (i.e. 
EPA and DHA), found a significantly lower rate of infections, fewer complications, and 
shorter length of hospital stay in the post-surgery patients receiving fish oil-containing 
emulsions compared with those receiving the control emulsions (Heller et al., 2006). 
Mortality was significantly decreased in those patients who received more than 0.1 g fish 
oil/kg per day. In stroke patients, lower proportions of serum PUFAs (which reflects the 
dietary intake of saturated and unsaturated fats) and higher proportions of saturated fatty 
acids have been found compared with controls (Iso et al., 2002). Furthermore, a higher 
content of serum omega-3 PUFAs in patients is associated with a decrease in the risk of 
stroke (Simon et al., 1995).  
 
Our laboratory has shown that in combination with DHA injection, animals maintained 
on a DHA-enriched diet after compression SCI had an improved recovery after injury, 
increased neuronal and oligodendrocytes survival and axonal preservation (Huang et al., 
2007a; Ward et al. 2010 in press).  This suggests that oral supplementation with omega-3 
PUFA can enhance neuroprotection. In contrast, i.v. acute treatment with AA after spinal 
cord hemisection in rats had detrimental consequences (King et al., 2006). Along with the 
evidence that enrichment of omega-6 PUFA in leukocytes may influence pro-
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inflammatory signalling, this suggests that parenteral preparations with a considerable 
omega-6 component, such as soybean oil-containing preparations, would not be 
beneficial after SCI (Calder, 2003, 2009, 2010; Michael-Titus, 2007). Thus, PUFAs 
could be considered for dietary supplementation after SCI, as well as a preventative role, 
in populations at high risk of neurotrauma, such as military personnel, as suggested in a 
recent study on head injury (Bailes et al., 2010). Troops going into areas of conflict, 
where risk of traumatic injury is high, could  supplement their dietary intake with long 
chain omega-3 PUFAs, thus providing the potential of reducing neurological sequelae 
following traumatic brain injury or SCI.  
 
Apart from the acute neuroprotective effect at the injury site, it is also important to 
explore other potential benefits of omega-3 PUFAs for people living with chronic SCI. It 
has been shown that omega-3 PUFA supplementation for 6 months could contribute to an 
improvement in functional capabilities such as strength endurance in the arm (Javierre et 
al., 2006). The parameters used in this study were a timed repetition task and the time 
taken to cover a 90 m track with 6 % slope.  Individuals with SCI have identified the 
recovery of autonomic functions as a high priority for improving their quality of life 
(Anderson, 2004).  Due to the neuroprotective effects of DHA and EPA at the injury site 
and the reduction of axonal pathology (King et al., 2006; Huang et al., 2007a; Ward et al., 
2010; Lim et al., in press), which could be related directly or indirectly to functions other 
than motor recovery, it is important to look at the impact of omega-3 PUFAs on outcome 
measures such as loss of bladder control and the development of neuropathic pain, which 
has a high incidence in the SCI community and remains a challenge to treat.  
 
EPA and DHA in fish oil are mainly in the form of triacylglycerols. However, EPA and 
DHA may also be ingested as purified ethyl esters or free fatty acids. The advantages of 
using purified fish oil products is that compounds such as other fatty acids, cholesterol 
and other environmental contaminants can be removed.  Kim et al. (2010) suggested a 
4% (wt/ wt) fish oil or 1% purified omega-3 PUFA ethyl esters as a  reasonable dose for 
animal feeding studies designed to probe the biological properties of omega-3 PUFA 
relevant to humans. This level of intake delivers 2.4% of total energy as omega-3PUFA, 
which is within the range consumed by humans and used in human clinical trials. 
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Previous studies in our laboratory have demonstrated structural changes in cell 
membranes in the spinal cord after 12 weeks of omega-3 PUFA dietary supplementation 
(270 mg/kg/day of EPA and DHA; ratio 1.5:1; Dyall et al., 2007) and significant 
improvement in outcome after SCI (Huang et al., 2007a) using an average daily dose of 
300-400 mg/kg of DHA (0.3 %) in the ethyl ester form, although this was only assessed 
in addition to an i.v. bolus of DHA (250 nmol/kg) 30 min after SCI. A target dietary dose 
of maximum 400 mg/kg long-chain omega-3 PUFA will be used in the studies that 
follow. This dose is comparable to the present recommended daily total amount of EPA 
and DHA in healthy adults. 
 
6.1.4 Aims 
 
The aim of this chapter was to explore in more depth the impact of dietary manipulation 
with omega-3 PUFA on SCI.  In the first part of the chapter, we present the results 
obtained in compression SCI with a dietary intervention after SCI based on EPA, 
preceded by an acute i.v. bolus of EPA or saline (vehicle).  In the final part of the chapter, 
we present a pilot study on the dietary supplementation with DHA in the compression 
model of SCI. 
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6.2 RESULTS 
 
The four experimental groups used in the study in the first part of the chapter will be 
referred to as the following: 
 
1. IV saline, control diet or control group: SCI, followed by i.v. saline injection at 
30 min and control diet for 4 weeks. 
2. IV EPA, control diet: SCI, followed by i.v. EPA injection (250 nmol/kg) at 30 
min, followed by control diet for 4 weeks. 
3. IV saline, EPA diet: SCI, followed by i.v. saline injection, followed by EPA diet 
(approximately 150 mg/kg/day) for 4 weeks. 
4. IV EPA, EPA diet: SCI, intravenous EPA injection as above, followed by EPA 
diet (approximately 150 mg/kg/day) for 4 weeks. 
 
6.2.1 I: Effect of EPA on the locomotor recovery following compression SCI 
 
The IV EPA and control diet group had the best locomotor outcome overall (BBB= 12.9 
(Fig. 6.1) but this was not significantly different from the control group (IV saline, 
control diet; BBB = 10.8). Animals treated with an EPA-enriched diet following i.v. 
saline injection, had a significantly worse BBB score compared to control diet animals 
receiving i.v. saline (BBB = 5, day 28; p<0.05). This was already apparent within the first 
week after SCI (Fig. 6.1) and the group remained the worst out of the four groups in 
terms of locomotor recovery. The EPA injection appeared to counteract the detrimental 
effect of the EPA- enriched diet (BBB = 11.6; p<0.001), thus leading to a locomotor 
score similar to the control group. 2Way RM ANOVA revealed that there was a 
significant effect of time (F=71.96, p<0.05), the interaction time and treatment was 
significant (F=2.43, p<0.05), but overall the effect of treatment with EPA (acute i.v. and 
dietary) was not (F=2.34, p>0.05).  
 
There was no significant difference in the sub scores between groups at 28 days (p>0.05; 
One-way ANOVA; Fig. 6.2). An assessment of animals that regained frequent or 
consistent stepping, showed that none in the IV saline, EPA diet group regained stepping 
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function, compared to 4 out of 6 in the control group, 3 out of 6 in the IV EPA, EPA diet 
group, and 5 out of 6 in the acute EPA injection and control diet group (Table 6.2) 
 
 
Figure 6.1 The effect of treatment with dietary EPA on locomotor recovery after 
compression SCI. The animals received saline or EPA (250 nmol/kg), 30 min after SCI 
and were then maintained on a control diet or EPA-enriched diet (150-170 mg/kg) for 28 
days. Bonferroni‟s post-hoc analysis revealed that recovery in the IV saline, EPA diet 
group was significantly worse than the control group (IV saline, control diet; *p<0.05) 
and also worse than the IV EPA, EPA diet group (###p<0.001). Error bars represent 
SEM, n=6 per  
group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
172 
 
 
BBB subscore subscore 28 d
IV
 s
al
in
e 
co
nt
ro
l d
ie
t
IV
 E
P
A
 c
on
tr
ol
 d
ie
t
IV
 s
al
in
e 
EP
A
 d
ie
t
IV
 E
P
A
 E
P
A
 d
ie
t
0
5
10
15
s
u
b
s
c
o
re
 
 
Figure 6.2 The effect of treatment with dietary EPA on BBB subscore after 
compression SCI. The animals received saline or EPA (250 nmol/kg), 30 min after SCI 
and were then maintained on a control diet or EPA-enriched diet (150-170 mg/kg) for 28 
days. There was no significant difference in the BBB sub score between treatment groups 
at 28 days (p>0.05; one-way ANOVA). Error bars represent SEM, n=6 per group.  
 
 
Number of frequent or consistent steppers after SCI and dietary EPA treatment 
 
 Group           Number of frequent/consistent steppers 
 
 
 IV saline, control diet    4/6 
 IV EPA, control diet    5/6 
 IV saline, EPA diet    0/6 
 IV EPA, EPA diet    3/6 
  
Table 6.2 The effect of treatment with dietary EPA on stepping after compression 
SCI. The animals received saline or EPA (250 nmol/kg), 30 min after SCI and were then 
maintained on a control diet or EPA-enriched diet (150-170 mg/kg) for 28 days.  4 out of 
6 rats in the IV saline, control diet group recovered frequent or consistent stepping 
compared to 0 out of 6 in the IV saline, EPA diet group.  Fischer exact test revealed no 
significant difference. 
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6.2.2 Effect of EPA treatment on bladder function  
 
On the day of surgery and days 3, 6 and 8 following SCI, bladder volume was measured 
using an ultrasound device as described in the Methods chapter. The volume in uninjured 
anaesthetised rats preceding surgery was 0.1 ± 0.03 ml (n=24). All groups had a transient 
increase in urine retention at day 3 post-surgery, with the IV saline, EPA diet group 
having the largest significant increase (2.18 ± 0.43  ml) compared to the control diet, 
saline injection group (0.74 ± 0.41 ml; Fig. 6.3A). By day 8, bladder volume was not 
significantly different from baseline (0.23 ± 0.11 ml in the control group). Despite the 
recovery in bladder function, in the IV saline, EPA diet group, there was a permanent 
increase in the size of the bladder width (Fig. 6.3B) found post mortem at 28 days 
compared to the other groups, which was significant compared to the control group (12.8 
± 1.1 mm vs. 8.0 ± 2.0 mm; p<0.05). Data was also collected regarding the day of 
resolution, or spontaneous voiding,  i.e. the day preceding at least 3 days of an empty 
bladder (absence of urinary retention), or the day preceding at least 3 days of a dry 
abdomen (absence of incontinence; Fig. 6.3C). Most animals were dry around 3 days 
after SCI and did not need manual bladder expression after 8-10 days. There was no 
significant difference in resolution of spontaneous voiding between groups, although 
there was a trend towards a delayed recovery in the IV saline, EPA diet group. 
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Figure 6.3 The effect of treatment with dietary EPA on the bladder after 
compression SCI. The animals received saline or EPA (250 nmol/kg), 30 min after SCI 
and were then maintained on a control diet or EPA-enriched diet (150-170 mg/kg) for 28 
days. (A) Calculation of bladder dimensions from ultrasound readings revealed that there 
was a significantly larger increase in bladder volume, or the amount of urine retention in 
the IV saline, EPA diet group compared to the control group (*p<0.05, Bonferrroni post-
hoc test) (B) Measurement of the bladder size at the termination of the experiment 
revealed a chronic significant increase in bladder width in the IV saline, EPA diet group 
compared to the control group (*p<0.05) (C) Additional records were collected 
throughout the experiment regarding the day of resolution (i.e. presence of an empty 
bladder); and the „day became dry‟ (i.e. absence of incontinence). This revealed no 
significant difference between groups (*p>0.05, one-way ANOVA). Results represent the 
mean and error bars represent SEM; n=6 per group. 
 
  
 
6.2.3 Effect of EPA treatment on the development of mechanical hypersensitivity 
 
 
The baseline withdrawal threshold assessed as described in the Methods chapter, 
preceding SCI was approximately 30 g. This threshold decreased significantly (p<0.01; 
F=8.4, 2 way RM ANOVA) in all groups, and by approximately 50 % in the IV saline, 
EPA diet group at 28 days, but this was not statistically significant compared to the 
control group receiving saline and the control diet (p>0.05; F=1.5; Fig. 6.4A). It was not 
possible to obtain a threshold measurement until establishment of plantar placement; 
therefore not all rats were assessed at each time point. Furthermore, not all rats developed 
hypersensitivity. In order to distinguish between those rats which did not develop 
hypersensitivity, a further analysis was carried out, with an arbitrary value of 10% 
decrease from individual baseline score designated as a cut-off. Based on these criteria, 
additional differences were noted in some animals between left and right hind paw 
hypersensitivity (Fig. 6.4B).  
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 Number in each group that developed a ≥10 % decrease in threshold from 
 the individual’s baseline score: 
 
 Group     Right hind paw  Left hind paw  Both paws 
 
 
 IV saline, control diet              4/5      4/5         3/5 
 IV EPA, control diet              5/6     5/6         5/6 
 IV saline, EPA diet              4/5      3/5         3/5 
 IV EPA, EPA diet             4/6       3/6         2/6 
 
Figure 6.4 The effect of treatment with dietary EPA on mechanical hypersensitivity 
after compression SCI. The animals received saline or EPA (250 nmol/kg) 30 min after 
SCI and were then maintained on a control diet or EPA-enriched diet (150-170 mg/kg) 
for 28 days.  (A) Mechanical withdrawal thresholds decreased from baseline values at 7, 
14, 21 and 28 days after SCI. The number assessed in each group varied at each time 
point depending on re establishment of plantar placement. Results represent mean ± 
SEM. (B) The number per group that developed hypersensitivity based on an arbitrary 
value of 10% decrease from the individual‟s baseline score as a cut-off. Not all animals 
developed hypersensitivity based on these criteria. The analysis was further divided into 
right, left or both hind paws, highlighting the differences compared to when the values 
were combined.  
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6.2.4 Effect of EPA treatment on the fatty acid composition of red blood cells 
 
Red blood cells (RBCs) were harvested at the time of tissue collection at 28 days and sent 
to the University of Stirling (Prof. Gordon Bell) for lipid analysis. In the group that 
received the EPA supplemented diet, a significant increase (1-2 fold; p<0.05) was noted 
in the total omega-3 content of RBCs, particularly of EPA, where the amount increased 
by 8-fold compared to the control diet group (Table 6.3). There was a small, but 
significant (p<0.05) increase in DHA content (less than one-fold) and no observed 
change in the total amount of saturated or monounsaturated fatty acids between the 
groups. A small, but significant decrease in total omega-6 fatty acids, including 
arachidonic acid, docosapentaenoic acid and docosatetraenoic acid was noted. There was 
also a significant increase in 18:1 dimethylacetal. 
 
 
6.2.5 Effect of EPA treatment on tissue markers of injury after SCI 
 
6.2.5.1 Injury epicentre  
 
Toluidine blue staining on epicentre sections revealed extensive damage and cavitation in 
all groups, surrounded by a small amount of tissue sparing (Fig. 6.5).  
 
Due to time constraints, analyses on further histological markers were carried out only in 
the control diet and IV saline, and IV saline and EPA diet groups. 
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Table 6.3 Fatty acid composition of red blood cells. Data expressed as % total fatty 
acids in animals that received control or EPA enriched diet after SCI. 
 
Fatty acid     Control diet      EPA diet 
 
Saturated 
   14:00 0.26 ± 0.02  0.24 ± 0.02 
   15:00 0.28 ± 0.01  0.31 ± 0.02 
   16:00 23.41 ± 0.26 24.01 ± 0.44 
   18:00 21.51 ± 0.48 20.54 ± 0.39 
   20:00 0.15 ± 0.01 0.15 ± 0.01 
   22:00 0.49 ± 0.03 0.50 ± 0.02 
   24:00:00 1.27 ± 0.07 1.35 ± 0.05 
   Total  47.35 ± 0.74 47.13 ± 0.42 
   
Monounsaturated  
   16:1n-9 0.31 ± 0.02 0.34 ± 0.05 
   16:1n-7 0.26 ± 0.02 0.29 ± 0.03 
   18:1n-9 4.53 ± 0.19 4.24 ± 0.21 
   18:1n-7 2.27 ± 0.07 2.18 ± 0.05 
   20:1n-9 0.08 ± 0.00 0.08 ± 0.00 
   24:1n-9 0.62 ± 0.04 0.62 ± 0.03 
   Total  8.06 ± 0.24 7.74 ± 0.22 
   
Omega-6 PUFA 
   18:2n-6 8.45 ± 0.23 8.90 ± 0.35 
   20:2n-6 0.30 ± 0.01 0.38 ± 0.06 
   20:3n-6 0.33 ± 0.02 0.33 ± 0.02 
   20:4n-6 (AA) 22.88 ± 0.45 20.50 ± 0.65* 
   22:4n-6 1.79 ± 0.05  1.18 ± 0.06* 
   22:5n-6 0.64 ± 0.06  0.37 ± 0.01* 
   Total  34.39 ± 0.73  31.64 ± 0.56* 
   
Omega-3 PUFA 
   20:5n-3 (EPA) 0.15 ± 0.04  1.22 ± 0.05* 
   22:5n-3  0.91 ± 0.06  1.93 ± 0.07* 
   22:6n-3 (DHA) 1.83 ± 0.09  2.39 ± 0.12* 
   Total  2.90 ± 0.14  5.53 ± 0.19* 
   
Dimethylacetal (DMA) 
   16:0DMA 2.51 ± 0.08 2.67 ± 0.08 
   18:0DMA 3.33 ± 0.08 3.39 ± 0.08 
   18:1DMAs 1.48 ± 0.08 1.90 ± 0.10* 
   Total  7.31 ± 0.16 7.96 ± 0.17 
   
TOTAL 100.00 ± 0.00  100.00 ± 0.00 
Data represents mean ± SEM, n=6 per diet group. *p<0.05 compared to the control group
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Figure 6.5 The effect of treatment with dietary EPA on cavity formation after compression SCI. The animals received saline or EPA 
(250 nmol/kg), 30 min after SCI and were then maintained on a control or EPA-enriched diet (150-170 mg/kg) for 28 days. Toluidine blue 
staining on transverse sections throughout the epicentre at 28 days revealed extensive damage and cavitation in all groups. Each row 
represents one animal from each group and each column is aligned at an equivalent thoracic level.  
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Macrophages/microglia and cavitation 
 
ED1 staining showed that macrophages were present inside the cystic cavities and in the 
surrounding spared tissue (Fig. 6.6). Quantification revealed that macrophages consisted 
approximately 8% of the whole section area in the control group (Fig. 6.7A). There was 
no significant difference in the amount of macrophages between the control and IV 
saline, and IV saline and EPA diet groups (p>0.05; Fig. 6.7A). There appeared to be more 
extensive cavitation in the IV saline, EPA diet group, which had the worst BBB score. 
Following quantification there was a slight increase in cavity size in the IV saline, EPA 
diet group compared to the control group, but this was not significant (Fig. 6.7B). The 
damage was possibly too severe for accurate analysis in the epicentre; therefore further 
analyses were carried out on tissue approximately 5 mm rostral to the injury site.  
 
6.2.5.2 Rostral to the injury epicentre 
 
Macrophages/microglia 
 
There was little or no cavitation 5 mm rostral to the injury site. However, macrophages 
were found scattered throughout the white matter, as well as confined to the dorsal 
columns and sometimes clustered in distinct areas (Fig. 6.8A-B). Quantification 
confirmed a smaller amount of macrophages at this distance compared to the epicentre 
(approximately 3.5 % compared to 8 % in the control diet and IV saline group in the 
epicentre; Fig. 6.8C). However, there was no significant difference in the amount of 
macrophages between the control diet and IV saline and the IV saline, EPA diet groups 
(p>0.05; Fig 6.8C). 
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Figure 6.6 The effect of treatment with dietary EPA on ED1 staining in the injury epicentre after compression SCI. The animals 
received saline 30 min after SCI and were then maintained on a control diet or EPA-enriched diet (150-170 mg/kg) for 28 days. Each row of 
panels represents one animal from each group and each column is aligned at an equivalent thoracic level. There was extensive ED1 labelled 
cells throughout the epicentre and inside areas of cavitation. Scale bar = 100 μm.
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Figure 6.7. The effect of treatment with dietary EPA on ED1 staining and cavity size 
after compression SCI. The animals received saline 30 min after SCI and were then 
maintained on a control diet or EPA-enriched diet (150-170 mg/kg) for 28 days. (A) 
Quantification of ED1 macrophages in the epicentre at 28 days revealed no significant 
differences between the two groups (p>0.05). (B) Measurements were taken to calculate 
the cavity size in the transverse sections but there was no significant difference between 
the two groups (p>0.05). Results represent mean ± SEM; n=6 per group. 
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Figure 6.8 The effect of treatment with dietary EPA on the presence of macrophages 
in the rostral segment after compression SCI. The animals received saline 30 min after 
SCI and were then maintained on a control diet or EPA-enriched diet (150-170 mg/kg) 
for 28 days. (A-B) ED1 labelled macrophages approximately 5 mm rostral to the injury 
site. (C) Quantification revealed that there was no significant difference (p>0.05) 
between the control diet and IV saline group and the IV saline, EPA diet group. Results 
represent mean ± SEM; n=6 per group. Scale bar = 50 μm. 
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Phagocytic microglia, identified by large and rounded cells were found in most of the 
rostral sections, alongside microglia with a „resting‟ morphology. Since the phagocytic 
phenotype was not seen in all areas in all sections and due to the different sizes of 
phagocytic compared to activated and resting microglia, the quantification was performed 
in the dorsal and ventral horns only, on activated microglia where no phagocytic 
microglia/ macrophages were visible (Fig. 6.9A, B). The ED1 analysis above would have 
already accounted for these since phagocytic microglia/macrophages express both the 
ED1 and Iba1 markers. There was no significant difference between the two groups in the 
microglial labelling in the dorsal and ventral horns (p>0.05; Fig. 6.9C, D). 
 
 
Figure 6.9 The effect of treatment with dietary EPA on microglia (Iba1) staining 
after compression SCI. The animals received saline 30 min after SCI and were then 
maintained on a control diet or EPA-enriched diet (150-170 mg/kg) for 28 days.  (A, B) 
Images showing Iba1 labelling in the dorsal (A) and ventral (B) horns. (C, D) 
Quantification of microglia (Iba1) in the dorsal (C) and ventral (D) horns revealed that 
there was no significant difference between the two groups (p>0.05). Results represent 
mean ± SEM; n=6 per group. Scale bar = 50 μm. 
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Neuronal survival 
 
Quantification of neurones in the rostral segment was carried out by counting of NeuN 
labelled cells in specific areas in the dorsal and ventral horns and normalisation to 
uninjured control tissue at the same spinal level (Fig. 6.10A-F).  
 
Figure 6.10 The effect of treatment with dietary EPA on neuronal survival after 
compression SCI. Animals received saline 30 min after SCI followed by control diet or 
EPA-enriched diet (150-170 mg/kg) for 28 days. Representative sections showing NeuN 
labelled neurones in the dorsal (A, C, E) and ventral (B, D, E) horns of naive (A, B), IV 
saline and control diet (C, D), or IV saline and EPA diet (E, F). Scale bar = 100 µm.  
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In naïve control animals, NeuN-immunoreactive neurones were present throughout the 
grey matter of the spinal cord (Fig. 6.10A, B) There was a reduction of approximately 
20% in the dorsal horn and 40% in the ventral horn at this rostral level after SCI (Figs. 
6.10 C, D and 6.11). However, there was no significant difference in neuronal survival at 
this level between the control diet and IV saline and the IV saline, EPA diet groups 
(p>0.05; Fig. 6.10E, F and 6.11), although there was a tendency to an increased neuronal 
loss in the dorsal horn after PUFA supplementation.   
 
 
 
Figure 6.11 Quantification of neuronal survival in the grey matter. Quantification 
revealed a loss of approximately 20% in the dorsal horn and 40% in the ventral horns 
compared to uninjured control tissue. There was no significant difference in the amount 
of neuronal survival at this level between the two SCI groups (p>0.05). Results represent 
mean ± SEM; n=6 per group. 
 
 
Oligodendrocyte survival 
 
Images of oligodendrocytes in the rostral segment were captured from the areas shown in 
Fig. 6.12. Detailed quantification, by counting, was carried out on the control diet and IV 
saline group and the IV saline, EPA diet group, and this was normalised to uninjured 
control tissue at the same level (Fig. 6.13). There was a loss of approximately 60±12.4 % 
in the corticospinal tracts as well as a 20-40 % loss in other areas of the white matter. 
There was no significant difference in oligodendrocyte survival between the two groups 
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although there was a clear trend towards a greater loss in the dorsal columns in the IV 
saline, EPA group compared to control diet and IV saline group (61.4 ± 15.9 % vs 31.6 ± 
20.3 %; p>0.05; Fig. 6.13). 
 
 
Figure 6.12 The effect of treatment with dietary EPA on APC staining after 
compression SCI. Animals received saline 30 min after SCI followed by control or EPA-
enriched diet (150-170 mg/kg) for 28 days. Images show representative APC labelled 
oligodendrocytes in the white matter of naïve (A, D, G, J) IV saline and control diet 
tissue (B, E, H, K), and IV saline and EPA diet tissue (C, F, I, L). Scale bar = 100 μm. 
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Figure 6.13 Quantification of treatment with dietary EPA on APC staining after 
compression SCI. There was a greater loss in the corticospinal tracts than in other areas 
of the white matter. There was no significant difference (p>0.05) in oligodendrocyte 
survival between the two SCI groups although there was a trend towards a greater loss in 
the IV saline and EPA diet group in the dorsal columns. 
 
 
Axonal damage 
 
Using the non-phosphorylated neurofilament marker SMI32, an analysis was carried out 
of the number of SMI32 immunoreactive particles in specific areas of the white matter 
(Fig. 6.14). In normal, uninjured spinal cord at the same level, SMI32 labelling was seen 
as numerous, regular-sized punctate particles and in an even distribution (Fig. 6.14A, D, 
G, J). Following SCI, swollen particles of various sizes were seen in a haphazard 
distribution, indicating severe axonal disruption and cytoskeletal damage, and there was 
an overall loss in number (Fig. 6.14 B, E, H, K). The greatest loss was in the 
corticospinal tracts and dorsal columns (95.3 ± 1.4 % and 77.4 ± 6.5 %). There was no 
significant difference in number between the IV saline and control diet, and IV saline and 
EPA diet groups (p>0.05; Fig. 6.15).  
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Figure 6.14 The effect of treatment with dietary EPA on SMI32 staining after 
compression SCI. Animals received saline 30 min after SCI followed by control or EPA-
enriched diet (150-170 mg/kg) for 28 days. Representative images of SMI32 labelling in 
areas of uninjured tissue (A, D, G, J), IV saline and control diet (B, E, H, K), and IV 
saline and EPA diet tissue (C, F, I, L) 5 mm rostral to the injury site. Scale bar = 100 μm.  
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Figure 6.15 Quantification of treatment with dietary EPA on SMI32 staining after 
compression SCI. Animals received saline 30 min after SCI followed by control or EPA-
enriched diet (150-170 mg/kg) for 28 days. There was an overall loss after SCI in the 
dorsal columns, corticospinal tract, ventral white matter and ventrolateral white matter, 
but no significant difference between the two treatment groups (p>0.05).
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6.2.6 II: The effect of DHA dietary supplementation pre- and post-SCI  
 
For the DHA pre-treatment study, there were four groups, with 6-7 rats per group. The 
level of supplementation was approximately 270-320 mg/kg DHA daily. 
 
Groups: 
 
1. control + control:  4 weeks control diet, SCI, then 4 weeks control diet 
2. control + DHA:  4 weeks control diet, SCI, then 4 weeks DHA enriched diet 
3. DHA + control: 4 weeks DHA enriched diet, SCI, then 4 weeks control diet 
4. DHA + DHA:  4 weeks DHA enriched diet, SCI, then 4 weeks DHA  
   enriched diet  
 
Unexpectedly, there was an uncharacteristic loss of animals in this first 4 group 
experiment. In the first week, three animals died in the control group, none in the DHA + 
DHA group, and one in each of the other two groups. In addition, five were excluded 
after surgical problems, or because movement of the hindlimbs occurred within four 
hours of the SCI. This meant that the initial numbers were reduced by approximately 1/3 
and the remaining size of the groups decreased markedly the power of the statistical 
analysis. After a first analysis of the data from this first experiment, it was decided to 
repeat the experiment, but due to the lack of time, we focused on just two groups. 
Therefore, the experiment was repeated with 2 of the 4 groups (DHA + control and 
control + control) but it was decided not to pool the results. Therefore, a summary of the 
results from the two separate experiments is presented below. 
 
6.2.6.1 Experiment 1 
 
Locomotor outcome 
 
Based on the BBB score, recovery in the control group reached a plateau at 28 days of 7.5 
± 1.7; i.e. movement of all joints of the hindlimb/plantar placement but no stepping (Fig. 
6.16). Some rats in the other groups regained stepping function (Table 6.4). Two-way 
RM ANOVA revealed a significant effect for the time factor (p<0.05; F=63.08), but no 
significant effect of the treatment factor (p>0.05; F=0.934) 
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Figure 6.16 I. Effect of treatment with dietary DHA on locomotor recovery after 
SCI. Animals consumed control or DHA (330 mg/kg) for 28 days before and control or 
DHA (270-320 mg/kg) after SCI. There was no significant difference in the BBB score 
between treatment groups (p>0.05). Error bars represent SEM; no. of animals per group 
in brackets. 
 
 
Stepping: 
Some rats regained occasional stepping function: 1 out of 4 in the control + control diet 
group (Table 6.4). The Fischer exact statistical test revealed no significant difference 
between groups (p>0.05). 
 
Table 6.4 Effect of treatment with dietary DHA on stepping following SCI 
 
 Group          Number of stepping animals 
 
 
 control + control diet    1 / 4 
 control + DHA diet    0 / 4 
 DHA + control diet    3 / 4 
 DHA + DHA diet    4 / 6 
  
Animals received control or DHA (270-320 mg/kg) for 28 days before and after SCI. 
There was no significant difference between groups (p>0.05).   
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Due to the unexpected loss of animals in the preceding experiment, a repeat was 
performed with two groups, 8-9 rats per group: 
 
1. Control:  4 weeks control diet, SCI, then 4 weeks control diet 
2. DHA:   4 weeks DHA enriched diet, SCI, then 4 weeks control diet 
 
6.2.6.2 Experiment 2 
 
Locomotor outcome 
 
Based on the BBB score, recovery in the control group reached a plateau at 28 days of 
9.19±1.7; i.e. occasional uncoordinated stepping (Fig. 6.17). Two-way RM ANOVA 
revealed a significant interaction (p<0.05; F=1.981) and significant difference over time 
(p<0.01; F=26.96) but no significant difference between the two treatment groups, 
despite a trend towards worse recovery in the DHA enriched group (p>0.05; F=1.844).  
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Figure 6.17 II. Effect of treatment with dietary DHA on locomotor recovery after 
SCI. Animals consumed control or DHA (330 mg/kg) for 28 days before SCI and control 
for 28 days after SCI. There was no significant difference in the BBB score between 
treatment groups (p>0.05). Error bars represent SEM; no. of animals per group in 
brackets. 
 
 
Stepping: 
Some rats regained occasional stepping function: 4 out of 8 in the control diet group; and 
3 out of 9 in the DHA pre-treated group. The Fischer exact statistical test revealed no 
significant difference between the two groups (p>0.05; data not shown). 
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6.3 DISCUSSION 
 
In the current chapter the impact of dietary manipulation with EPA or DHA on the 
response to compression SCI has been assessed. The effects of acute i.v. EPA injection, 
with or without EPA dietary enrichment were explored and also the potential 
prophylactic effects of dietary DHA. The EPA study highlighted unexpectedly a possible 
risk associated with high dietary EPA after SCI. The DHA study remained inconclusive 
and did not reveal a clear beneficial prophylactic effect of dietary DHA in SCI.  
 
6.3.1 EPA study 
 
In the EPA diet study, the animals receiving the EPA bolus injection alone had the best 
locomotor outcome, but this was not statistically significant. We found that animals 
treated with an EPA-enriched diet following an i.v. saline injection had a significantly 
worse functional outcome. EPA injection restored this effect to control values. The poor 
recovery in the EPA diet group was apparently not correlated with increased neuronal, 
neurofilament, or oligodendrocyte loss, although there was a trend towards fewer 
oligodendrocytes and neurones in some areas of the cord; nor was it correlated with a 
change in the amount of microglia/macrophages at the injury epicentre or 5 mm rostral to 
the injury site. There was no significant difference in weight between animals before SCI 
or the amount of food consumed. All groups lost body weight progressively following 
SCI (average weight loss of 6 % over the first week, data not shown) but regained more 
than their pre-SCI weight by 28 days, except for the IV saline, EPA diet group which 
continued to weigh significantly less (10 % less than pre-SCI weight, data not shown). 
Interestingly, in a parallel assessment of the changes in hindlimb muscle tissue after SCI 
(i.e. muscle samples collected after 28 days), despite the IV saline and EPA diet group 
faring worse in locomotor outcome, there was significant prevention of the atrophy of the 
soleus muscle and prevention of the loss of regenerative satellite/stem cells in the 
hindlimbs of the same animals compared to the control group (Begum and Robson, 
unpublished).  
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6.3.1.1 Locomotor recovery 
 
Animals receiving an enriched EPA diet following SCI had a worse neurological 
recovery, and this was apparent in both the BBB score and BBB sub score analysis. Data 
from the BBB sub score can provide additional information in a less severe SCI, such as 
rotation of the paws, but this is once plantar stepping is regained, to distinguish between 
finer aspects of coordination (Lankhorst et al, 1999). It was interesting to note that 
considering the recovery of stepping, no animal regained stepping in the IV saline, EPA-
enriched diet group, compared to 4 out of 6 in the control group (IV saline, control diet), 
5 out of 6 in the IV EPA, control diet group and 3 out of 6 in the IV EPA, EPA diet 
group. However, likely due to the small group size, this was not statistically significant.  
 
6.3.1.2 Bladder function 
 
Bladder volume was calculated using ultrasound measurements. There are alternative 
methods of measuring urinary tract dysfunction. The most common method is 
cystometric urodynamic analysis, which is essentially similar to clinical cystometry, 
where a urethral catheter is implanted into the bladder dome and then filled with saline 
while recording intravesical pressure to examine the relationship between bladder volume 
and pressure during filling and micturition. Ultrasound offers a quick, minimally invasive 
and effective alternative and in rats, increases in bladder volume are proportional to the 
severity of SCI (Pikov et al., 2001; Wrathall et al., 2006). 
 
The pattern of urinary tract dysfunction observed here is in agreement with other 
laboratories in thoracic contusion models (Pikov, et al., 2001; Mitsui et al, 2005; de Groat 
and Yoshimura, 2006).  Care was taken to assess the bladder at the same time of day, at 
each time point: 1-2 h following manual expression of the bladder and performance of the 
BBB tests. A restriction was not made on the amount of water that was consumed before 
the measurements, but this was minimal since most eating/drinking takes place during the 
night in the active phase of the day/night cycle of the animals. Following compression 
SCI, there was an initial period of flaccid paralysis of the urethral sphincter (noticed by 
wet abdomens) lasting approximately 3 days. This was followed by areflexia - an 
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increase in urinary retention (bladder volume) at day 3, which is a result of the 
development of a dyssynergia between the bladder and urethral sphincter (Blaivas et al., 
1981; Kaplan et al., 1991). The IV saline, EPA-enriched diet group had the largest 
significant increase in bladder volume compared to the control group. Urinary retention 
(or storage) is sympathetically mediated, whereas micturition is elicited by 
parasympathetic activation. Normal lower urinary tract function requires the coordinated 
activity of the sympathetic, parasympathetic and somatic nervous systems. SCI induces 
profound changes in bladder innervation, particularly afferent, circuitry, morphology and 
structure (Beattie et al., 1993; for review, Inskip et al., 2009). In the first study to 
document using this technique, bladder volume was 0.089 ± 0.04 ml in uninjured rats, 
which was similar to our observations (0.1 ± 0.03 ml); 3.51 ± 0.47 ml on day 4 post-
injury and decreased to 1.83 ± 0.50 ml by day 8 (Kierstead et al., 2005). The contusion 
injury resulted in a more severe paralysis (BBB score of approximately 6 at day 28) 
compared to our model (BBB 10.8 at day 28 in the control group). If injury severity is 
correlated with bladder function (Pikov et al., 2001; Wrathall et al., 2006), this explains a 
less severe bladder impairment in our model based on volume size at day 3. Increased 
bladder size did not persist in our model, but returned to baseline values at day 8. We did 
find a permanent change in the width of the bladder at 28 days post-mortem. A similar 
observation, i.e. an increase in bladder weight, has been reported elsewhere (Mitsui et al., 
2005). The increase in bladder capacity is caused by bladder overdistension during the 
areflexic period. The increased pressure, due to bladder outlet resistance, induces the 
bladder hypertrophy that is reflected in the increased bladder width (Mitsui et al., 2005). 
Since there was recovery of bladder function in all groups by approximately day 8, these 
results imply that there was a partial recovery of coordination by parasympathetic 
pathways innervating bladder smooth muscle and somatic motor neurons that supply the 
external urethral sphincter.  
 
Histological studies could be extended to study the sprouting or sparing of pathways 
implicated in the CNS control of micturition that are located in the lumbosacral cord. 
These include the bladder afferents projecting to the dorsal horn, and the somatic dorsal 
lateral motor and spinal parasympathetic nuclei that coordinate the activity of the urinary 
bladder, urethra, and urethral sphincter. These regions of lumbosacral cord are innervated 
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by descending pathways from the brainstem, among which are axons containing 
corticotrophin releasing factor (CRF) and serotonergic (using 5-HT) and noradrenergic 
(using DβH) axons. Studies elsewhere have correlated a reduced loss of these markers 
after SCI with an improvement in bladder function (Mitsui et al., 2005).  
 
6.3.1.3 Sensory outcome 
 
Hypersensitivity is the phenomenon of enhanced sensitivity to pain, whereas allodynia is 
a perception of pain in response to an innocuous stimulus. The dynamic plantar 
aesthesiometer, or automated mechanical plantar withdrawal test has been used to 
measure hypersensitivity or the development of neuropathic pain following SCI 
(Anderson et al., 2005), spinal nerve ligation (Ozsoylar et al., 2008) and spinal root 
avulsion (Chew et al., oral communication, ISRT annual meeting, London, 2009). Before 
this, manual von Frey filaments have been used to demonstrate at-level and below-level 
mechanical hypersensitivity or allodynia after SCI (Christensen et al., 1996; Hulsebosch 
et al., 2000). The fundamental difference is that the automated test can set a fixed 
„latency‟ of withdrawal with more quantitative measurements of both weight and time, 
removing human error due to variable force applied by the investigator using manual von 
Frey hairs. It also does not rely on experimenter judgement of positive paw withdrawal. 
In this way it can be used reliably and robustly between experimenters and laboratories. 
Here, measurements were taken upon establishment of hind paw plantar placement and 
weight support, which was on average between 7-14 days after injury; therefore, not all 
rats were measured at each time point.  However, we noted a significantly decreased 
withdrawal threshold in all treatment groups, which is indicative of the development of 
below-level hypersensitivity and central sensitization, documented in previous studies 
after thoracic hemisection or contusion (Christensen et al., 1996; Christensen and 
Hulsebosch, 1997; Hulsebosch et al., 2000). Hypersensitivity can be the result of 
neurones which are part of the ascending somatosensory pathways, such as the neurones 
in the dorsal horn, becoming pathophysiologically hyperexcitable, leading to the 
phenomenon of central sensitisation (Woolf, 1983; Christensen and Hulsebosch, 1997; 
Drew et al., 2001; Hains et al., 2003; Lampert et al., 2006). Central sensitization is the 
state of heightened excitability of central dorsal horn neurones in that they respond 
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quicker and their responses are greater and longer lasting: they do not equate to the extent 
of the stimulus. The central sensitization phenomenon is believed to be the cause of why 
painful symptoms can last far longer than the initial stimulus, and when put into the 
context of patients, is commonly termed „chronic pain‟. Chronic neuropathic pain 
behaviour in SCI models has been directly related to increases in CGRP 
immunoreactivity (Christensen and Hulsebosch, 1997), metabotropic glutamate receptors 
(Mills and Hulsebosch, 2002), and NGF (Gwak et al., 2003).  Mechanical allodynia or 
hypersensitivity in the hindlimbs following clip compression SCI has also been shown to 
coincide with a reduction in serotoninergic immunoreactivity below the level of the 
lesion (Bruce et al., 2002), suggesting that in this model, below level neuropathic pain 
behaviour was due to loss of descending antinociceptive supraspinal control from the 
brain stem onto dorsal horn neurones. Differences were noted in our study between 
left/right hindpaws. Based on the criteria implemented, in some animals there was 
development of hypersensitivity in one hind paw but not the other. These were likely due 
to asymmetric lesions and were also apparent in the locomotor recovery. In some cases 
before stepping function was regained, one side showed more extensive movement than 
the other.  
 
The inflammatory response may also have an important role in pro-nociception and 
central sensitization after SCI, through release of cytokines and chemokines such as IFN-
γ, IL-1β, TNF-α from macrophages, neutrophils and T-lymphocytes, which sensitise 
dorsal horn neurones (Trivedi et al., 2006; Thacker et al., 2007). Microglia have recently 
been recognized as powerful modulators of pain in SCI, by producing factors, such as 
ATP and fractalkine (Milligan and Watkins, 2009), that in turn activate and sensitise 
dorsal horn neurones (Nesic et al., 2005; Hains and Waxman, 2006; Gwok et al., 2008; 
Clark et al., 2008; Detloff et al., 2008; Hulsebosch et al., 2009; Marchand et al., 2009). 
Inhibition of the microglial p38 MAP kinase phosphorylation pathway attenuates the 
hypersensitivity that develops post SCI (Crown et al., 2008).  
 
Various approaches have been used to model neuropathic pain following SCI, including 
contusion and hemisection injuries at the thoracic level (Christensen and Hulsebosch, 
1997a; Bennett et al., 2000); anterolateral lesions of the spinothalamic tract (Ovelmen-
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Levitt et al., 1995;Vierck, Jr. and Light, 2000) and ischaemia (Hao et al., 1991). Not all 
rats developed hypersensitivity in our model, but this is not unusual. Clinically >65 % of 
people with SCI develop neuropathic pain (de Miguel and Kraychete, 2009; Miladinovic, 
2009) and in the majority of cases, chronic central pain develops within several months to 
years following injury (Christensen et al., 1996; Christensen MD and Hulsebosch, 1997; 
Richards et al., 1980). Therefore, it appears that compression to the spinal cord could be a 
useful and representative model for testing the development of neuropathic pain after 
SCI. In order to validate the apparent development of hypersensitivity, it would be 
necessary in future studies to take more than one baseline reading. Other researchers in 
our laboratories have shown that there is a slight decrease in the latency of withdrawal 
following the first baseline recording (Chew et al., personal communication). Gender 
differences have also been documented to play a role in the development of at-level 
allodynia during different stages of their oestrogen cycle (Hubscher et al., 2010). Females 
were chosen for our study and are preferred for SCI contusion or compression 
experiments, since it is easier to manage bladder expression and to avoid urinary tract 
infections. The best time of day to take readings has also been debated, to the extent that 
some laboratories reverse the light-dark cycle of their animals, in order to take readings 
during their dark (active) cycle (Hulsebosch et al., 1996). 
 
Management of chronic pain after SCI is poor and remains a clinical challenge. 
Downstream metabolites of omega-3 PUFA, such as resolvin E1 and resolvin D1 have 
recently been shown to have more impact than either morphine or COX-2 inhibitors in 
central inflammatory evoked pain, and can attenuate inflammatory pain by regulating the 
synaptic plasticity in spinal cord dorsal horn neurones, which have been strongly 
implicated in the generation of persistent pain (Woolf and Salter, 2000; Xu et al., 2010). 
Although no effect was seen in this study, it would certainly be worth pursuing research 
in this area, in order to explore in more depth the effect of omega-3 PUFA on the 
development of neuropathic pain after SCI. 
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6.3.1.4 Cavitation and the presence of macrophages/microglia 
 
Histological analysis showed extensive damage in the epicentre of all groups, with 
widespread cavitation but there was no significant difference in cavity size between the 
two groups analysed, in the case of the EPA study. Macrophages were present inside the 
cystic cavities of the epicentre and in the surrounding spared tissue. Due to the extensive 
cavitation and very little spared tissue, further analysis was carried out in rostral 
segments, 5 mm from the epicentre.  
 
In rostral segments, there was no difference between the amounts of ED1- or Iba1-
labelled macrophages/microglia in the two groups. As seen by Popovich at al. (1997), 
there were macrophages predominantly confined to the dorsal columns but also scattered 
throughout the tissue, as well as in clusters, the location of which was variable from 
animal to animal. These walled off clusters have previously been documented to be 
surrounded by reactive astrocytes, demarcating damaged tissue and preventing the spread 
of leukocytes through the CNS parenchyma (Sofroniew et al., 2009, Fig. 3.12 in chapter 
3). However, this also presents a barrier to regeneration of axons through the injury site 
(Silver and Miller, 2004). Most research is aimed at disrupting this barrier, or preventing 
its formation, for example by digesting CSPGs, to enhance axon regeneration or 
sprouting (Moon et al., 2001; Bradbury et al., 2002). It would be interesting to explore 
the spread of inflammation above and below the injury site, and the integrity of the 
astroglial barrier, and generally, the astrocytic response, after PUFA treatment.  
 
The analysis was carried out differently for ED1 and Iba1. In the rostral region, an overall 
measurement of the entire transverse section appeared to best represent the amount of 
ED1 macrophage/microglia in the tissue compared to high power images in specific 
locations, which might have missed some of the accumulations of cells. However, for 
Iba1, high power images were preferred, since using low power images meant it was not 
possible to detect the fine processes of the resting microglia phenotype. In future, it 
would be useful to quantify the ratio of ED1:Iba1 double-labelled 
macrophages/microglia. An attempt to do this was made using MetaMorph® software. 
However, there were difficulties in setting the analysis criteria to get an accurate output, 
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due to the variability in background staining in each animal, combined with the variable 
morphologies of the microglia.  
 
6.3.1.5 Neuronal loss 
 
There was no difference in neuronal number in the dorsal and ventral horns between the 
EPA-enriched diet and control diet groups. The extent of neuronal loss at this time point 
correlates with the protracted neuronal loss seen by Huang et al. (2007b) in the 
establishment of the compression model of SCI in our laboratory (approximately 20% at 
28 days in the rostral region), although the analysis carried out here was slightly different. 
Huang et al. (2007a, b), analysed images taken at 40x magnification and the entire image 
was counted at 7 days and 6 weeks, rather than images taken at 20x magnification here, 
with a count made on a box placed over the image. Despite this, consistent with their 
observations, a greater relative loss was found in the ventral, compared to the dorsal horn 
areas (40 % vs. 20 %). The reason for this dorsolateral sparing is not known, but may 
reflect differences in the intrinsic vulnerability of the cells, or mechanical effects such as 
transmission of compressive stress into the intermediate and ventral grey matter by the 
overlying dorsal columns (Huang et al., 2007b).  
 
Most neuronal loss is considered to be the result of necrosis caused by the original injury 
(Faden et al., 1988; Panter et al., 1990; Wrathall et al., 1992) and it has been documented 
that in contrast to compression SCI, after contusion SCI there is no further neuronal loss 
after 3 days (Grossman, et al., 2001). However, a number of other studies have shown the 
occurrence of neuronal apoptosis after contusion SCI (Crowe et al., 1997; Liu et al., 
1997; Lou et al., 1998). Secondary pathogenesis such as ischaemia, glutamate-induced 
toxicity (Liu et al., 1999), inflammation and free radical production could contribute to 
neuronal loss. Since there is a prolonged inflammatory response and microglia are known 
to produce toxic substances, such as nitric oxide and TNF-α (Chao et al., 1992; Si et al., 
1998; Liu et al., 2002), these glial cells have been implicated in neuronal loss after SCI.  
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6.3.1.6 White matter pathology 
 
Ward et al. (2010) showed a decrease in the non-phosphorylated component of 
neurofilament (SMI32) following compression SCI. The method of analysis was slightly 
different, with the use of multiple small sample boxes, rather than using the whole image 
taken with the 40x objective, and the results expressed counts per area. After converting 
these values to a percentage of loss compared to the uninjured control tissue, they equated 
to an approximate 60 % loss in the DC; and 50 % in the VWM and 42 % in the VLWM 
at 7 days (Ward et al., PhD thesis). In our study, there was a more dramatic loss of non-
phosphorylated neurofilament rostral to the injury site at 4 weeks following SCI - 95 % in 
the CST and 77 % in the DC. This might be due to the later time point of analysis, but 
also the injury severity was worse in this study (BBB score of 11 vs.12 in the control 
group at 4 weeks here).There was no significant difference in the number of SMI32-
labelled axons between the control group and the group exposed to a higher level of 
dietary EPA. The loss of axons in the white matter following human SCI is almost always 
incomplete (Bunge et al., 1993; Norenberg et al., 2004; Guest et al., 2005).  Studies of 
these surviving axons demonstrate that they are abnormally myelinated, with thinner 
myelin sheaths than uninjured axons (Gledhill et al., 1973; Griffiths, 1983; Totoiu and 
Keirstead, 2005). Spinal cord axons can remyelinate following injury (Bunge et al., 
1961).  However, abnormally myelinated axons are still observed at chronic time points 
following injury. It would be interesting to look in the tissue from this study, at the 
effects of the dietary treatment on myelin, such as proteolipid protein (PLP) and myelin 
basic protein (MBP), two major structural proteins that make up CNS myelin (Norton and 
Cammer, 1984).   
 
Myelin is essential for normal nervous system function and a loss of myelin after SCI has 
critical effects on nerve physiology.  Demyelination results in a larger membrane 
capacitance and a decrease in conduction velocity which, in turn, contributes to an 
increased refractory period and a higher frequency of overt conduction failure.  These 
alterations have a critical effect on neurological function following experimental (Bunge 
et al., 1961; Blight, 1983; Nashmi and Fehlings, 2001b) and human (Norenberg et al., 
2004; Guest et al., 2005; Smith and Jeffery, 2006) SCI. Strategies to prevent 
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demyelination or to promote remyelination are now extensively investigated in the field 
of SCI (for review see McDonald and Belegu, 2006).   
 
Oligodendrocytes are the cells responsible for the myelination of axons in the CNS, and 
remyelination of injured axons. There was a loss in the number of oligodendrocytes after 
compression SCI compared to naïve controls and this was greatest in the CST, consistent 
with other laboratories (Crowe et al., 1997; Li et al., 1999; McTigue et al., 2001; 
McEwen and Springer, 2005) and with what was found at 7 days in the epicentre in one 
of our previous studies (Huang et al., 2007a). There was no significant difference 
between treatment groups, although there was a trend towards a greater loss in the dorsal 
columns of the segment rostral to the injury epicentre in the IV saline, EPA diet group, 
compared to the control group. It is generally recognized that white matter damage is 
more critical in SCI than grey matter damage (Eidelberg et al., 1981).  
 
In summary, there was no correlation between the marked worsening of the motor 
outcome after dietary intake of EPA, and tissue markers of injury. It is not clear why 
there was no correlation of the usual injury markers with behavioural outcome in this 
study. Studies where there is an improvement in locomotor outcome tend to show, 
overall, a correlation with neuronal and/or oligodendrocyte loss (Huang et al., 2007a; Lim 
et al., in press). However, there are exceptions – Kostyk et al. (2008) reported worse 
locomotor recovery in a transgenic mouse compared to wildtype controls after spinal 
contusion, whilst paradoxically, the tissue exhibited robust axon growth within the lesion. 
 
6.3.1.7 The EPA diet and fatty acid composition of red blood cells  
 
Analysis of serum or RBCs is a widely used method of indicating uptake of dietary fatty 
acids. In the EPA study, animals consumed approximately 150-170 mg/kg, and this was 
enough to enrich the EPA content in RBCs by eight fold compared to the control group. 
DHA content also increased by a relatively smaller but significant amount and this is 
likely to come from the small percentage present in the oil (5-10 %), or conversion of 
EPA to DHA, which is also possible (Rapopport et al., 2007). In our study, the omega-6 
content was significantly lowered in parallel, particularly AA, docosapentaenoic (22:5) 
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and docosatetraenoic (22:4). Supplementation with omega-3 PUFA can displace AA 
structurally from phospholipids, causing a subsequent decrease in AA membrane content, 
and this has been demonstrated in several other dietary studies (Carlson et al., 1992; 
Watanabe et al., 2003; Valenzuela et al., 2005; Calder 2007; Dyall et al., 2007; this list is 
not exhaustive). In future studies, baseline levels should be obtained prior to SCI, to 
confirm the fatty acid level content was similar for all animals preceding the injury.  
 
The control diet used here contained a small percentage of fatty acids (1.38 % linoleic 
acid, 0.11 % linolenic acid, 0.11 % omega-3 and 0.52% saturated fatty acids, see 
Appendix 2). A control diet should not lack omega-3 PUFA completely, since omega-3 
PUFA  confer neuroprotection intrinsically, as demonstrated in an ex vivo study after 
omega-3 PUFA dietary deficiency in a model of ischaemia on hippocampal slices 
exposed to oxygen and glucose deprivation (Moreira et al., 2009). For the EPA oil, the 
composition was 70 % EPA and the rest made up of a combination of DHA (5-10 %), 
AA and other fatty acids (see materials and methods, Chapter 2). The EPA delivered in 
the diet was in ethyl ester form.  
 
Based on another study carried out in our laboratory (Dyall et al., 2007), we have 
established that after this type of supplementation, omega-3 PUFAs are taken up into all 
major classes of nervous tissue phospholipids. The brain is highly enriched in DHA, with 
phosphatidylethanolamine (PE) and phosphatidylserine (PS) containing the highest levels 
(Salem Jr et al., 2001). Many previous studies have shown that dietary intake of omega-3 
PUFAs affects brain levels of fatty acids in all the major classes of phospholipids 
(Chernenko et al., 1989; Saito et al., 2003; Dyall et al., 2007). The change in these levels 
will likely have a significant impact on membrane fluidity, cell signaling and competition 
of PUFA for enzymatic reactions. Evidence for this could be obtained in a repeat 
experiment, using freshly harvested tissue samples and Western blot analysis, to measure 
activation of the proteins involved in downstream signaling pathways of PUFA, such as 
Akt and ERK (Lu et al., 2010; Moereira et al., 2010) or COX2 expression (Huang et al., 
2007a). 
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6.3.1.8 The EPA bolus and EPA diet target different SCI processes  
 
It is not clear whether i.v. EPA alone is significantly neuroprotective, as although our 
results showed that the BBB outcome was better after the i.v. EPA injection alone in the 
present study compared to control, this was not statistically significant. In another study 
in our laboratory, i.v. EPA administered 30 min after compression SCI demonstrated 
significant neuronal and oligodendrocyte protective effects at 7 days, although the effect 
for locomotor outcome was not significant at 7 days, but was significantly better in the 
EPA group when all time points were considered during the first recovery week (Lim et 
al, in press). However, overall it was not as effective as an equivalent dose of DHA 
administered as a bolus. In our laboratory, we do experience some differences from 
surgeon to surgeon in the severity of the injury, which makes it difficult to directly 
compare results between experimenters. It is possible that the severity of SCI could affect 
the efficacy of a treatment. However, the BBB score of control groups in both this study 
and that of Lim et al. (in press) were approximately 3 at day 7. It is also not clear yet why 
the acute and chronic effects of EPA intervention are so different, and in particular why 
EPA in the diet immediately after SCI has such a significant negative effect. The 
combination of an acute i.v. bolus of EPA with dietary enrichment is likely to affect a 
multitude of pathogenetic mechanisms which are involved in trauma-induced damage and 
both are likely to affect different SCI processes. The acute bolus will likely be targeting 
ischemic, apoptotic and excitotoxic events, whereas the dietary enrichment will only start 
to increase levels of EPA in the blood and tissue after a delay of several hours. This is at 
a time when secondary injury events will be occurring, such as interaction with the 
immune system, damage to the blood-brain-barrier, degeneration of surviving axons and 
further loss of neuronal and non-neuronal cells. We need to characterize in detail the 
exact mechanism and targets of the omega-3 PUFAs, in order to confirm whether one or 
a combination of these processes are being targeted. Further studies could also address 
the issue of whether the negative effects are dose-related.  
 
The clearance of omega-3 in plasma after intravenous delivery is within seconds-minutes. 
Large proportions of omega-3 taken up from blood as free fatty acids are bound to bovine 
serum albumin or acylated into phospholipids and retained in the liver, heart, lung, 
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kidney, bone marrow, spleen, gastrointestinal tract, brown adipose tissue and skeletal 
muscle (Nilsson and Becker, 1995), whereas the remainder is either transported by a fatty 
acid binding protein to the endoplasmic reticulum, or lost by β-oxidation in mitochondria 
or peroxisomes (Rapopport 2007). Similar to DHA, a fraction of the EPA bolus could be 
targeting TREK channels, while another portion is likely to be converted  into its 
metabolites by COX and lipoxygenase activities and affect inflammatory cell trafficking. 
Results from this thesis suggest that the acute EPA injection would have a modest 
influence on neutrophils after SCI. Retinoid X receptors and the peroxisome proliferator-
activated receptors are also targets for omega-3 fatty acids, and they are upregulated after 
SCI (Genovese et al., 2005; Schrage et al., 2006; Mucida et al., 2007). Our laboratory is 
currently exploring the importance of TREK channels in the effect of the i.v. omega-3 
bolus, using a specific TREK-1 antagonist called spadin, a secreted peptide derived from 
the neurotensin receptor 3 (Mazella et al., 2010). 
 
6.3.1.9 Possible explanation of the apparent detrimental effects of the EPA diet  
 
The results from the study using dietary EPA-enrichment are somewhat unexpected. On 
the one hand, the EPA diet appeared to have a detrimental effect on locomotor outcome, 
whilst the acute injection of EPA did not. There was no change in global markers of 
macrophages/microglia after i.v. (Chapter 4) or dietary EPA treatment, but this does not 
rule out the possibility that certain subtypes of these cells - such as the less neurotoxic, 
growth-promoting “M2” macrophage phenotype Kigerl et al. (2009), or the blood-derived 
population, could have been reduced by the actions of EPA or its metabolites at earlier 
time points. It was not possible to assess this with the markers used. Resolvin E1 is 
known to be active at nanomolar concentrations. Therefore, even after the ingestion of 
moderate amounts of the EPA-enriched diet, active levels of E-series resolvins could 
have been reached in the first few days after SCI. As discussed in Chapter 3, resolvins 
have potent effects as immune regulators and they interact with receptors expressed on 
phagocytic leukocytes (Arita et al., 2007; Spite et al., 2009; Krishnamoorthy et al., 2010; 
Ohira et al., 2010). The use of intra-vital microscopy has demonstrated that i.v. 
administration of RvE1 (100 ng) rapidly reduced leukocyte rolling by approximately 40% 
in mouse cremaster muscle venules (Spite et al., 2009). Therefore, it could be speculated 
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that the detrimental effects of an enriched EPA diet may be due to the early reduction of 
the M2 macrophage response, or the blood-derived macrophages, leaving the neurotoxic 
“M1” phenotype to dominate the lesion and persist there indefinitely.  
 
 Schechter et al., (2009) demonstrated with the use of adoptive transfer experiments and 
bone marrow chimeras, which were able to functionally distinguish between the resident 
microglia and the infiltrating monocyte-derived macrophages, that selective ablation of 
infiltrating monocyte-derived macrophages following SCI using either antibody-mediated 
depletion or by diphtheria toxin, impaired recovery. Most studies have shown that 
depleting this subset of macrophages is beneficial to recovery from SCI (Blight, 1994; 
Taoka et al., 1997; Popovich et al., 1999; Eng and Lee, 2003; Gris et al., 2004). Schechter 
et al. (2009) alluded to a novel unique role associated with this subset of infiltrating 
blood-derived macrophages in SCI recovery, which cannot be provided by the activated 
resident microglia. The authors go on to propose that limited recovery following SCI can 
be attributed in part to the inadequate, untimely, spontaneous recruitment of monocytes 
(Schechter et al., 2009). They showed that boosting this pool of monocytes by adoptive 
transfer resulted in an improved outcome.  
 
Since the detrimental effects to locomotor recovery were already apparent in the first few 
days after starting the diet, it is also possible that EPA could be affecting repair of the 
blood-brain barrier or prolonging bleeding time (Mortensen et al., 1983; Nelson et al., 
1991) by decreasing aggregation of platelets (Goodnight et al., 1981; Nelson et al., 1991; 
Wander et al., 1991). It would be possible to testblood-brain barrier integrity by using 
permeability tests, e.g. with HRP injection (Schnell et al., 1999), or Evans blue (Uyama 
et al., 1988). Both DHA and EPA, but EPA in particular is known to reduce platelet 
aggregation (Hirai et al., 1982; Park and Harris, 2002). PUFA are known to have 
reversible anti-coagulant/platelet aggregation and clotting properties, and are given with 
warfarin or aspirin in the prevention of stroke, and this has been without clinical concerns 
(Bays et al, 2007). However, the anti-aggregating impact of omega-3 PUFAs can vary 
between species. In particular, intake of EPA and DHA has been reported to increase 
PUFA levels in platelets (Zhu et al., 1994), lead to increased mesenteric bleeding time 
(Mark et al., 1994), and be effective in limiting platelet reactivity in rats and cats 
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(Wojenski et al., 1991; Bright et al., 1994). It would therefore be worth considering 
whether the EPA enriched diet prolongs bleeding duration after SCI, by analysing the 
spread of haemorrhage by staining tissue with the diaminobenzidine (DAB) method, such 
as shown in the image below (Fig. 6.18), generated in tissue from our SCI animals, 
testing platelet reactivity as in the above studies; or by measuring clotting time from fresh 
blood samples.  
 
Figure 6.18 Areas of haemorrhage in transverse sections of the injury epicentre 4 h 
after SCI. Transverse sections were labelled with DAB, which revealed the presence of 
red blood cells. Images are serial sections, approximately 150 µm apart, taken from the 
same animal. 
 
PUFAs are anti-oxidant and anti-inflammatory compounds (Mori et al, 2003; Sarsilmaz 
et al., 2003; Richard et al., 2008). The degree of unsaturation makes these compounds 
more oxidisable and omega-3 fatty acid preparations can undergo extensive oxidation, 
especially if stored under inadequate temperature and light conditions. This could 
contribute to potential toxicity. Several studies have suggested that increased PUFA 
incorporation may exacerbate the susceptibility of tissues to free radical-mediated lipid 
peroxidation (Lamers et al., 1988, Luostarinen et al., 1997; Véricel et al., 2003). Bays 
(2007) recently reviewed the safety considerations of omega-3 fatty acid therapy. For 
example, due to the potential presence of environmental toxins such as mercury, 
polychlorinated biphenyls, dioxins, and other contaminants, results in swine suggest that 
EPA may functionally impair the induction/expression of adhesion molecules (Kim et al., 
1995). Therefore, PUFA ingestion may reduce cell membrane integrity and tissue 
viability under circumstances of an increased oxidative stress, such as an 
ischaemic/reperfusion challenge (McCord et al., 1985), or compression SCI. Results from 
our laboratory with DHA supplementation so far suggest otherwise, however this cannot 
be ruled out for EPA.   
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6.3.2 DHA studies 
 
The results from the DHA pre-treatment experiments did not reveal a significant 
beneficial prophylactic effect of DHA. This was surprising, but may be due to the 
insufficient power of the studies or masked by the severity of the injury as discussed 
earlier. Others have shown improved neurological outcome when animals were pre-
treated with DHA before in other models involving neuronal loss (Umemura, et al., 1995; 
Pan et al., 2009), and when i.v. and dietary DHA were given after SCI (Huang, et al., 
2007a), as well as pre- and post- injury DHA exposure in in vitro models of neuronal 
injury (Gladman et al., communication FENS meeting Amsterdam July 2010). Moreover, 
preliminary results obtained in our laboratory using fat-1 transgenic mice (Kang et al., 
2004), which produce a higher level of endogenous omega-3 PUFA from omega-6 
PUFAs in the diet, showed better locomotor outcome after SCI than their wild-type 
littermates (Lim et al., communication FENS meeting Amsterdam July 2010). These 
results suggest that a potential prophylactic treatment with DHA for SCI cannot be ruled 
out yet. 
 
Based on the mortality and number of stepping animals in the first study with dietary 
DHA, there appeared to be a slight indication that there was a beneficial effect from DHA 
prophylactic treatment. There was no significant difference between the groups in 
locomotor recovery following pre-treatment with DHA in the second study. There was no 
significant difference in the intake of the two diets and there was no difference in body 
weight between the two groups before SCI, or after SCI in the first study. It was 
estimated that three quarters of the intended dose (400 mg/kg/rat) was ingested during the 
experiment. This was less than the dose given by Huang et al. (2007a), but the beneficial 
dietary effect in that study was only seen when intravenous DHA was also administered. 
It is possible that sufficient levels were not reached in our study. Two brain injury studies 
showing a beneficial effect of DHA, administered the compounds for 6 weeks 
intraperitoneally (Pan et al., 2009) and 8 weeks via the diet (300 mg/kg/day Umemura et 
al., 1995). From data generated in a parallel experiment in our laboratory, where 
uninjured Sprague-Dawley rats received 400 mg/kg/day for 8 weeks, we know that levels 
of DHA in liver tissue increase after this exposure up to two-fold and the amount of AA 
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is reduced (Osman communication, British Pharmacological Society, UK, 2007), 
therefore there are tissue structural changes. However, the levels reached in the spinal 
cord by 4 weeks may not have been sufficient to exert effects on recovery after SCI. Or it 
may be, as found before, that the mechanism of neuroprotection by DHA after SCI 
requires the fast, intravenous delivery of DHA after SCI (Huang et al., 2007a). It has been 
shown that DHA may activate positive regulators of cell survival by up-regulating Akt, 
extracellular-signal-regulated kinase (ERK) and/or the Bcl-2-mediated pro-survival 
cascade. DHA can also attenuate inflammatory cytokine and free radical production 
(Akbar et al., 2005; Florent et al., 2006; German et al., 2006). DHA pre-treatment in rats 
subjected to focal cerebral ischemia/reperfusion injury reduced the size of infarction, 
decreased blood-brain barrier disruption, brain oedema and inflammatory cell infiltration 
(Pan et al., 2009; Umemera et al., 1995a).  
 
There has been no evidence in our laboratory so far of a detrimental effect of dietary 
DHA post-SCI. There has been only one study reported, where post-treatment with DHA 
and AA by intraperitoneal injection was reported to exacerbate neurological damage 
following ischemia/reperfusion injury, possibly via increasing damage from reactive 
oxygen species (ROS) and oxidative stress (Yang., et al, 2007). DHA induced 
enlargement of areas of cerebral infarction and increased impairment of motor activity, in 
a dose-dependent manner. The mechanisms explored showed an increase in 
metalloproteinase (MMP) activity, inflammatory cell infiltration, COX-2 expression and 
caspase 3 activity. In future, it will be necessary to look at histological markers at the 
injury site to address the effects of DHA prophylactic treatment for SCI in more detail.  
 
Before SCI there was no difference in weight between the two groups in the second DHA 
experiment, but 4 weeks after SCI the DHA group weighed significantly less (25 g 
difference between groups, data not shown) with no significant decrease in food intake. It 
has been shown that dietary supplementation of n-3 PUFA in fish oil reduces weight gain 
(Hassanali et al., 2010). Anti-obesity effects of DHA are not well-understood or 
documented (for review, Li et al., 2008). In one study where weight measurements were 
recorded, Umemura et al. (1995) reported no difference in weight between the control 
and DHA groups before the injury (middle cerebral artery thrombosis) but tissue was 
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harvested at 24 h post-injury. Therefore, it is not possible to ascertain whether weight 
similarity was maintained between groups after the brain injury, or even if the protective 
effects of the DHA pre-treatment were sustained.  
 
In conclusion, EPA dietary treatment following SCI revealed a potential detrimental 
effect in locomotor recovery but this was not correlated with histological markers. DHA 
prophylaxis appeared to have no significant effect on outcome following SCI. Further 
work is required in order to explore any detrimental or neuroprotective effect of dietary 
manipulation with these PUFA in SCI.  
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Chapter 7: General Discussion 
7.1 Summary 
The most important findings from the studies carried out in this thesis were as follows: 1) 
the time course of the neutrophil and macrophage/microglial response in the rat static 
compression model of SCI is similar to the inflammation time course documented in 
other models of SCI, although lymphocytes detected in tissue were few in number. A 
systemic response was also observed in the liver after SCI and laminectomy surgery. 2) 
The neuroprotective effects of acute DHA or EPA injection following compression SCI 
are unlikely to be related to a major effect on the acute component of the inflammatory 
response. An overall modest effect of the two omega-3 PUFA was observed on 
neutrophil infiltration to the epicentre. Cytokine/chemokines in the epicentre and an acute 
phase protein (CRP) in the plasma related to leukocyte trafficking and systemic 
inflammation were all observed to precede the peak of neutrophil infiltration to the injury 
site. DHA reduced CRP levels, but neither EPA nor DHA reduced levels of the 
cytokine/chemokines. 3) In an alternative injury model, rat contusion SCI, acute DHA 
injection was found to improve hind limb function at a higher dose (500 nmol/kg) than in 
compression SCI (250 nmol/kg), but was not significantly correlated with neuronal and 
non-neuronal histological markers in the spinal cord. 4) The dietary treatment with EPA 
and DHA in rat compression SCI revealed a possible detrimental effect of EPA, whereas 
pre-treatment with DHA had no significant effect on locomotor outcome. 
 
7.2 DHA and EPA are pleiotrophic compounds with functional differences 
As the field has progressed alongside the course of this doctoral research project, 
functional differences between DHA and EPA are becoming more apparent and 
documented in the literature. Parallel in vitro studies in our laboratory in neuronal models 
of mechanical stretch and hypoxia (Gladman et al., 2010), are helping to tease apart the 
differences between DHA and EPA in their potency, targets and effects in protection 
against apoptotic cell death. Pre-treatment with DHA and EPA reduced neuronal and 
non-neuronal cell death in the mechanical stretch and hypoxia models; but EPA did not 
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have protective effects after hypoxic injury, in clear contrast with DHA (Gladman et al, 
communication, FENS meeting Amsterdam July 2010). 
Historically, both DHA and EPA have been used together in their naturally occurring 
form, e.g. as components of fish oil, in fish oil supplements or other preparations 
containing fish oil, and until recently, were thought to share very similar characteristics. 
In combination, they are well tolerated and have been shown to have significant potential 
for beneficial effects in various neurological conditions, reinforcing their potential for 
rapid translation into clinical use. Used separately, after SCI, in acute bolus or in a dietary 
enrichment, of these two PUFA, DHA appears to be the leading molecule with 
neuroprotective properties after SCI (King et al., 2006; Huang, et al., 2007a; Lim et al., in 
press). A detailed dose-response study is yet to be performed, with both administration 
regimes, in order to see if the neuroprotective effects of DHA or EPA can be further 
enhanced after SCI. Multiple injections might also increase neuroprotection, but only if 
the processes that the omega-3 PUFAs are targeting are still relevant within the window 
of treatment considered. This latter aspect is particularly important in the context of 
neurotrauma, where beneficial mechanisms may only be possible to harness within a very 
limited and well-defined time period after injury. 
Differences between DHA and EPA have been demonstrated in models of inflammation. 
For example, both DHA and EPA suppress proliferation of T cells, but by different 
mechanisms: EPA, but not DHA, enhances expression of cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4), a protein associated with the inhibition of T cell 
proliferation (Ly et al., 2006). DHA is more effective than EPA in reducing acute 
inflammatory processes such as infiltration of lymphocytes and expression of cytokines 
(Tomobe et al., 2000). However, others have found that pure EPA is the more potent 
inhibitor for upregulation of proinflammatory cytokines from LPS-stimulated human 
macrophages, compared to EPA-rich media (45% EPA /10% DHA), pure DHA and 
DHA-rich media (10% EPA/50% DHA) (Mickleborough et al., 2009). DHA 
demonstrated a much less potent effect on neutrophil chemotaxis after 4 weeks of dietary 
enrichment with EPA ethyl ester and DHA ethyl ester (Terano et al., 1987). Clearly, there 
remains a lot to be unravelled regarding the differences between the effects of EPA and 
DHA and it is very likely that these differences are model/context/species dependent.  
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One of the biggest recent advances in the field of lipidomics is the characterisation and 
classification of a large family of bioactive metabolites of DHA and EPA, including the 
resolvins, maresins and neuroprotectins (Serhan et al., 2000; Hong et al., 2003; 
Bannenberg et al., 2005; Serhan et al., 2009). These compounds were isolated from 
inflammatory exudates and appear to be more potent than either of their parent 
compounds, playing an active role in the switch to resolution of inflammation (For 
review, see Lawrence, et al., 2002; Serhan et al., 2004). It is very likely therefore, that the 
different effects of DHA and EPA are related to the action of these metabolites.   
7.3 The acute PUFA injection targets different SCI processes to those targeted by 
dietary enrichment  
The cascade of events that occur following SCI involve a complex sequence of processes. 
The acute bolus appears to be targeting pathological events that occur within the first 30 
min – 1 h after SCI such as cell death, excitotoxic signalling, and eicosanoid synthesis 
initiated from the fast release of AA from cell membranes. The effect of the acute bolus is 
lost if delayed to 3 h post-SCI (Huang et al., 2007a). PUFA delivered in the diet will start 
to accumulate in tissue hours after SCI, therefore targeting different events to the bolus, 
such as prolonged secondary damage, causing spread of neuronal and non-neuronal loss 
from the injury site.  
The results presented here on the effect of the omega-3 PUFA dietary treatments in SCI 
are in contrast to a number of studies in the literature indicating intrinsic beneficial 
neurological effects of PUFA supplementation, such as in TBI models (Bailes et al., 
2010), or stroke (Nguemeni et al., 2010). It will be important to analyse in future, the 
tissue levels of omega-3 PUFA achieved in the spinal cord in our DHA dietary studies. 
The results of the dietary DHA post-SCI treatment data here are in agreement with Huang 
et al. (2007a), where the diet was only effective after combination with the i.v. bolus of 
DHA. Due to the characteristics of this injury, it cannot be ruled out that neuroprotection 
in SCI can be achieved exclusively with oral exposure to high levels of DHA. 
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7.4 The inflammatory response after SCI: a double-edged sword? 
The modest effect of omega-3 PUFAs on inflammation after SCI is in contrast with 
several studies demonstrating their anti-inflammatory properties (see Table 6.1, chapter 
6). It is likely that the dynamics of the inflammatory response are different after SCI in 
comparison to those in non-CNS inflammatory models, or the timing of intervention of 
the omega-3 PUFA bolus or dietary treatments after SCI are not in synchrony with the 
timing of the same critical targets of the fatty acids that influence leukocyte trafficking or 
cytokine regulation in non-CNS models. The effects of omega-3 PUFAs on chronic 
inflammatory markers after SCI are yet to be studied in full detail histologically (see 
Future Work). 
It is an exciting time to be researching the inflammatory response after SCI. A lot has 
been learned recently about the dual nature of the response, which is a complex conflict 
between both neurotoxic and neuroprotective processes. We still have a long way to go 
before we will understand all the factors that could contribute towards a „successful‟ 
outcome when manipulating the inflammatory response after SCI and why residual 
inflammation persists in chronic SCI, despite improvements in neurological outcome 
after several anti-inflammatory treatment strategies (Bao et al., 2004, 2005; Fleming et 
al., 2008, 2009). It is considered by some researchers that there is a significant paucity of 
blood-derived immune infiltration after injuries to the CNS in vertebrates, particularly in 
the brain compared to the spinal cord (Schnell et al., 1999; Schecter et al., 2009). These 
discoveries encourage the exploration of the potential for the immune response to play an 
active beneficial role in recovery of the CNS to injury. It is tempting to consider that 
perhaps we can manipulate the response after SCI and drive it to a more beneficial 
resolution of inflammation. There have already been several successful attempts 
preclinically (Rapalino et al., 1998; Popovich et al., 1999; Hauben et al., 2000a, b; Bao et 
al., 2004, 2005; Gris et al., 2004; Schechter et al., 2009) but there remains disagreement 
on whether the enhancement or the prevention of particular processes of inflammation is 
the way forward. Animal strain differences highlight the fact that within a genetically 
heterogeneous human population, attempts to manipulate inflammation to promote repair 
or minimize secondary injury will yield variable results (Kigerl et al., 2006). Since 
diverse strains and species will continue to be used to model the human condition, future 
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studies need to continue to define how leukocyte populations vary between 
strains/species in the context of outcomes that are relevant to CNS repair (Donnelly et al.,  
2007).  
 
7.5 Consideration of the histological evaluation following SCI 
The histological markers assessed in our studies showed robust changes related to SCI, 
but they did not correlate with the behavioural outcome, for example in the study on 
dietary EPA. The markers used here have been effective for histological assessment of 
omega-3 PUFA treatment in previous SCI studies in our laboratory (King et al., 2006; 
Huang et al., 2007a; Lim et al., in press; Ward et al., 2010). Neuronal or oligodendrocyte 
loss at the thoracic level in the injury epicentre is not directly related to locomotor 
function per se, but is an indicator of neuroprotection and the amount of spread of the 
initial injury.  Spared tissue, particularly the white matter, is a more direct correlate of 
locomotor function measured using the BBB score (Bresnahan, et al., 1987; Stokes et al., 
1992; Basso et al., 1995, 1996, 2002; Popovich et al., 1999). The SMI32 labelling after 
SCI revealed different sizes of axons, which may invalidate the method of making a total 
count to reflect axonal pathology and protection. A more extensive and detailed analysis 
of the white matter, for example, with the axonal (SMI32 immunoreactive) counts, would 
be to separate the large swollen axons from the smaller labelled axons and might better 
reflect the behavioural outcome. It will also be worth in future to look at preservation of 
specific tracts related to locomotor function, such as the corticospinal or rubrospinal 
tracts for example, by labelling spinal cord sections with PKCγ (Mori et al, 1990), or by 
injecting a tracer such as BDA (biotinylated dextran amine), before harvesting the tissue 
(Angelucci et al., 1996). This would give an idea of the amount of regeneration or 
sprouting of axons, which may account more directly for locomotor outcome. The use of 
MR in vivo imaging of the cord to assess lesion size will reduce the need to collect 
separate tissue for multiple time points. Further development of this technique is needed, 
regarding the quality of imaging, but some studies have begun to use this technique 
(Fleming et al., 2009).  
Immunohistological analysis is limited methodologically when there are problems with a 
high noise: signal ratio in damaged tissue, this was particularly a problem when using the 
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diamonobenzidine (DAB) method at earlier time points after injury (Chapter 3). This 
makes cell counting tricky, especially of faintly labelled cells. The markers used to assess 
macrophages in this thesis allowed some insight into the spread of distribution of 
macrophages. However, ED1 or Iba1 labelling, expressed as a percentage of the area of 
tissue is only a blunt tool and does not reflect the functional properties of macrophages. 
Instead, function will be better predicted by quantifying how much a selection of surface 
or cytoplasmic antigens are up- or down-regulated. These changes may occur without 
changes in absolute cell numbers. Another quantitative assessment might be made based 
on real-time PCR (RT-PCR) of the injury site, but this cannot distinguish between the 
cell types contributing to the release of various factors. If a proinflammatory phenotype 
of macrophages is defined by increased release of TNF-α or IL-1β for example, RT-PCR 
can measure this increase but neurones and astrocytes are also known to release these 
products. FACS analysis offers an alternative method, by giving the opportunity to isolate 
and label the different cell types in the injury site. However, it is not easy to remove the 
leukocytes present in blood vessels in this location. A vascular rinse may not remove all 
blood cells from the blood vessels in the injury epicentre.  
7.6 Future work 
 
The findings from the studies documented in this thesis have resulted in a series of 
questions that remain to be answered and some of these are summarised below, with a set 
of proposed experiments to address them. Some preliminary experimental steps have 
already been taken to explore these questions. 
 
Is there a linear dose-response to omega-3 PUFA treatment after SCI? 
 
In chapter 5, after contusion SCI, i.v. DHA was found to be effective on a specific motor 
aspect of functional recovery at a higher dose (500 nmol/kg) than used after compression 
and hemisection SCI (250nmol/kg) (King et al., 2006; Huang et al., 2007a) but the effect 
was not significant overall in the global BBB score. It could be that a different, higher 
dose would be more effective in this model. Heurteaux et al. (2006) found a U-shaped 
response for acute i.v. ALA in a model of cerebral ischemia. The processes of ischaemia 
and the targets for DHA and EPA could be similar to the targets for ALA, and therefore, 
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multiple doses and/or multiple injection studies should be considered. Specific 
antagonists for postulated targets, such as for TREK-1, could be used to confirm the 
mechanisms underlying the effect of PUFA. Such experiments are in progress in our 
laboratory. 
 
In addition, it would be useful to directly compare the efficacy of omega-3 PUFA with 
another potentially translatable treatment, such as minocycline or riluzole. This would 
enable a direct comparison of our treatment, in our experimental conditions, to other 
neuroprotection strategies which are considered for clinical translation.  
 
Could the study of PUFA and the inflammatory response after SCI be expanded? 
 
Since there is a lot of research demonstrating the anti-inflammatory potential of omega-3 
PUFA and their metabolites, and the inflammatory reaction after SCI remains to be 
understood fully, it would be worth expanding the exploration of the inflammatory 
response after PUFA in SCI: 
 
 What happens to neutrophil numbers between 1-7 days after SCI? The 
immunohistochemical analysis could be expanded to include further time points 
to more accurately measure indices of inflammation such as the precise time point 
of resolution of the neutrophil response at the injury epicentre. This time point 
may be altered by treatment with omega-3 PUFAs in a similar way to that 
demonstrated with resolvin E1 (Serhan et al., 2008; Fig. 7.1).  
 Since COX and LOX metabolise EPA and DHA, do levels of COX change in the 
epicentre after SCI after PUFA treatment? This could be addressed by Western 
blot analysis as shown by Huang et al. (2007a). An increase in COX-2 expression 
was reported 3 and 24 h after compression SCI.  
 Are resolvins present in the SCI injury site? These can be measured using lipid 
analysis by mass spectrometry, and will be possible when we obtain the resolvin 
standards, which are not yet widely available.  
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 Is there a prolonged systemic inflammation in other vital organs after SCI, and 
how does it respond to PUFA? Gris et al. (2008) have reported the presence of 
neutrophils in other tissues after SCI. Alongside the tissue harvested in our 
studies, lung and kidney tissue has been collected in order to answer this question 
in future by immunohistochemical analysis of the tissue. 
 Does the i.v. injection of DHA or EPA affect the dynamics of cell adhesion or 
transmigration through the endothelium/blood-brain barrier? Intra-vital 
microscopy is a tool that has been used to demonstrate the effects of RvE1 on 
leukocytes (Spite et al., 2009). Even more powerful imaging techniques are 
available in vivo to allow the visualization and quantification of a robust 
recruitment of neutrophils to spinal cord microvasculature within the lesion site, 
where they begin to tether and roll onto endothelial cells as early as 15 min after 
SCI, before their entry into the injured spinal cord (Stirling et al., 2009). 
Visualization in real-time of leukocyte dynamics in blood vessels around SCI 
lesion sites should be helpful in future studies that target particular immune 
subsets in the circulation to modulate the extent of secondary injury after SCI. 
 Are there macrophages of the M1 or M2 phenotype in the injury site after rat or 
mouse compression SCI, and what is the time course of their response? The 
immunohistochemical markers documented by Kigerl et al. (2009) have so far 
been characterised in mouse tissue but not yet in the rat, or in our laboratory.  
 Does DHA or EPA applied directly to isolated macrophages, affect the activation 
of the M1/M2 phenotypes? Bone-marrow derived macrophage cultures were 
established while on a short visit to the laboratory of Dr. Philip Popovich, during 
this doctoral work (Fig. 7.2). The nitrite assay and real-time PCR analysis of 
secreted cytokines from the supernatant of unstimulated and stimulated 
macrophages in culture were used to define the M1 and M2 phenotypes. It would 
be interesting to see if omega-3 PUFA applied to these macrophage cultures affect 
the phenotype, based on the release of the same products.  
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  
Figure 7.1 Creating M1 or M2 macrophages in vitro. (A-C) Bone marrow-
derived macrophages (A) stimulated with LPS + interferon-γ or IL-4 differentiate 
into M1 (B) or M2 (C) phenotypes, respectively. CD 16/32 labels both polarized 
phenotype of M1 (red) or M2 macrophages in vitro. Nitrite assay (D) and Q-RT-
PCR confirmation of gene expression profiles (E-G) specific for M1 or M2 
macrophages. MO represents unstimulated macrophages. 
 
Can the detrimental effects of the EPA diet after SCI be confirmed and what are the 
mechanisms underlying it? 
 What is the cause of the apparent detrimental effect of dietary EPA after SCI? 
Tissue could be taken at early time points (1-3 days) to assess coagulation, 
haemorrhage and blood-brain barrier damage. There is a simple test to measure 
clotting time in fresh blood samples that has been developed in the trauma 
research group at Barts and The London (Brohi et al., 2003). DAB labelling on 
perfused spinal cord could be assessed for spread of haemorrhage from the same 
injured animals (Chapter 6). Injection of HRP or Evans Blue before perfusion 
could be used to assess permeability of the blood-brain barrier (Chapter 6). 
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 The histological assessment of macrophages/microglia could be improved. In SCI 
tissue labelled with both Iba1 and ED1 (Fig. 7.3), there was colocalisation of 
most, but not all cells. It would be interesting to measure the degree of 
colocalisation and whether treatment affects it. This is difficult to assess at present 
due to the different morphologies of resting and activated/phagocytic microglia.  
  
Figure 7.2 Macrophages/microglia in the ventral white matter 5 mm rostral to the 
injury site. Each row of panels represents one section from each group labelled with ED1 
(red) or Iba1 (green). Yellow represents co localisation of the two markers. 
 
7.7 The challenges in SCI preclinical research/methodological design and translation  
Several lessons have been learned from managing the rat SCI studies documented in this 
thesis. For functional neurological recovery, the BBB test is a good starting point and the 
best for the early stages of locomotor recovery, before stepping is recovered. When 
recovery of finer movements and coordination begins, other tests such as the grid, ladder, 
or beam walk and sensory tests such as tape removal, mechanical or thermal sensitivity 
will reflect a wider set of functions and continuing recovery that might not be apparent in 
the BBB scale. However, SCI models are demanding, and multiplying tests in the same 
animals can prove very challenging. 
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When working alone, the significant amount of care required in the recovery period post-
SCI, besides the behavioural testing, limits the addition of extra tests and/or experimental 
groups. It takes a considerable amount of time to master the SCI surgery and create 
reproducible injuries. The severity of the SCI could influence the efficacy of compounds 
so it is imperative that the severity of the injury or tissue sparing is set to one that offers a 
wide window of opportunity to assess the efficacy of treatments.  
In future studies, an alternative delivery method of the diet could be considered, e.g. by 
gavage (although more stressful for the animal), since the amount of the powder diet 
consumed per rat was difficult to monitor accurately. We preferred not to use the gavage 
method in this study to avoid possible damage to the SCI site from restraining the animal. 
Rats were housed in groups and there was a different number of animals per cage (n=2-
4/cage). The most accurate method would be to house animals individually to monitor the 
exact dose ingested, so that this data could be correlated with individual outcome 
measurements. However, this is not ideal and can cause distress. A more concentrated 
dose could be delivered in a smaller volume or given in a concentrated pellet in addition 
to normal diet to ensure that the full dose is given and the same per rat. In addition it 
would be important to establish the fatty acid tissue levels before and after dietary 
intervention and SCI.  
The choice of female rats was preferred in our experiments, since it was less complicated 
to manually express their bladders after SCI than males and they tend to have a lower rate 
of bladder infections. It is important to note that some variability in outcome after SCI 
may be influenced by the timing of the oestrus cycle of female rats, which is every 3 
days. Indeed, there are studies that have shown the protective effect of oestrogen 
(Samantaray et al., 2010; Chaovipoch et al., 2006), so the influence of oestrogen should 
be considered in the analysis of results of SCI experiments. It would be worth considering 
the use of male rats in future experiments, or to use females at synchronised oestrus 
cycles in order to reduce the amount of variability between groups. 
 
Different injury levels were used for the contusion (T8) and compression (T12) SCI 
experiments in this thesis and similar comparisons between these models and levels have 
been made in the literature. Although the purpose here was to repeat the effect of DHA 
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(Huang et al., 2007a) in another SCI model, it was not strictly a direct replication. In 
addition, although it was attempted to replicate the severity in both models, the severity 
was higher in the contusion model (BBB=10 at 28 days) compared to the compression 
model (BBB=12 at 28 days), which may have contributed to the need for a higher dose in 
the contusion experiment.  
 
The clinical relevance of making an intervention within 30 minutes of SCI is debateable. 
This timeframe is possible to achieve by some emergency services in largely populated 
areas with helicopter assistance. However, in more remote places in the world, an SCI 
patient may only receive medical attention hours after their injury. This means a 
treatment with a larger window of efficacy would be more likely to reach translation. Pre-
treatment studies are useful to gain mechanistic information and indeed, prophylactic 
treatment by ingesting high levels of omega-3 PUFAs would be possible for the military, 
before going into areas of conflict. However, it might not be realistic for ordinary 
civilians to increase their consumption of omega-3 PUFAs in order to prevent the rare 
chance of a SCI. 
 
When considering the transfer of a regime of treatment with DHA or EPA to humans, the 
interpretation of experimental data with regard to physiological relevance is complicated 
by the fact that different forms of omega-3 PUFAs have been used by researchers, and 
their bioavailability/ bioactivity may differ (Kim et al., 2010). Studies have used 
processed oil supplements, where DHA and EPA are present as glyceride esters 
(Christensen, et al., 1994; Sadou, et al., 1995). Ethyl esters of PUFA are another form 
used, such as in the dietary experiments performed in this research project, as well as the 
free fatty acid (FFA) form, used here for the i.v. bolus studies. Fatty acid absorption and 
supply to tissues can vary considerably with the nutritional state and the herbivore–
carnivore status of the species examined (Zhou et al., 2001). It is worth taking these 
factors into account when designing a protocol for clinical trials and deciding on the 
optimum dietary or parenteral delivery method of fatty acids, when a certain level/tissue 
and plasma exposure or composition is required.  
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A grading system for translation of systemically administered preclinical treatments has 
recently been proposed, in order to identify the strongest candidates for translation to the 
clinic (Kwon et al., 2010; Appendix 5). It represents a systematic approach to developing 
an objective method of evaluating the extent to which the preclinical literature supports 
the translation of a particular experimental treatment into human trials. The approach 
used included an evaluation of a number of factors that are thought to be important in 
considering the "robustness" of a therapy's efficacy, including the animal species and 
injury models that have been used to test it, the time window of efficacy, the types of 
functional improvements affected by it, and whether efficacy has been independently 
replicated. These factors were then scored and the grading system applied to a series of 
potential neuroprotective treatments for acute SCI. For example, erythropoeietin would 
score 34 points out of a potential 100, in part due to the large number of studies. Using 
the same criteria, based on published studies (including poster presentations), DHA 
would score 16.  EPA would score 13. To put these scores into perspective, the highest 
score using this model was 48, by minocycline. The authors suggested that one could 
consider translating a treatment that was found in a single laboratory to be effective in a 
rodent model of SCI with a score of 13 (Kwon et al., 2010). Assessments such as these 
will likely play a great role in future decisions for funding SCI research. Meetings such as 
the most recent Spinal Research Trust meeting (September 2010, Zurich) themed “On the 
way to translation” will likely recommend the use of objective modelling and scoring of 
this type to reduce the risk of failure in translation, as the common goal remains: to find 
realistic therapies for the future of SCI management. 
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Appendices 
Appendix 1. Care sheets for SCI studies 
Compression Daily Checks 
PREOP WEIGHT: 
Date:     Day 1 after SCI   Animal no: 
Weight:    Dehydrated:  Yes No (saline given?) 
AM Bladder:  tight   average   flaccid        Urine:      cloudy      clear      blood 
     large  medium   small 
PM Bladder:  tight   average   flaccid        Urine:      cloudy      clear      blood 
     large  medium   small 
Notes: animal wet, dry, infection? If dry for 3 consecutive days, bladder checks can stop 
Date:     Day 2     
Weight:    Dehydrated:  Yes No WET:      Yes         No 
AM Bladder:  tight   average   flaccid        Urine:      cloudy      clear      blood 
     large  medium   small 
PM Bladder:  tight   average   flaccid        Urine:      cloudy      clear      blood 
     large  medium   small 
Notes: 
Date:     Day 3     
Weight:    Dehydrated:  Yes No        WET:      Yes         No 
AM Bladder:  tight   average   flaccid        Urine:      cloudy      clear      blood 
     large  medium   small 
PM Bladder:  tight   average   flaccid        Urine:      cloudy      clear      blood 
     large  medium   small 
Continue to check until day 7 and then vdaily until bladder function resumes
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Appendix 2. Composition of the control diet used in chapter 6 
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Appendix 3. BBB score sheet 
 
 
(Reproduced from material from the  Reeve-Irvine Research Techniques course, 2008) 
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Appendix 4. Basso, Beattie, and Bresnahan Locomotor Rating Scale  
 
0 No observable hindlimb (HL) movement 
1 Slight movement of one or two joints, usually the hip and/or knee 
2 Extensive movement of one joint or extensive movement of one joint and slight movement of one other 
joint 
3 Extensive movement of two joints 
4 Slight movement of all three joints of the HL 
5 Slight movement of two joints and extensive movement of the third 
6 Extensive movement of two joints and slight movement of the third 
7 Extensive movement of all three joints of the HL 
8 Sweeping with no weight support or plantar placement of the paw with no weight support 
9 Plantar placement of the paw with weight support in stance only (i.e., when stationary) or occasional, 
frequent, or consistent weight-supported dorsal stepping and no plantar stepping 
10 Occasional weight-supported plantar steps; no FL–HL coordination 
11 Frequent to consistent weight-supported plantar steps and no FL–HL coordination 
12 Frequent to consistent weight-supported plantar steps and occasional FL–HL coordination 
13 Frequent to consistent weight-supported plantar steps and frequent FL–HL coordination 
14 Consistent weight-supported plantar steps, consistent FL–HL coordination, and predominant paw 
position during locomotion is rotated (internally or externally) when it makes initial contact with the 
surface as well as just before it is lifted off at the end of stance; or frequent plantar stepping, consistent FL–
HL coordination, and occasional dorsal stepping 
15 Consistent plantar stepping and consistent FL–HL coordination and no toe clearance or occasional toe 
clearance during forward limb advancement; predominant paw position is parallel to the body at initial 
contact 
16 Consistent plantar stepping and consistent FL–HL coordination during gait and toe clearance occurs 
frequently during forward limb advancement; predominant paw position is parallel at initial contact and 
rotated at lift off 
17 Consistent plantar stepping and consistent FL–HL coordination during gait and toe clearance occurs 
frequently during forward limb advancement; predominant paw position is parallel at initial contact and lift 
off 
18 Consistent plantar stepping and consistent FL–HL coordination during gait and toe clearance occurs 
consistently during forward limb advancement; predominant paw position is parallel at initial contact and 
rotated at lift off 
19 Consistent plantar stepping and consistent FL–HL coordination during gait, toe clearance occurs 
consistently during forward limb advancement, predominant paw position is parallel at initial contact and 
lift off, and tail is down part or all of the time 
20 Consistent plantar stepping and consistent coordinated gait, consistent toe clearance, predominant paw 
position is parallel at initial contact and lift off, and trunk instability; tail consistently up 
21 Consistent plantar stepping and coordinated gait, consistent toe clearance, predominant paw position is 
parallel throughout stance, and consistent trunk stability; tail consistently up 
 
(Reproduced from Basso et al., 2006) 
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Appendix 5. Preclinical Grading Scale (Reproduced from Kwon et al., 2010) 
 
Animal Species In Which Efficacy* Has Been Demonstrated     Points 
Primate model of traumatic SCI         8 
Large animal model of traumatic SCI (dog, cat, rabbit, pig, sheep)     6 
Rat model of traumatic SCI         4 
Mouse model of traumatic SCI         2 
Maximum Score:          20 
Injury Paradigms In Which Efficacy* Has Been Demonstrated In     Points 
Cervical contusion SCI models         6 
Thoracic contusion SCI model         3 
Cervical clip compression SCI model        6 
Thoracic clip compression SCI models        3 
Cervical partial transection sharp SCI model       1 
Thoracic partial transection sharp SCI model       1 
Maximum Score:          20 
Time Window of Efficacy*         Points 
Efficacy demonstrated with treatment delay of 12 or more hours     8 
Efficacy demonstrated with treatment delay of 4 or more hours, but less than 12 hours   6 
Efficacy demonstrated with treatment delay of 1 hour or more, but less than 4 hours   3 
Efficacy demonstrated when treatment given immediately at time of injury /within/less than 1 h  2 
Efficacy demonstrated when treatment given prior to injury      1 
Maximum Score:          20 
Demonstration of “Clinically Meaningful” Efficacy      Points 
THORACIC SCI MODEL: Achievement of plantar weight-support (i.e. BBB of 9) versus controls that do 
not, or the achievement of consistent forelimb-hindlimb coordination (i.e. BBB of 14) versus. controls that 
do not, in a study with associated improvements in non-behavioral outcomes (eg. Tissue sparing). 
           4 
THORACIC SCI MODEL: Significant improvement in other locomotor or motor behavioral tests (e.g. 
quantitative gait analysis, inclined plane, swimming) or other non-motor behavioral tests (eg. Pain, 
autonomic dysreflexia) in a study that also demonstrates associated improvements in non-behavioral 
outcomes (e.g. Tissue sparing). 
           4 
CERVICAL SCI: Significant improvement in some motor function test (e.g. Food pellet reaching, 
grasping, quantitative “gait” assessment) in a study that also demonstrates associated improvements in non-
behavioral outcomes. 
           4 
CERVICAL SCI: significant improvements in other non-motor behavioral tests (e.g. Pain, autonomic 
dysreflexia), in a study that also demonstrates associated improvements in non-behavioral outcomes 
           4 
DOSE RESPONSE demonstrated in a single study using either the thoracic or cervical SCI model. The 
dose “response” is defined by improvements in either behavioral or non-behavioral outcomes with 
changing doses of the therapy. 
           4 
Maximum Score:          20 
Independent Reproducibility / Replication       Points 
More than 10 independent laboratories report on the beneficial effects of the therapy   20 
5-10 Independent laboratories report on the beneficial effects of the therapy.    12 
3-4 Independent laboratories report on the beneficial effects of the therapy.    7 
2 Independent laboratories report on the beneficial effects of the therapy.    3 
1 independent laboratory reporting on the beneficial effects of the therapy    0 
1 independent laboratory reports on the negative results on the therapy     -3 
2-3 independent laboratories report on the negative results of the therapy    -7 
4-9 independent laboratories report on the negative results of the therapy    -12 
More than 9 independent laboratories report on the negative results of the therapy   -20 
Maximum Score:          20 
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Appendix 6. Calculation for preperation of PUFA supplemented food 
 
e.g. DHA 400 mg/kg/day 
 
For rat weight 200 g:      80 mg DHA/rat/day 
CRODA oil approx 75 % DHA, therefore:  107 mg/oil/rat/day 
 
s.g. oil = 1.0, therefore 107 mg oil = 107 µl oil 
if rat eats 30 g/day, then 107 µl oil in 30 g food, or 3.6 ml oil/kg diet 
 
EPA oil purity: 70 % 
 
Therefore, 114 mg oil (114 µl) in 30 g powder or 3.8 ml oil/kg diet 
